BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Llovet JM, Bustamante J, Castells A, Vilana R, Ayuso Mdel C, Sala M, Brú C, Rodés J, Bruix J. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology. 1999;29:62-67. [PMID: 9862851 DOI: 10.1002/hep.510290145] [Cited by in Crossref: 765] [Cited by in F6Publishing: 692] [Article Influence: 34.8] [Reference Citation Analysis]
Number Citing Articles
1 Malone CD, Mattrey RF, Fetzer DT. Contrast-Enhanced Ultrasound (CEUS) for the Diagnosis and Management of Hepatocellular Carcinoma: Current Status and Future Trends. Curr Hepatology Rep 2016;15:307-16. [DOI: 10.1007/s11901-016-0324-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
2 Gerard B, Bleiberg H. Treatment of hepatocarcinoma. Curr Oncol Rep 2004;6:184-91. [PMID: 15066229 DOI: 10.1007/s11912-004-0048-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
3 Ng KK, Vauthey J, Pawlik TM, Lauwers GY, Regimbeau J, Belghiti J, Ikai I, Yamaoka Y, Curley SA, Nagorney DM, Ng IO, Fan ST, Poon RT. Is Hepatic Resection for Large or Multinodular Hepatocellular Carcinoma Justified? Results From a Multi-Institutional Database. Ann Surg Oncol 2005;12:364-73. [DOI: 10.1245/aso.2005.06.004] [Cited by in Crossref: 167] [Cited by in F6Publishing: 80] [Article Influence: 10.4] [Reference Citation Analysis]
4 Clark HP, Carson WF, Kavanagh PV, Ho CP, Shen P, Zagoria RJ. Staging and current treatment of hepatocellular carcinoma. Radiographics 2005;25 Suppl 1:S3-23. [PMID: 16227495 DOI: 10.1148/rg.25si055507] [Cited by in Crossref: 68] [Cited by in F6Publishing: 47] [Article Influence: 4.5] [Reference Citation Analysis]
5 Choi Y, Kim JW, Cha H, Han KH, Seong J. Overall response of both intrahepatic tumor and portal vein tumor thrombosis is a good prognostic factor for hepatocellular carcinoma patients receiving concurrent chemoradiotherapy. J Radiat Res 2014;55:113-20. [PMID: 23772086 DOI: 10.1093/jrr/rrt082] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
6 Sasaki R, Kanda T, Kato N, Yokosuka O, Moriyama M. Hepatitis C virus-associated hepatocellular carcinoma after sustained virologic response. World J Hepatol 2018;10:898-906. [PMID: 30631394 DOI: 10.4254/wjh.v10.i12.898] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
7 Lin CC, Hung CF, Chen WT, Lin SM. Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma with Portal Vein Thrombosis: Impact of Early Response to 4 Weeks of Treatment. Liver Cancer 2015;4:228-40. [PMID: 26734578 DOI: 10.1159/000367737] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
8 Dalton-Fitzgerald E, Tiro J, Kandunoori P, Halm EA, Yopp A, Singal AG. Practice patterns and attitudes of primary care providers and barriers to surveillance of hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol 2015;13:791-8.e1. [PMID: 25019694 DOI: 10.1016/j.cgh.2014.06.031] [Cited by in Crossref: 60] [Cited by in F6Publishing: 57] [Article Influence: 8.6] [Reference Citation Analysis]
9 Yang T, Zhang J, Lu JH, Yang LQ, Yang GS, Wu MC, Yu WF. A new staging system for resectable hepatocellular carcinoma: comparison with six existing staging systems in a large Chinese cohort. J Cancer Res Clin Oncol. 2011;137:739-750. [PMID: 20607551 DOI: 10.1007/s00432-010-0935-3] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 3.0] [Reference Citation Analysis]
10 Johnson P, Bruix J. Hepatocellular carcinoma and the art of prognostication. Journal of Hepatology 2000;33:1006-8. [DOI: 10.1016/s0168-8278(00)80137-3] [Cited by in Crossref: 16] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
11 Ayogu JI, Odoh AS. Prospects and Therapeutic Applications of Cardiac Glycosides in Cancer Remediation. ACS Comb Sci 2020;22:543-53. [PMID: 32786321 DOI: 10.1021/acscombsci.0c00082] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
12 Sano S, Nakata S, Wada S, Kuroiwa M, Sakai H, Kusama K, Machida T, Nishio A, Ito I, Sodeyama H. Pathological complete response by advanced hepatocellular carcinoma with massive macrovascular invasion to hepatic arterial infusion chemotherapy: a case report. World J Surg Oncol 2019;17:229. [PMID: 31878937 DOI: 10.1186/s12957-019-1772-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
13 Han KH, Park JY. Chemotherapy for advanced hepatocellular carcinoma. J Gastroenterol Hepatol 2008;23:682-4. [PMID: 18410601 DOI: 10.1111/j.1440-1746.2008.05444.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
14 Sherman M. Staging for hepatocellular carcinoma: An embarrassment of riches. J Hepatol 2016;64:535-6. [PMID: 26682728 DOI: 10.1016/j.jhep.2015.11.040] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
15 Ohtsubo K, Watanabe H, Tsuchiyama T, Mouri H, Yamaguchi Y, Motoo Y, Okai T, Sanada J, Matsui O, Kitamura T, Fujiki R, Tokuuye K, Sawabu N. Advanced hepatocellular carcinoma treated effectively with irinotecan via hepatic arterial infusion followed by proton beam therapy. J Infect Chemother 2009;15:316-21. [PMID: 19856070 DOI: 10.1007/s10156-009-0702-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
16 Ye HH, Ye JZ, Xie ZB, Peng YC, Chen J, Ma L, Bai T, Chen JZ, Lu Z, Qin HG, Xiang BD, Li LQ. Comprehensive treatments for hepatocellular carcinoma with tumor thrombus in major portal vein. World J Gastroenterol 2016;22:3632-43. [PMID: 27053855 DOI: 10.3748/wjg.v22.i13.3632] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
17 Leal JN, Gonen M, Covey AM, Erinjeri JP, Getrajdman G, Sofocleous CT, D'Angelica M, DeMatteo RP, Abou-Alfa GK, Jarnagin WR, Fong Y, Brown KT. Locoregional Therapy for Hepatocellular Carcinoma with and without Extrahepatic Spread. J Vasc Interv Radiol 2015;26:1112-21. [PMID: 26038273 DOI: 10.1016/j.jvir.2015.04.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
18 Kumar A, Srivastava DN, Chau TT, Long HD, Bal C, Chandra P, Chien le T, Hoa NV, Thulkar S, Sharma S, Tam le H, Xuan TQ, Canh NX, Pant GS, Bandopadhyaya GP. Inoperable hepatocellular carcinoma: transarterial 188Re HDD-labeled iodized oil for treatment--prospective multicenter clinical trial. Radiology 2007;243:509-19. [PMID: 17456873 DOI: 10.1148/radiol.2432051246] [Cited by in Crossref: 43] [Cited by in F6Publishing: 31] [Article Influence: 3.1] [Reference Citation Analysis]
19 Xu M, Xie X, Xie X, Xu Z, Liu G, Zheng Y, Huang G, Wang W, Zheng S, Lü M. Sorafenib suppresses the rapid progress of hepatocellular carcinoma after insufficient radiofrequency ablation therapy: An experiment in vivo. Acta Radiol 2013;54:199-204. [DOI: 10.1258/ar.2012.120249] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 4.0] [Reference Citation Analysis]
20 Zou J, Zhu W, Meng H, Luo P, Zhang J. Efficacy and safety of selective internal radiotherapy versus sorafenib for intermediate-locally advanced hepatocellular carcinoma: a systematic review and meta-analysis. Expert Rev Gastroenterol Hepatol 2019;13:271-9. [PMID: 30791765 DOI: 10.1080/17474124.2019.1570135] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
21 Lin OS, Keeffe EB, Sanders GD, Owens DK. Cost-effectiveness of screening for hepatocellular carcinoma in patients with cirrhosis due to chronic hepatitis C. Aliment Pharmacol Ther. 2004;19:1159-1172. [PMID: 15153169 DOI: 10.1111/j.1365-2036.2004.01963.x] [Cited by in Crossref: 121] [Cited by in F6Publishing: 89] [Article Influence: 7.1] [Reference Citation Analysis]
22 An J, Kim HI, Chang S, Shim JH. Continued value of the serum alpha-fetoprotein test in surveilling at-risk populations for hepatocellular carcinoma. PLoS One 2020;15:e0238078. [PMID: 32845895 DOI: 10.1371/journal.pone.0238078] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Liu Y, Li Y, Wang X, Huang Y, Zhang Q, Shi K, Ran C, Hou J, Wang X. Fufang Banmao Capsule, a Traditional Chinese Medicinal Formulation, Enhances the Survival of Patients with Hepatocellular Carcinoma and Vp3-4 Portal Vein Tumor Thrombosis Undergoing Supportive Treatment. J Altern Complement Med 2020;26:956-65. [PMID: 32614605 DOI: 10.1089/acm.2019.0334] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
24 Chen JS, Wang Q, Chen XL, Huang XH, Liang LJ, Lei J, Huang JQ, Li DM, Cheng ZX. Clinicopathologic characteristics and surgical outcomes of hepatocellular carcinoma with portal vein tumor thrombosis. J Surg Res. 2012;175:243-250. [PMID: 21601221 DOI: 10.1016/j.jss.2011.03.072] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 1.9] [Reference Citation Analysis]
25 Tateishi R, Shiina S, Teratani T, Obi S, Sato S, Koike Y, Fujishima T, Yoshida H, Kawabe T, Omata M. Percutaneous radiofrequency ablation for hepatocellular carcinoma: An analysis of 1000 cases. Cancer 2005;103:1201-9. [DOI: 10.1002/cncr.20892] [Cited by in Crossref: 553] [Cited by in F6Publishing: 474] [Article Influence: 34.6] [Reference Citation Analysis]
26 Eom BW, Lee JH, Lee JS, Kim MJ, Ryu KW, Choi IJ, Cho SJ, Lee JY, Rhee J, Nam BH, Kim YW. Survival analysis of gastric cancer patients with tumor thrombus in the portal vein. J Surg Oncol 2012;105:310-5. [PMID: 21898415 DOI: 10.1002/jso.22083] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
27 Llovet JM, Moitinho E, Sala M, Bataller R, Rodríguez-Iglesias P, Castells A, Fernández J, Planas R, Navasa M, Bruix J, Rodés J. Prevalence and prognostic value of hepatocellular carcinoma in cirrhotic patients presenting with spontaneous bacterial peritonitis. J Hepatol 2000;33:423-9. [PMID: 11019998 DOI: 10.1016/s0168-8278(00)80278-0] [Cited by in Crossref: 22] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
28 Ajit Y, Sudarsan H, Saumya G, Abhishek A, Navneet R, Piyush R, Anil A, Arun G. Transarterial chemoembolization in unresectable hepatocellular carcinoma with portal vein thrombosis: a perspective on survival. Oman Med J. 2014;29:430-436. [PMID: 25584161 DOI: 10.5001/omj.2014.114] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
29 Pao TH, Hsueh WT, Chang WL, Chiang NJ, Lin YJ, Liu YS, Lin FC. Radiotherapy for inferior vena cava tumor thrombus in patients with hepatocellular carcinoma. BMC Cancer 2019;19:560. [PMID: 31182065 DOI: 10.1186/s12885-019-5654-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
30 European Association for Study of Liver. European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. Eur J Cancer. 2012;48:599-641. [PMID: 22424278 DOI: 10.1016/j.ejca.2011.12.021] [Cited by in Crossref: 273] [Cited by in F6Publishing: 247] [Article Influence: 30.3] [Reference Citation Analysis]
31 J. Cheng S, Pratt DS, Freeman RB, Kaplan MM, Wong JB. LIVING-DONOR VERSUS CADAVERIC LIVER TRANSPLANTATION FOR NON-RESECTABLE SMALL HEPATOCELLULAR CARCINOMA AND COMPENSATED CIRRHOSIS: A DECISION ANALYSIS1: . Transplantation 2001;72:861-8. [DOI: 10.1097/00007890-200109150-00021] [Cited by in Crossref: 85] [Cited by in F6Publishing: 75] [Article Influence: 4.3] [Reference Citation Analysis]
32 Jun CH, Yoon JH, Cho E, Shin SS, Cho SB, Kim HJ, Park CH, Kim HS, Choi SK, Rew JS. Barcelona clinic liver cancer-stage C hepatocellular carcinoma: A novel approach to subclassification and treatment. Medicine (Baltimore) 2017;96:e6745. [PMID: 28445298 DOI: 10.1097/MD.0000000000006745] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
33 Benzoni E, Lorenzin D, Favero A, Adani G, Baccarani U, Molaro R, Zompicchiatti A, Saccomano E, Avellini C, Bresadola F, Uzzau A. Liver Resection for Hepatocellular Carcinoma: a Multivariate Analysis of Factors Associated with Improved Prognosis. the Role of Clinical, Pathological and Surgical Related Factors. Tumori 2007;93:264-8. [DOI: 10.1177/030089160709300306] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 3.3] [Reference Citation Analysis]
34 Zanetto A, Campello E, Spiezia L, Burra P, Simioni P, Russo FP. Cancer-Associated Thrombosis in Cirrhotic Patients with Hepatocellular Carcinoma. Cancers (Basel). 2018;10. [PMID: 30453547 DOI: 10.3390/cancers10110450] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 9.0] [Reference Citation Analysis]
35 Cao F, Shen L, Qi H, Xie L, Song Z, Chen S, Fan W. Tree-based classification system incorporating the HVTT-PVTT score for personalized management of hepatocellular carcinoma patients with macroscopic vascular invasion. Aging (Albany NY) 2019;11:9544-55. [PMID: 31682230 DOI: 10.18632/aging.102403] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
36 Siriwardana RC, Lo CM, Chan SC, Fan ST. Role of portal vein embolization in hepatocellular carcinoma management and its effect on recurrence: a case-control study. World J Surg 2012;36:1640-6. [PMID: 22411084 DOI: 10.1007/s00268-012-1522-3] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
37 Demirci S, Doğan A, Başak N, Telci D, Dede B, Orhan C, Tuzcu M, Şahin K, Şahin N, Özercan İH, Şahin F. A Schiff base derivative for effective treatment of diethylnitrosamine-induced liver cancer in vivo. Anticancer Drugs 2015;26:555-64. [PMID: 25714251 DOI: 10.1097/CAD.0000000000000221] [Cited by in Crossref: 14] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
38 Jiang Y, Tang H, Wang Z, Sun Y, Meng W, Wang G, Li H, Yi S, Wang G, Yang Y, Chen G. Two Nomograms to Select Hepatocellular Carcinoma Patients with Macroscopic Vascular Invasion for Hepatic Resection. J Cancer 2018;9:3287-94. [PMID: 30271488 DOI: 10.7150/jca.25899] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
39 Huang TS, Shyu YC, Turner R, Chen HY, Chen PJ. Diagnostic performance of alpha-fetoprotein, lens culinaris agglutinin-reactive alpha-fetoprotein, des-gamma carboxyprothrombin, and glypican-3 for the detection of hepatocellular carcinoma: a systematic review and meta-analysis protocol. Syst Rev. 2013;2:37. [PMID: 23738605 DOI: 10.1186/2046-4053-2-37] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 3.3] [Reference Citation Analysis]
40 Lin CL, Kao JH. Optimal management of hepatocellular carcinoma: challenges and opportunities. J Gastroenterol Hepatol 2010;25:1336-8. [PMID: 20659219 DOI: 10.1111/j.1440-1746.2010.06373.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
41 Chien SC, Chen CY, Cheng PN, Liu YS, Cheng HC, Chuang CH, Chang TT, Chiu HC, Lin YJ, Chiu YC. Combined Transarterial Embolization/Chemoembolization-Based Locoregional Treatment with Sorafenib Prolongs the Survival in Patients with Advanced Hepatocellular Carcinoma and Preserved Liver Function: A Propensity Score Matching Study. Liver Cancer 2019;8:186-202. [PMID: 31192155 DOI: 10.1159/000489790] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 2.7] [Reference Citation Analysis]
42 Yao Q, Zhang H, Xiong B, Zheng C. Combination of sorafenib and TACE inhibits portal vein invasion for intermediate stage HCC: a single center retrospective controlled study. Oncotarget 2017;8:79012-22. [PMID: 29108283 DOI: 10.18632/oncotarget.20745] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
43 Yeung YP, Lo CM, Liu CL, Wong BC, Fan ST, Wong J. Natural history of untreated nonsurgical hepatocellular carcinoma. Am J Gastroenterol. 2005;100:1995-2004. [PMID: 16128944 DOI: 10.1111/j.1572-0241.2005.00229.x] [Cited by in Crossref: 100] [Cited by in F6Publishing: 89] [Article Influence: 6.3] [Reference Citation Analysis]
44 Li XL, Guo WX, Hong XD, Yang L, Wang K, Shi J, Li N, Wu MC, Cheng SQ. Efficacy of the treatment of transarterial chemoembolization combined with radiotherapy for hepatocellular carcinoma with portal vein tumor thrombus: A propensity score analysis. Hepatol Res. 2016;46:1088-1098. [PMID: 26783741 DOI: 10.1111/hepr.12657] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
45 Sakamoto K, Nagano H. Surgical treatment for advanced hepatocellular carcinoma with portal vein tumor thrombus. Hepatol Res. 2017;47:957-962. [PMID: 28618075 DOI: 10.1111/hepr.12923] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
46 Huang J, Deng Q, Wang Q, Li KY, Dai JH, Li N, Zhu ZD, Zhou B, Liu XY, Liu RF. Exome sequencing of hepatitis B virus-associated hepatocellular carcinoma. Nat Genet. 2012;44:1117-1121. [PMID: 22922871 DOI: 10.1038/ng.2391] [Cited by in Crossref: 263] [Cited by in F6Publishing: 237] [Article Influence: 29.2] [Reference Citation Analysis]
47 Ibrahim SM, Lewandowski RJ, Sato KT, Gates VL, Kulik L, Mulcahy MF, Ryu RK, Omary RA, Salem R. Radioembolization for the treatment of unresectable hepatocellular carcinoma: a clinical review. World J Gastroenterol 2008;14:1664-9. [PMID: 18350597 DOI: 10.3748/wjg.14.1664] [Cited by in CrossRef: 66] [Cited by in F6Publishing: 52] [Article Influence: 5.1] [Reference Citation Analysis]
48 Keane FK, Hong TS. Role and Future Directions of External Beam Radiotherapy for Primary Liver Cancer. Cancer Control 2017;24:1073274817729242. [PMID: 28975835 DOI: 10.1177/1073274817729242] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
49 Yang B, Li CL, Guo WH, Qin TQ, Jiao H, Fei ZJ, Zhou X, Duan LJ, Liao ZY. Intra-arterial ethanol embolization augments response to TACE for treatment of HCC with portal venous tumor thrombus. BMC Cancer 2018;18:101. [PMID: 29378532 DOI: 10.1186/s12885-018-3989-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
50 Greten TF, Papendorf F, Bleck JS, Kirchhoff T, Wohlberedt T, Kubicka S, Klempnauer J, Galanski M, Manns MP. Survival rate in patients with hepatocellular carcinoma: a retrospective analysis of 389 patients. Br J Cancer. 2005;92:1862-1868. [PMID: 15870713 DOI: 10.1038/sj.bjc.6602590] [Cited by in Crossref: 115] [Cited by in F6Publishing: 107] [Article Influence: 7.2] [Reference Citation Analysis]
51 Kishi Y, Hasegawa K, Sugawara Y, Kokudo N. Hepatocellular carcinoma: current management and future development-improved outcomes with surgical resection. Int J Hepatol. 2011;2011:728103. [PMID: 21994868 DOI: 10.4061/2011/728103] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 3.5] [Reference Citation Analysis]
52 Wong N, Haydon A, Kemp W, Wijeratne P, Roberts S. Improved survival trend of patients with hepatocellular carcinoma at an Australian tertiary hospital between 1995-2009. Intern Med J 2013;43:197-203. [PMID: 22372378 DOI: 10.1111/j.1445-5994.2012.02755.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
53 Cho IR, Lee HW, Song KJ, Kim BK, Kim SU, Kim DY, Ahn SH, Seong J, Han KH, Park JY. Conditional survival estimate in patients with Barcelona Clinic Liver Cancer stage B/C hepatocellular carcinoma treated with hepatic arterial infusion chemotherapy with/without concurrent radiotherapy. Oncotarget 2017;8:79914-26. [PMID: 29108373 DOI: 10.18632/oncotarget.20321] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
54 Singal AG, Conjeevaram HS, Volk ML, Fu S, Fontana RJ, Askari F, Su GL, Lok AS, Marrero JA. Effectiveness of hepatocellular carcinoma surveillance in patients with cirrhosis. Cancer Epidemiol Biomarkers Prev. 2012;21:793-799. [PMID: 22374994 DOI: 10.1158/1055-9965.epi-11-1005] [Cited by in Crossref: 157] [Cited by in F6Publishing: 86] [Article Influence: 17.4] [Reference Citation Analysis]
55 Henderson JM, Sherman M, Tavill A, Abecassis M, Chejfec G, Gramlich T. AHPBA/AJCC consensus conference on staging of hepatocellular carcinoma: consensus statement. HPB (Oxford). 2003;5:243-250. [PMID: 18332995 DOI: 10.1080/13651820310015833] [Cited by in Crossref: 85] [Cited by in F6Publishing: 80] [Article Influence: 7.7] [Reference Citation Analysis]
56 Han K, Kim JH, Ko GY, Gwon DI, Sung KB. Treatment of hepatocellular carcinoma with portal venous tumor thrombosis: A comprehensive review. World J Gastroenterol 2016;22:407-16. [PMID: 26755886 DOI: 10.3748/wjg.v22.i1.407] [Cited by in CrossRef: 35] [Cited by in F6Publishing: 35] [Article Influence: 8.8] [Reference Citation Analysis]
57 Keane FK, Tanguturi SK, Zhu AX, Dawson LA, Hong TS. Radiotherapy for liver tumors. Hepat Oncol 2015;2:133-46. [PMID: 30190993 DOI: 10.2217/hep.15.7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
58 Minagawa M, Makuuchi M. Treatment of hepatocellular carcinoma accompanied by portal vein tumor thrombus. World J Gastroenterol. 2006;12:7561-7567. [PMID: 17171782 DOI: 10.3748/wjg.v12.i47.7561] [Cited by in CrossRef: 180] [Cited by in F6Publishing: 166] [Article Influence: 12.9] [Reference Citation Analysis]
59 Valls C, Cos M, Figueras J, Andía E, Ramos E, Sánchez A, Serrano T, Torras J. Pretransplantation diagnosis and staging of hepatocellular carcinoma in patients with cirrhosis: value of dual-phase helical CT. AJR Am J Roentgenol. 2004;182:1011-1017. [PMID: 15039179 DOI: 10.2214/ajr.182.4.1821011] [Cited by in Crossref: 73] [Cited by in F6Publishing: 59] [Article Influence: 4.3] [Reference Citation Analysis]
60 Kodama H, Aikata H, Murakami E, Miyaki D, Nagaoki Y, Hashimoto Y, Azakami T, Katamura Y, Kawaoka T, Takaki S, Hiramatsu A, Waki K, Imamura M, Kawakami Y, Takahashi S, Ishikawa M, Kakizawa H, Awai K, Kenjo M, Nagata Y, Chayama K. Clinical outcome of esophageal varices after hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with major portal vein tumor thrombus. Hepatol Res 2011;41:1046-56. [PMID: 22032677 DOI: 10.1111/j.1872-034X.2011.00857.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
61 Farrell C, Halpen A, Cross TJ, Richardson PD, Johnson P, Joekes EC. Ultrasound surveillance for hepatocellular carcinoma: service evaluation of a radiology-led recall system in a tertiary-referral centre for liver diseases in the UK. Clin Radiol. 2017;72:338.e11-338.e17. [PMID: 28041651 DOI: 10.1016/j.crad.2016.10.019] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
62 Shu X, McCulloch M, Xiao H, Broffman M, Gao J. Chinese herbal medicine and chemotherapy in the treatment of hepatocellular carcinoma: a meta-analysis of randomized controlled trials. Integr Cancer Ther. 2005;4:219-229. [PMID: 16113029 DOI: 10.1177/1534735405279927] [Cited by in Crossref: 48] [Cited by in F6Publishing: 31] [Article Influence: 3.2] [Reference Citation Analysis]
63 Chang TS, Wu YC, Tung SY, Wei KL, Hsieh YY, Huang HC, Chen WM, Shen CH, Lu CH, Wu CS. Alpha-Fetoprotein Measurement Benefits Hepatocellular Carcinoma Surveillance in Patients with Cirrhosis. Am J Gastroenterol. 2015;110:836-844; quiz 845. [PMID: 25869392 DOI: 10.1038/ajg.2015.100] [Cited by in Crossref: 62] [Cited by in F6Publishing: 57] [Article Influence: 10.3] [Reference Citation Analysis]
64 Gramenzi A, Golfieri R, Mosconi C, Cappelli A, Granito A, Cucchetti A, Marinelli S, Pettinato C, Erroi V, Fiumana S, Bolondi L, Bernardi M, Trevisani F; BLOG (Bologna Liver Oncology Group). Yttrium-90 radioembolization vs sorafenib for intermediate-locally advanced hepatocellular carcinoma: a cohort study with propensity score analysis. Liver Int. 2015;35:1036-1047. [PMID: 24750853 DOI: 10.1111/liv.12574] [Cited by in Crossref: 69] [Cited by in F6Publishing: 62] [Article Influence: 9.9] [Reference Citation Analysis]
65 Kim RD, Reed AI, Fujita S, Foley DP, Mekeel KL, Hemming AW. Consensus and controversy in the management of hepatocellular carcinoma. J Am Coll Surg. 2007;205:108-123. [PMID: 17617340 DOI: 10.1016/j.jamcollsurg.2007.02.025] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
66 But DY, Lai CL, Yuen MF. Natural history of hepatitis-related hepatocellular carcinoma. World J Gastroenterol. 2008;14:1652-1656. [PMID: 18350595 DOI: 10.3748/wjg.14.1652] [Cited by in CrossRef: 135] [Cited by in F6Publishing: 125] [Article Influence: 10.4] [Reference Citation Analysis]
67 Varghese J, Kedarisetty CK, Venkataraman J, Srinivasan V, Deepashree T, Uthappa MC, Ilankumaran K, Govil S, Srinivas Reddy M, Rela M. Combination of TACE and Sorafenib Improves Outcomes in BCLC Stages B/C of Hepatocellular Carcinoma: A Single Centre Experience. Annals of Hepatology 2017;16:247-54. [DOI: 10.5604/16652681.1231585] [Cited by in Crossref: 34] [Cited by in F6Publishing: 24] [Article Influence: 8.5] [Reference Citation Analysis]
68 Chung SM, Yoon CJ, Lee SS, Hong S, Chung JW, Yang SW, Seong NJ, Jang ES, Kim JW, Jeong SH. Treatment outcomes of transcatheter arterial chemoembolization for hepatocellular carcinoma that invades hepatic vein or inferior vena cava. Cardiovasc Intervent Radiol 2014;37:1507-15. [PMID: 24464259 DOI: 10.1007/s00270-014-0841-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
69 Yuan D, Gao Z, Zhao J, Zhang H, Wang J. 125I seed implantation for hepatocellular carcinoma with portal vein tumor thrombus: A systematic review and meta-analysis. Brachytherapy 2019;18:521-9. [DOI: 10.1016/j.brachy.2019.01.014] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 4.5] [Reference Citation Analysis]
70 Molla MD, Dessie G, Akalu Y, Ayelign B. Hepatocellular Expression of SIRT1 and Its Effect on Hepatocellular Carcinoma Progression: A Future Therapeutic Perspective. Int J Hepatol 2020;2020:2374615. [PMID: 32607257 DOI: 10.1155/2020/2374615] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
71 Wakayama K, Kamiyama T, Yokoo H, Kakisaka T, Kamachi H, Tsuruga Y, Nakanishi K, Shimamura T, Todo S, Taketomi A. Surgical management of hepatocellular carcinoma with tumor thrombi in the inferior vena cava or right atrium. World J Surg Oncol. 2013;11:259. [PMID: 24093164 DOI: 10.1186/1477-7819-11-259] [Cited by in Crossref: 46] [Cited by in F6Publishing: 35] [Article Influence: 5.8] [Reference Citation Analysis]
72 Colombo M. Hepatitis C virus and hepatocellular carcinoma. Best Practice & Research Clinical Gastroenterology 1999;13:519-28. [DOI: 10.1053/bega.1999.0045] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 0.8] [Reference Citation Analysis]
73 Rim CH, Kim CY, Yang DS, Yoon WS. Comparison of radiation therapy modalities for hepatocellular carcinoma with portal vein thrombosis: A meta-analysis and systematic review. Radiotherapy and Oncology 2018;129:112-22. [DOI: 10.1016/j.radonc.2017.11.013] [Cited by in Crossref: 34] [Cited by in F6Publishing: 26] [Article Influence: 11.3] [Reference Citation Analysis]
74 Letreut Y, Hardwigsen J, Ananian P, Saisse J, Gregoire E, Richa H, Campan P. Resection of Hepatocellular Carcinoma with Tumor Thrombus in the Major Vasculature. A European Case-Control Series. Journal of Gastrointestinal Surgery 2006;10:855-62. [DOI: 10.1016/j.gassur.2005.12.011] [Cited by in Crossref: 89] [Cited by in F6Publishing: 79] [Article Influence: 5.9] [Reference Citation Analysis]
75 Graf J, Stengel A. Psychological Burden and Psycho-Oncological Interventions for Patients With Hepatobiliary Cancers-A Systematic Review. Front Psychol 2021;12:662777. [PMID: 34025526 DOI: 10.3389/fpsyg.2021.662777] [Reference Citation Analysis]
76 Li Q, Wang J, Sun Y, Cui YL, Juzi JT, Li HX, Qian BY, Hao XS. Efficacy of postoperative transarterial chemoembolization and portal vein chemotherapy for patients with hepatocellular carcinoma complicated by portal vein tumor thrombosis--a randomized study. World J Surg. 2006;30:2004-2011; discussion 2012-2013. [PMID: 17058027 DOI: 10.1007/s00268-006-0271-6] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 3.1] [Reference Citation Analysis]
77 Arai K, Fukumoto T, Kido M, Tanaka M, Kuramitsu K, Kinoshita H, Komatsu S, Tsugawa D, Terai S, Matsumoto T, Goto T, Asari S, Toyama H, Ajiki T, Ku Y. Preoperative neutrophil-to-lymphocyte ratio as a predictor of survival after reductive surgery plus percutaneous isolated hepatic perfusion for hepatocellular carcinoma: a retrospective analysis. Surg Today. 2017;47:385-392. [PMID: 27465474 DOI: 10.1007/s00595-016-1384-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
78 Zhao WP, Li H, Guo J, Cai L, Duan Y, Hou X, Du H, Shao X, Diao Z, Li C. Hepatocellular carcinoma with type II-III portal vein tumour thrombosis: treatment using transarterial chemoembolisation and microwave ablation. Br J Radiol 2021;94:20200415. [PMID: 33245679 DOI: 10.1259/bjr.20200415] [Reference Citation Analysis]
79 Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, Fan ST, Wong J. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 2002;35:1164-1171. [PMID: 11981766 DOI: 10.1053/jhep.2002.33156] [Cited by in Crossref: 1745] [Cited by in F6Publishing: 1460] [Article Influence: 91.8] [Reference Citation Analysis]
80 Katagiri S, Yamamoto M. Multidisciplinary treatments for hepatocellular carcinoma with major portal vein tumor thrombus. Surg Today. 2014;44:219-226. [PMID: 23591833 DOI: 10.1007/s00595-013-0585-6] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 5.1] [Reference Citation Analysis]
81 Makuuchi M, Sano K. The surgical approach to HCC: our progress and results in Japan. Liver Transpl. 2004;10:S46-S52. [PMID: 14762839 DOI: 10.1002/lt.20044] [Cited by in Crossref: 102] [Cited by in F6Publishing: 93] [Article Influence: 6.0] [Reference Citation Analysis]
82 Regimbeau JM, Abdalla EK, Vauthey JN, Lauwers GY, Durand F, Nagorney DM, Ikai I, Yamaoka Y, Belghiti J. Risk factors for early death due to recurrence after liver resection for hepatocellular carcinoma: results of a multicenter study. J Surg Oncol. 2004;85:36-41. [PMID: 14696085 DOI: 10.1002/jso.10284] [Cited by in Crossref: 99] [Cited by in F6Publishing: 91] [Article Influence: 5.8] [Reference Citation Analysis]
83 Igaki H, Nakagawa K, Shiraishi K, Shiina S, Kokudo N, Terahara A, Yamashita H, Sasano N, Omata M, Ohtomo K. Three-dimensional conformal radiotherapy for hepatocellular carcinoma with inferior vena cava invasion. Jpn J Clin Oncol. 2008;38:438-444. [PMID: 18495749 DOI: 10.1093/jjco/hyn038] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
84 Lee JS, Chu IS, Heo J, Calvisi DF, Sun Z, Roskams T, Durnez A, Demetris AJ, Thorgeirsson SS. Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology. 2004;40:667-676. [PMID: 15349906 DOI: 10.1002/hep.20375] [Cited by in Crossref: 599] [Cited by in F6Publishing: 519] [Article Influence: 35.2] [Reference Citation Analysis]
85 Llovet JM, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology. 1999;30:1434-1440. [PMID: 10573522 DOI: 10.1002/hep.510300629] [Cited by in Crossref: 1259] [Cited by in F6Publishing: 1087] [Article Influence: 57.2] [Reference Citation Analysis]
86 Santoyo J, Suárez M, Fernández J, Jiménez M, Ramírez C, Pérez Daga A, Bondia J, de la Fuente A. Tratamiento quirúrgico del hepatocarcinoma en el paciente cirrótico: ¿resección o trasplante? Cirugía Española 2001;70:42-8. [DOI: 10.1016/s0009-739x(01)71839-8] [Cited by in Crossref: 5] [Article Influence: 0.3] [Reference Citation Analysis]
87 Fukumoto T, Tominaga M, Kido M, Takebe A, Tanaka M, Kuramitsu K, Matsumoto I, Ajiki T, Ku Y. Long-term outcomes and prognostic factors with reductive hepatectomy and sequential percutaneous isolated hepatic perfusion for multiple bilobar hepatocellular carcinoma. Ann Surg Oncol. 2014;21:971-978. [PMID: 24201744 DOI: 10.1245/s10434-013-3305-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
88 Zheng W, Li Z, Nguyen AT, Li C, Emelyanov A, Gong Z. Xmrk, kras and myc transgenic zebrafish liver cancer models share molecular signatures with subsets of human hepatocellular carcinoma. PLoS One. 2014;9:e91179. [PMID: 24633177 DOI: 10.1371/journal.pone.0091179] [Cited by in Crossref: 39] [Cited by in F6Publishing: 25] [Article Influence: 5.6] [Reference Citation Analysis]
89 Wang W, Shen J, Wang C, Ren B, Zhu X, Ni C. Safety and Feasibility of Helical I-125 Seed Implants Combined with Transcatheter Arterial Chemoembolization in Hepatocellular Carcinomas with Main Portal Vein Tumor Thrombus. Cardiovasc Intervent Radiol 2019;42:1420-8. [DOI: 10.1007/s00270-019-02256-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
90 Mokdad AA, Singal AG, Yopp AC. Advances in Local and Systemic Therapies for Hepatocellular Cancer. Curr Oncol Rep 2016;18:9. [PMID: 26769114 DOI: 10.1007/s11912-015-0494-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
91 Fukushima D, Imai S, Nishino N, Hamada K, Horikawa Y, Shiwa Y, Nishida S, Koyanagi R, Wada H, Sakuma H. A case of complete remission of advanced hepatocellular carcinoma with type III portal vein tumor thrombosis treated using transarterial chemoembolization with microspheres and radiation therapy. Clin J Gastroenterol 2020;13:847-54. [PMID: 32350739 DOI: 10.1007/s12328-020-01124-5] [Reference Citation Analysis]
92 Sandhu DS, Tharayil VS, Lai JP, Roberts LR. Treatment options for hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol. 2008;2:81-92. [PMID: 19072372 DOI: 10.1586/17474124.2.1.81] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 1.8] [Reference Citation Analysis]
93 Ji M, Liu Z, Chang ET, Yu X, Wu B, Deng L, Feng Q, Wei K, Liang X, Lian S, Quan W, Wang P, Du Y, Liang Z, Xia S, Lin H, Li F, Cheng W, Chen W, Yuan Y, Ye W. Mass screening for liver cancer: results from a demonstration screening project in Zhongshan City, China. Sci Rep 2018;8:12787. [PMID: 30143694 DOI: 10.1038/s41598-018-31119-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
94 Akinwande O, Kim D, Edwards J, Brown R, Philips P, Scoggins C, Martin RC 2nd. Is radioembolization ((90)Y) better than doxorubicin drug eluting beads (DEBDOX) for hepatocellular carcinoma with portal vein thrombosis? A retrospective analysis. Surg Oncol. 2015;24:270-275. [PMID: 26133576 DOI: 10.1016/j.suronc.2015.06.008] [Cited by in Crossref: 11] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
95 Feng CP, Tang HM, Huang S, Hou SZ, Liang J, Huang W, Lai XP. Evaluation of the effects of the water-soluble total flavonoids from Isodon lophanthoides var.gerardianus (Benth.) H. Hara on apoptosis in HepG2 cell: Investigation of the most relevant mechanisms. J Ethnopharmacol 2016;188:70-9. [PMID: 27132715 DOI: 10.1016/j.jep.2016.04.042] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
96 Ohta M, Nakanishi C, Kawagishi N, Hara Y, Maida K, Kashiwadate T, Miyazawa K, Yoshida S, Miyagi S, Hayatsu Y, Kawamoto S, Matsuda Y, Okada Y, Saiki Y, Ohuchi N. Surgical resection of recurrent extrahepatic hepatocellular carcinoma with tumor thrombus extending into the right atrium under cardiopulmonary bypass: a case report and review of the literature. Surg Case Rep. 2016;2:110. [PMID: 27726114 DOI: 10.1186/s40792-016-0241-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
97 Tarantino L, Ambrosino P, Di Minno MN. Contrast-enhanced ultrasound in differentiating malignant from benign portal vein thrombosis in hepatocellular carcinoma. World J Gastroenterol. 2015;21:9457-9460. [PMID: 26327753 DOI: 10.3748/wjg.v21.i32.9457] [Cited by in CrossRef: 41] [Cited by in F6Publishing: 36] [Article Influence: 8.2] [Reference Citation Analysis]
98 de Villa V, Lo CM. Liver transplantation for hepatocellular carcinoma in Asia. Oncologist. 2007;12:1321-1331. [PMID: 18055852 DOI: 10.1634/theoncologist.12-11-1321] [Cited by in Crossref: 81] [Cited by in F6Publishing: 76] [Article Influence: 6.2] [Reference Citation Analysis]
99 Ganapathy-Kanniappan S, Kunjithapatham R, Geschwind JF. Glyceraldehyde-3-phosphate dehydrogenase: a promising target for molecular therapy in hepatocellular carcinoma. Oncotarget. 2012;3:940-953. [PMID: 22964488 DOI: 10.18632/oncotarget.623] [Cited by in Crossref: 55] [Cited by in F6Publishing: 50] [Article Influence: 6.9] [Reference Citation Analysis]
100 Yu JI, Park HC. Radiotherapy as valid modality for hepatocellular carcinoma with portal vein tumor thrombosis. World J Gastroenterol. 2016;22:6851-6863. [PMID: 27570422 DOI: 10.3748/wjg.v22.i30.6851] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 26] [Article Influence: 7.3] [Reference Citation Analysis]
101 Liu M, Shi J, Mou T, Wang Y, Wu Z, Shen A. Systematic review of hepatic arterial infusion chemotherapy versus sorafenib in patients with hepatocellular carcinoma with portal vein tumor thrombosis. J Gastroenterol Hepatol. 2020;35:1277-1287. [PMID: 32052876 DOI: 10.1111/jgh.15010] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
102 Hashem S, ElHefnawi M, Habashy S, El-Adawy M, Esmat G, Elakel W, Abdelazziz AO, Nabeel MM, Abdelmaksoud AH, Elbaz TM, Shousha HI. Machine Learning Prediction Models for Diagnosing Hepatocellular Carcinoma with HCV-related Chronic Liver Disease. Comput Methods Programs Biomed 2020;196:105551. [PMID: 32580053 DOI: 10.1016/j.cmpb.2020.105551] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 6.0] [Reference Citation Analysis]
103 Sherman CB, Behr S, Dodge JL, Roberts JP, Yao FY, Mehta N. Distinguishing Tumor From Bland Portal Vein Thrombus in Liver Transplant Candidates With Hepatocellular Carcinoma: the A-VENA Criteria. Liver Transpl 2019;25:207-16. [PMID: 30246323 DOI: 10.1002/lt.25345] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 12.0] [Reference Citation Analysis]
104 Elbaz T, Waked I, El-Akel W, Shaker MK, Abdelaziz AO, Yousif M, El-Bendary M, Zaky S, AbdAllah M, Hassany M, Esmat G, Doss W. Impact of successful HCV treatment using direct acting antivirals on recurrence of well ablated hepatocellular carcinoma. Expert Rev Anti Infect Ther 2021;:1-8. [PMID: 34253123 DOI: 10.1080/14787210.2021.1951230] [Reference Citation Analysis]
105 Yu C, Song C, Lv J, Zhu M, Yu C, Guo Y, Yang L, Chen Y, Chen Z, Jiang T, Ma H, Jin G, Shen H, Hu Z, Li L; China Kadoorie Biobank Collaborative Group. Prediction and clinical utility of a liver cancer risk model in Chinese adults: A prospective cohort study of 0.5 million people. Int J Cancer 2021;148:2924-34. [PMID: 33521941 DOI: 10.1002/ijc.33487] [Reference Citation Analysis]
106 Byun HK, Kim HJ, Im YR, Kim DY, Han K, Seong J. Dose escalation by intensity modulated radiotherapy in liver-directed concurrent chemoradiotherapy for locally advanced BCLC stage C hepatocellular carcinoma. Radiotherapy and Oncology 2019;133:1-8. [DOI: 10.1016/j.radonc.2018.12.025] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 5.5] [Reference Citation Analysis]
107 Pesi B, Ferrero A, Grazi GL, Cescon M, Russolillo N, Leo F, Boni L, Pinna AD, Capussotti L, Batignani G. Liver resection with thrombectomy as a treatment of hepatocellular carcinoma with major vascular invasion: results from a retrospective multicentric study. Am J Surg. 2015;210:35-44. [PMID: 25935229 DOI: 10.1016/j.amjsurg.2014.09.041] [Cited by in Crossref: 27] [Cited by in F6Publishing: 19] [Article Influence: 4.5] [Reference Citation Analysis]
108 Nagamatsu H, Hiraki M, Mizukami N, Yoshida H, Iwamoto H, Sumie S, Torimura T, Sata M. Intra-arterial therapy with cisplatin suspension in lipiodol and 5-fluorouracil for hepatocellular carcinoma with portal vein tumour thrombosis. Aliment Pharmacol Ther. 2010;32:543-550. [PMID: 20500734 DOI: 10.1111/j.1365-2036.2010.04379.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 2.2] [Reference Citation Analysis]
109 Toya R, Murakami R, Baba Y, Nishimura R, Morishita S, Ikeda O, Kawanaka K, Beppu T, Sugiyama S, Sakamoto T, Yamashita Y, Oya N. Conformal radiation therapy for portal vein tumor thrombosis of hepatocellular carcinoma. Radiother Oncol. 2007;84:266-271. [PMID: 17716760 DOI: 10.1016/j.radonc.2007.07.005] [Cited by in Crossref: 79] [Cited by in F6Publishing: 65] [Article Influence: 5.6] [Reference Citation Analysis]
110 Lee JW, Yun M, Cho A, Han KH, Kim DY, Lee SM, Lee JD. The predictive value of metabolic tumor volume on FDG PET/CT for transarterial chemoembolization and transarterial chemotherapy infusion in hepatocellular carcinoma patients without extrahepatic metastasis. Ann Nucl Med. 2015;29:400-408. [PMID: 25652647 DOI: 10.1007/s12149-015-0956-8] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
111 Chen MY, Wang YC, Wu TH, Lee CF, Wu TJ, Chou HS, Tsang NM, Chan KM, Lee WC. Efficacy of External Beam Radiation-Based Treatment plus Locoregional Therapy for Hepatocellular Carcinoma Associated with Portal Vein Tumor Thrombosis. Biomed Res Int 2016;2016:6017406. [PMID: 27999803 DOI: 10.1155/2016/6017406] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
112 Mahady SE, Charlton B, Fitzgerald P, Koorey DJ, Perry JF, Waugh RC, McCaughan GW, Strasser SI. Locoregional therapies for hepatocellular carcinoma: which patients are most likely to gain a survival advantage? J Gastroenterol Hepatol 2010;25:1299-305. [PMID: 20594260 DOI: 10.1111/j.1440-1746.2010.06267.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
113 Giannini E, Risso D, Botta F, Romagnoli P, Malfatti F, Fumagalli A, Testa E, Podestà E, Chiarbonello B, Polegato S, Testa R. Prognosis of hepatocellular carcinoma in anti-HCV positive cirrhotic patients: a single-centre comparison amongst four different staging systems. J Intern Med 2004;255:399-408. [PMID: 14871465 DOI: 10.1046/j.1365-2796.2003.01284.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis]
114 Su LJ, Hsu SL, Yang JS, Tseng HH, Huang SF, Huang CY. Global gene expression profiling of dimethylnitrosamine-induced liver fibrosis: from pathological and biochemical data to microarray analysis. Gene Expr 2006;13:107-32. [PMID: 17017125 DOI: 10.3727/000000006783991872] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
115 Bruix J, Llovet JM. Locoregional treatments for hepatocellular carcinoma. Baillieres Best Pract Res Clin Gastroenterol. 1999;13:611-622. [PMID: 10654923 DOI: 10.1053/bega.1999.0051] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 0.6] [Reference Citation Analysis]
116 Edeline J, Crouzet L, Campillo-gimenez B, Rolland Y, Pracht M, Guillygomarc’h A, Boudjema K, Lenoir L, Adhoute X, Rohou T, Boucher E, Clément B, Blanc J, Garin E. Selective internal radiation therapy compared with sorafenib for hepatocellular carcinoma with portal vein thrombosis. Eur J Nucl Med Mol Imaging 2016;43:635-43. [DOI: 10.1007/s00259-015-3210-7] [Cited by in Crossref: 52] [Cited by in F6Publishing: 46] [Article Influence: 8.7] [Reference Citation Analysis]
117 Avila MA, Berasain C, Sangro B, Prieto J. New therapies for hepatocellular carcinoma. Oncogene. 2006;25:3866-3884. [PMID: 16799628 DOI: 10.1038/sj.onc.1209550] [Cited by in Crossref: 269] [Cited by in F6Publishing: 237] [Article Influence: 17.9] [Reference Citation Analysis]
118 Roayaie S, Jibara G, Taouli B, Schwartz M. Resection of hepatocellular carcinoma with macroscopic vascular invasion. Ann Surg Oncol. 2013;20:3754-3760. [PMID: 23884750 DOI: 10.1245/s10434-013-3074-7] [Cited by in Crossref: 44] [Cited by in F6Publishing: 41] [Article Influence: 5.5] [Reference Citation Analysis]
119 Abdelaziz AO, Abdelhalim H, Elsharkawy A, Shousha HI, Abdelmaksoud AH, Soliman ZA, Seif MI, Sayed DB, Farouk MH, Elbaz TM, Nabeel MM. Liver stiffness measurement changes following hepatocellular carcinoma treatment with percutaneous microwave ablation or transarterial chemoembolization: a cohort study. Eur J Gastroenterol Hepatol 2019;31:685-91. [PMID: 30640743 DOI: 10.1097/MEG.0000000000001343] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
120 Wang L, Li Q, Zhang J, Lu J. A Novel Prognostic Scoring Model Based on Albumin and γ-Glutamyltransferase for Hepatocellular Carcinoma Prognosis. Cancer Manag Res 2019;11:10685-94. [PMID: 31920379 DOI: 10.2147/CMAR.S232073] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
121 Kondili LA, Lala A, Gunson B, Hubscher S, Olliff S, Elias E, Bramhall S, Mutimer D. Primary hepatocellular cancer in the explanted liver: outcome of transplantation and risk factors for HCC recurrence. Eur J Surg Oncol. 2007;33:868-873. [PMID: 17258882 DOI: 10.1016/j.ejso.2006.10.001] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
122 Li MF, Leung HW, Chan AL, Wang SY. Network meta-analysis of treatment regimens for inoperable advanced hepatocellular carcinoma with portal vein invasion. Ther Clin Risk Manag. 2018;14:1157-1168. [PMID: 30013351 DOI: 10.2147/tcrm.s162898] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
123 Ikeda M, Okusaka T, Ueno H, Morizane C, Kojima Y, Iwasa S, Hagihara A. Predictive factors of outcome and tumor response to systemic chemotherapy in patients with metastatic hepatocellular carcinoma. Jpn J Clin Oncol 2008;38:675-82. [PMID: 18716041 DOI: 10.1093/jjco/hyn087] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
124 Wang K, Guo W, Li N, Shi J, Zhang C, Lau WY, Wu M, Cheng S. Alpha-1-fucosidase as a prognostic indicator for hepatocellular carcinoma following hepatectomy: a large-scale, long-term study. Br J Cancer. 2014;110:1811-1819. [PMID: 24569461 DOI: 10.1038/bjc.2014.102] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
125 Zhang X, Wan JX, Ke ZP, Wang F, Chai HX, Liu JQ. TMEM88, CCL14 and CLEC3B as prognostic biomarkers for prognosis and palindromia of human hepatocellular carcinoma. Tumour Biol 2017;39:1010428317708900. [PMID: 28718365 DOI: 10.1177/1010428317708900] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
126 Samuel D, Colombo M, El-Serag H, Sobesky R, Heaton N. Toward optimizing the indications for orthotopic liver transplantation in hepatocellular carcinoma. Liver Transpl. 2011;17 Suppl 2:S6-13. [PMID: 21858912 DOI: 10.1002/lt.22423] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 4.3] [Reference Citation Analysis]
127 Basso M, Basso M, Iaculli A, Pompili M, Riccardi L, Barbaro B, Rufini V, Cassano A, Castaldi P, Barone C. Complete Metabolic Response with Recanalization of Portal Vein Tumor Thrombosis after Sunitinib in a Patient with Advanced Hepatocellular Carcinoma. Case Rep Oncol 2010;3:391-6. [PMID: 21113349 DOI: 10.1159/000322135] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
128 Farinati F, Rinaldi M, Gianni S, Naccarato R. How should patients with hepatocellular carcinoma be staged?: Validation of a new prognostic system. Cancer 2000;89:2266-73. [DOI: 10.1002/1097-0142(20001201)89:11<2266::aid-cncr15>3.0.co;2-0] [Cited by in Crossref: 99] [Article Influence: 4.7] [Reference Citation Analysis]
129 John AR, Khan S, Mirza DF, Mayer AD, Buckels JA, Bramhall SR. Multivariate and univariate analysis of prognostic factors following resection in HCC: the Birmingham experience. Dig Surg. 2006;23:103-109. [PMID: 16763375 DOI: 10.1159/000093779] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.2] [Reference Citation Analysis]
130 Grasso A, Watkinson AF, Tibballs JM, Burroughs AK. Radiofrequency ablation in the treatment of hepatocellular carcinoma--a clinical viewpoint. J Hepatol. 2000;33:667-672. [PMID: 11059876 DOI: 10.1016/s0168-8278(00)80023-9] [Cited by in Crossref: 23] [Cited by in F6Publishing: 1] [Article Influence: 1.2] [Reference Citation Analysis]
131 Yokoo T, Patel AD, Lev-Cohain N, Singal AG, Yopp AC, Pedrosa I. Extrahepatic metastasis risk of hepatocellular carcinoma based on α-fetoprotein and tumor staging parameters at cross-sectional imaging. Cancer Manag Res 2017;9:503-11. [PMID: 29081671 DOI: 10.2147/CMAR.S147097] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
132 Niizeki T, Sumie S, Torimura T, Kurogi J, Kuromatsu R, Iwamoto H, Aino H, Nakano M, Kawaguchi A, Kakuma T, Sata M. Serum vascular endothelial growth factor as a predictor of response and survival in patients with advanced hepatocellular carcinoma undergoing hepatic arterial infusion chemotherapy. J Gastroenterol 2012;47:686-95. [DOI: 10.1007/s00535-012-0555-6] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 3.7] [Reference Citation Analysis]
133 Zhao H, Yan G, Zheng L, Zhou Y, Sheng H, Wu L, Zhang Q, Lei J, Zhang J, Xin R, Jiang L, Zhang X, Chen Y, Wang J, Xu Y, Li D, Li Y. STIM1 is a metabolic checkpoint regulating the invasion and metastasis of hepatocellular carcinoma. Theranostics 2020;10:6483-99. [PMID: 32483465 DOI: 10.7150/thno.44025] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
134 Park KW, Park JW, Choi JI, Kim TH, Kim SH, Park HS, Lee WJ, Park SJ, Hong EK, Kim CM. Survival analysis of 904 patients with hepatocellular carcinoma in a hepatitis B virus-endemic area. J Gastroenterol Hepatol 2008;23:467-73. [PMID: 17764529 DOI: 10.1111/j.1440-1746.2007.05112.x] [Cited by in Crossref: 82] [Cited by in F6Publishing: 80] [Article Influence: 5.9] [Reference Citation Analysis]
135 Yu JI, Park HC, Lim DH, Park W, Yoo BC, Paik SW, Koh KC, Lee JH. Prognostic index for portal vein tumor thrombosis in patients with hepatocellular carcinoma treated with radiation therapy. J Korean Med Sci. 2011;26:1014-1022. [PMID: 21860551 DOI: 10.3346/jkms.2011.26.8.1014] [Cited by in Crossref: 39] [Cited by in F6Publishing: 32] [Article Influence: 3.9] [Reference Citation Analysis]
136 Schlachterman A, Craft WW, Hilgenfeldt E, Mitra A, Cabrera R. Current and future treatments for hepatocellular carcinoma. World J Gastroenterol. 2015;21:8478-8491. [PMID: 26229392 DOI: 10.3748/wjg.v21.i28.8478] [Cited by in CrossRef: 94] [Cited by in F6Publishing: 81] [Article Influence: 18.8] [Reference Citation Analysis]
137 Romeo R, Colombo M. The natural history of hepatocellular carcinoma. Toxicology. 2002;181-182:39-42. [PMID: 12505282 DOI: 10.1016/s0300-483x(02)00252-4] [Cited by in Crossref: 19] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
138 Ando E, Tanaka M, Yamashita F, Kuromatsu R, Yutani S, Fukumori K, Sumie S, Yano Y, Okuda K, Sata M. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases. Cancer. 2002;95:588-595. [PMID: 12209752 DOI: 10.1002/cncr.10694] [Cited by in Crossref: 233] [Cited by in F6Publishing: 193] [Article Influence: 12.3] [Reference Citation Analysis]
139 Lee J, Park JO, Kim WS, Park SH, Park KW, Choi MS, Lee JH, Koh KC, Paik SW, Yoo BC. Phase II study of doxorubicin and cisplatin in patients with metastatic hepatocellular carcinoma. Cancer Chemother Pharmacol. 2004;54:385-390. [PMID: 15248028 DOI: 10.1007/s00280-004-0837-7] [Cited by in Crossref: 59] [Cited by in F6Publishing: 47] [Article Influence: 3.5] [Reference Citation Analysis]
140 Pleguezuelo M, Germani G, Marelli L, Xiruochakis E, Misseri M, Manousou P, Arvaniti V, Burroughs AK. Evidence-based diagnosis and locoregional therapy for hepatocellular carcinoma. Expert Review of Gastroenterology & Hepatology 2014;2:761-84. [DOI: 10.1586/17474124.2.6.761] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
141 Pereira A. Health and economic impact of posttransfusion hepatitis B and cost-effectiveness analysis of expanded HBV testing protocols of blood donors: a study focused on the European Union. Transfusion 2003;43:192-201. [DOI: 10.1046/j.1537-2995.2003.00280.x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 1.6] [Reference Citation Analysis]
142 Matsuo Y, Yoshida K, Nishimura H, Ejima Y, Miyawaki D, Uezono H, Ishihara T, Mayahara H, Fukumoto T, Ku Y, Yamaguchi M, Sugimoto K, Sasaki R. Efficacy of stereotactic body radiotherapy for hepatocellular carcinoma with portal vein tumor thrombosis/inferior vena cava tumor thrombosis: evaluation by comparison with conventional three-dimensional conformal radiotherapy. J Radiat Res 2016;57:512-23. [PMID: 27053259 DOI: 10.1093/jrr/rrw028] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 5.2] [Reference Citation Analysis]
143 Hua Q, Zhang D, Li Y, Hu Y, Liu P, Xiao G, Zhang T, Xue J. Prognostic Factors of Survival of Advanced Liver Cancer Patients Treated With Palliative Radiotherapy: A Retrospective Study. Front Oncol 2021;11:658152. [PMID: 34395242 DOI: 10.3389/fonc.2021.658152] [Reference Citation Analysis]
144 Maciel AC, Cerski CT, Moreira RK, Resende VL, Zanotelli ML, Matiotti SB. Hepatocellular carcinoma in patients undergoing orthotopic liver transplantation: radiological findings with anatomopathological correlation in Brazil. Arq Gastroenterol 2006;43:24-9. [DOI: 10.1590/s0004-28032006000100008] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]
145 Moriguchi M, Aramaki T, Nishiofuku H, Sato R, Asakura K, Yamaguchi K, Tanaka T, Endo M, Itoh Y. Sorafenib versus Hepatic Arterial Infusion Chemotherapy as Initial Treatment for Hepatocellular Carcinoma with Advanced Portal Vein Tumor Thrombosis. Liver Cancer 2017;6:275-86. [PMID: 29234631 DOI: 10.1159/000473887] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
146 Abdelaziz AO, Nabil MM, Abdelmaksoud AH, Shousha HI, Hashem MB, Hassan EM, Salah A, Omran DA, Elbaz TM. Tumor behavior of hepatocellular carcinoma after hepatitis C treatment by direct-acting antivirals: comparative analysis with non-direct-acting antivirals-treated patients. Eur J Gastroenterol Hepatol 2019;31:75-9. [PMID: 30199473 DOI: 10.1097/MEG.0000000000001264] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
147 Bialecki ES, Ezenekwe AM, Brunt EM, Collins BT, Ponder TB, Bieneman BK, Di Bisceglie AM. Comparison of liver biopsy and noninvasive methods for diagnosis of hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2006;4:361-368. [PMID: 16527701 DOI: 10.1016/s1542-3565(05)00977-8] [Cited by in Crossref: 43] [Cited by in F6Publishing: 12] [Article Influence: 2.9] [Reference Citation Analysis]
148 Llovet JM, Ruff P, Tassopoulos N, Castells L, Bruix J, El-Hariry I, Peachey M. A phase II trial of oral eniluracil/5-fluorouracil in patients with inoperable hepatocellular carcinoma. Eur J Cancer 2001;37:1352-8. [PMID: 11435064 DOI: 10.1016/s0959-8049(01)00100-9] [Cited by in Crossref: 17] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
149 Kurahashi S, Sano T, Natsume S, Senda Y, Yamaura H, Inaba Y, Shimizu Y. Surgical treatment after hepatic arterial infusion chemotherapy for hepatocellular carcinoma extending into the right atrium. Surg Case Rep 2015;1:47. [PMID: 26366344 DOI: 10.1186/s40792-015-0047-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
150 Llovet JM, Bruix J, Gores GJ. Surgical resection versus transplantation for early hepatocellular carcinoma: clues for the best strategy. Hepatology 2000;31:1019-21. [DOI: 10.1053/he.2000.6959] [Cited by in Crossref: 137] [Cited by in F6Publishing: 125] [Article Influence: 6.5] [Reference Citation Analysis]
151 Meng XC, Chen BH, Huang JJ, Huang WS, Cai MY, Zhou JW, Guo YJ, Zhu KS. Early prediction of survival in hepatocellular carcinoma patients treated with transarterial chemoembolization plus sorafenib. World J Gastroenterol 2018;24:484-93. [PMID: 29398869 DOI: 10.3748/wjg.v24.i4.484] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
152 Somma F, Stoia V, Serra N, D'Angelo R, Gatta G, Fiore F. Yttrium-90 trans-arterial radioembolization in advanced-stage HCC: The impact of portal vein thrombosis on survival. PLoS One 2019;14:e0216935. [PMID: 31141552 DOI: 10.1371/journal.pone.0216935] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
153 Tan Z, Lu J, Zhu G, Chen L, Wang Y, Zhang Q, Pan T, Wang J, Guo J, Teng G. Portal Vein Irradiation Stent Plus Chemoembolization versus External Radiotherapy Plus Chemoembolization in Hepatocellular Carcinoma with Portal Vein Tumour Thrombus: A Retrospective Study. Cardiovasc Intervent Radiol 2021;44:1414-22. [PMID: 34131776 DOI: 10.1007/s00270-021-02889-z] [Reference Citation Analysis]
154 Rust C, Gores GJ. Locoregional management of hepatocellular carcinoma. Surgical and ablation therapies. Clin Liver Dis. 2001;5:161-173. [PMID: 11218913 DOI: 10.1016/s1089-3261(05)70159-8] [Cited by in Crossref: 24] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
155 Chan SL, Mo FK, Wong CS, Chan CM, Leung LK, Hui EP, Ma BB, Chan AT, Mok TS, Yeo W. A study of circulating interleukin 10 in prognostication of unresectable hepatocellular carcinoma. Cancer. 2012;118:3984-3992. [PMID: 22180222 DOI: 10.1002/cncr.26726] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 3.8] [Reference Citation Analysis]
156 Matono R, Yoshiya S, Motomura T, Toshima T, Kayashima H, Masuda T, Yoshizumi T, Taketomi A, Shirabe K, Maehara Y. Factors linked to longterm survival of patients with hepatocellular carcinoma accompanied by tumour thrombus in the major portal vein after surgical resection. HPB (Oxford). 2012;14:247-253. [PMID: 22404263 DOI: 10.1111/j.1477-2574.2011.00436.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
157 Jang H, Kim TK, Burns PN, Wilson SR. CEUS: An essential component in a multimodality approach to small nodules in patients at high-risk for hepatocellular carcinoma. European Journal of Radiology 2015;84:1623-35. [DOI: 10.1016/j.ejrad.2015.05.020] [Cited by in Crossref: 37] [Cited by in F6Publishing: 25] [Article Influence: 6.2] [Reference Citation Analysis]
158 Ahn DW, Shim JH, Yoon JH, Kim CY, Lee HS, Kim YT, Kim YJ. Treatment and clinical outcome of needle-track seeding from hepatocellular carcinoma. Korean J Hepatol. 2011;17:106-112. [PMID: 21757981 DOI: 10.3350/kjhep.2011.17.2.106] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
159 Adhoute X, Pénaranda G, Raoul JL, Blanc JF, Edeline J, Conroy G, Perrier H, Pol B, Bayle O, Monnet O, Beaurain P, Muller C, Castellani P, Bronowicki J, Bourlière M. Prognosis of advanced hepatocellular carcinoma: a new stratification of Barcelona Clinic Liver Cancer stage C. European Journal of Gastroenterology & Hepatology 2016;28:433-40. [DOI: 10.1097/meg.0000000000000558] [Cited by in Crossref: 27] [Cited by in F6Publishing: 10] [Article Influence: 5.4] [Reference Citation Analysis]
160 Perini MV, Starkey G, Fink MA, Bhandari R, Muralidharan V, Jones R, Christophi C. From minimal to maximal surgery in the treatment of hepatocarcinoma: A review. World J Hepatol. 2015;7:93-100. [PMID: 25625000 DOI: 10.4254/wjh.v7.i1.93] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
161 Liu Y, Wang X, Jiang K, Zhang W, Dong J. The diagnostic value of tumor biomarkers for detecting hepatocellular carcinoma accompanied by portal vein tumor thrombosis. Cell Biochem Biophys. 2014;69:455-459. [PMID: 24500835 DOI: 10.1007/s12013-014-9817-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
162 Holliday EB, Tao R, Brownlee Z, Das P, Krishnan S, Taniguchi C, Minsky BD, Herman JM, Kaseb A, Raghav K, Conrad C, Vauthey JN, Aloia TA, Chun YS, Crane CH, Koay EJ. Definitive radiation therapy for hepatocellular carcinoma with portal vein tumor thrombus. Clin Transl Radiat Oncol 2017;4:39-45. [PMID: 29594206 DOI: 10.1016/j.ctro.2017.04.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
163 Yan B, Bai DS, Zhang C, Qian JJ, Jin SJ, Jiang GQ. Characteristics and risk differences of different tumor sizes on distant metastases of hepatocellular carcinoma: A retrospective cohort study in the SEER database. Int J Surg 2020;80:94-100. [PMID: 32619622 DOI: 10.1016/j.ijsu.2020.06.018] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
164 Nicolini A, Fasani P, Manini MA, Martinetti L, Forzenigo LV, Iavarone M, Crespi S, Rossi G, Biondetti P, Colombo M, Sangiovanni A. Transarterial embolization with microspheres in the treatment of monofocal HCC. Dig Liver Dis 2009;41:143-9. [PMID: 18436490 DOI: 10.1016/j.dld.2008.03.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
165 Rahimi R, Yopp A, Singal A. Current issues and future trends in surveillance for hepatocellular carcinoma. Clin Liver Disease. 2012;1:186-189. [PMID: 31186884 DOI: 10.1002/cld.115] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
166 Soriano A, Varona A, Gianchandani R, Moneva ME, Arranz J, Gonzalez A, Barrera M. Selection of patients with hepatocellular carcinoma for liver transplantation: Past and future. World J Hepatol 2016;8:58-68. [PMID: 26783421 DOI: 10.4254/wjh.v8.i1.58] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
167 Tanguturi SK, Wo JY, Zhu AX, Dawson LA, Hong TS. Radiation therapy for liver tumors: ready for inclusion in guidelines? Oncologist. 2014;19:868-879. [PMID: 25001265 DOI: 10.1634/theoncologist.2014-0097] [Cited by in Crossref: 42] [Cited by in F6Publishing: 25] [Article Influence: 6.0] [Reference Citation Analysis]
168 Ye JZ, Wang YY, Bai T, Chen J, Xiang BD, Wu FX, Li LQ. Surgical resection for hepatocellular carcinoma with portal vein tumor thrombus in the Asia-Pacific region beyond the Barcelona Clinic Liver Cancer treatment algorithms: a review and update. Oncotarget. 2017;8:93258-93278. [PMID: 29190996 DOI: 10.18632/oncotarget.18735] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
169 Cerrito L, Annicchiarico BE, Iezzi R, Gasbarrini A, Pompili M, Ponziani FR. Treatment of hepatocellular carcinoma in patients with portal vein tumor thrombosis: Beyond the known frontiers. World J Gastroenterol 2019;25:4360-82. [PMID: 31496618 DOI: 10.3748/wjg.v25.i31.4360] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 14] [Article Influence: 19.0] [Reference Citation Analysis]
170 Vilana R, Forner A, García Á, Ayuso C, Bru C. Carcinoma hepatocelular: diagnóstico, estadificación y estrategia terapéutica. Radiología 2010;52:385-98. [DOI: 10.1016/j.rx.2010.05.003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
171 Chen S, Peng Z, Wei M, Liu W, Dai Z, Wang H, Mei J, Cheong M, Zhang H, Kuang M. Sorafenib versus Transarterial chemoembolization for advanced-stage hepatocellular carcinoma: a cost-effectiveness analysis. BMC Cancer 2018;18:392. [PMID: 29621988 DOI: 10.1186/s12885-018-4308-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
172 Yang Q, Zhang W, Liu Q, Liu L, Wu L, Wang J, Yan Z, Luo J. TACE Combined with Implantation of Irradiation Stent Versus TACE Combine with Bare Stent for HCC Complicated by IVCTT. Cardiovasc Intervent Radiol 2016;39:1280-8. [DOI: 10.1007/s00270-016-1372-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
173 Kim Y, Ejaz A, Tayal A, Spolverato G, Bridges JF, Anders RA, Pawlik TM. Temporal trends in population-based death rates associated with chronic liver disease and liver cancer in the United States over the last 30 years. Cancer 2014;120:3058-65. [PMID: 24917245 DOI: 10.1002/cncr.28843] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 5.7] [Reference Citation Analysis]
174 Samonakis DN, Notas G, Christodoulakis N, Kouroumalis EA. Mechanisms of action and resistance of somatostatin analogues for the treatment of hepatocellular carcinoma: a message not well taken. Dig Dis Sci. 2008;53:2359-2365. [PMID: 18273705 DOI: 10.1007/s10620-007-0175-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
175 Rodriguez-Luna H, Balan V, Sharma P, Byrne T, Mulligan D, Rakela J, Vargas HE. Hepatitis C virus infection with hepatocellular carcinoma: not a controversial indication for liver transplantation. Transplantation. 2004;78:580-583. [PMID: 15446318 DOI: 10.1097/01.tp.0000129797.30999.69] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
176 Leykum LK, El-Serag HB, Cornell J, Papadopoulos KP. Screening for hepatocellular carcinoma among veterans with hepatitis C on disease stage, treatment received, and survival. Clin Gastroenterol Hepatol 2007;5:508-12. [PMID: 17382601 DOI: 10.1016/j.cgh.2007.01.014] [Cited by in Crossref: 55] [Cited by in F6Publishing: 47] [Article Influence: 3.9] [Reference Citation Analysis]
177 Wo JY, Dawson LA, Zhu AX, Hong TS. An emerging role for radiation therapy in the treatment of hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Surg Oncol Clin N Am. 2014;23:353-368. [PMID: 24560114 DOI: 10.1016/j.soc.2013.10.007] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
178 Stefaniuk P, Cianciara J, Wiercinska-Drapalo A. Present and future possibilities for early diagnosis of hepatocellular carcinoma. World J Gastroenterol. 2010;16:418-424. [PMID: 20101765 DOI: 10.3748/wjg.v16.i4.418] [Cited by in CrossRef: 111] [Cited by in F6Publishing: 98] [Article Influence: 10.1] [Reference Citation Analysis]
179 Wang W, Wang C, Shen J, Ren B, Yin Y, Yang J, Tang H, Zhu X, Ni C. Integrated I-125 Seed Implantation Combined with Transarterial Chemoembolization for Treatment of Hepatocellular Carcinoma with Main Portal Vein Tumor Thrombus. Cardiovasc Intervent Radiol 2021. [PMID: 34117503 DOI: 10.1007/s00270-021-02887-1] [Reference Citation Analysis]
180 Kirikoshi H, Saito S, Yoneda M, Fujita K, Mawatari H, Uchiyama T, Higurashi T, Goto A, Takahashi H, Abe Y. Outcome of transarterial chemoembolization monotherapy, and in combination with percutaneous ethanol injection, or radiofrequency ablation therapy for hepatocellular carcinoma. Hepatol Res. 2009;39:553-562. [PMID: 19527484 DOI: 10.1111/j.1872-034x.2009.00490.x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 14] [Article Influence: 2.7] [Reference Citation Analysis]
181 Gon H, Kido M, Tanaka M, Kinoshita H, Komatsu S, Tsugawa D, Awazu M, Toyama H, Matsumoto I, Itoh T, Fukumoto T. Growth velocity of the portal vein tumor thrombus accelerated by its progression, alpha-fetoprotein level, and liver fibrosis stage in patients with hepatocellular carcinoma. Surgery 2018;164:1014-22. [DOI: 10.1016/j.surg.2018.06.025] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
182 Haber PK, Puigvehí M, Castet F, Lourdusamy V, Montal R, Tabrizian P, Buckstein M, Kim E, Villanueva A, Schwartz M, Llovet JM. Evidence-Based Management of Hepatocellular Carcinoma: Systematic Review and Meta-analysis of Randomized Controlled Trials (2002-2020). Gastroenterology 2021;161:879-98. [PMID: 34126063 DOI: 10.1053/j.gastro.2021.06.008] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
183 Zhao Y, Zhu X, Wang H, Dong D, Gao S, Zhu X, Wang W. Safety and Efficacy of Transcatheter Arterial Chemoembolization Plus Radiotherapy Combined With Sorafenib in Hepatocellular Carcinoma Showing Macrovascular Invasion. Front Oncol. 2019;9:1065. [PMID: 31681599 DOI: 10.3389/fonc.2019.01065] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
184 Lafaro K, Grandhi MS, Herman JM, Pawlik TM. The importance of surgical margins in primary malignancies of the liver. J Surg Oncol. 2016;113:296-303. [PMID: 26659586 DOI: 10.1002/jso.24123] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 6.0] [Reference Citation Analysis]
185 Jarnagin W, Chapman WC, Curley S, D'Angelica M, Rosen C, Dixon E, Nagorney D;  American Hepato-Pancreato-Biliary Association;  Society of Surgical Oncology;  Society for Surgery of the Alimentary Tract. Surgical treatment of hepatocellular carcinoma: expert consensus statement. HPB (Oxford). 2010;12:302-310. [PMID: 20590903 DOI: 10.1111/j.1477-2574.2010.00182.x] [Cited by in Crossref: 71] [Cited by in F6Publishing: 56] [Article Influence: 7.1] [Reference Citation Analysis]
186 Sandrasegaran K, Tahir B, Nutakki K, Akisik FM, Bodanapally U, Tann M, Chalasani N. Usefulness of conventional MRI sequences and diffusion-weighted imaging in differentiating malignant from benign portal vein thrombus in cirrhotic patients. AJR Am J Roentgenol. 2013;201:1211-1219. [PMID: 24261359 DOI: 10.2214/ajr.12.10171] [Cited by in Crossref: 58] [Cited by in F6Publishing: 10] [Article Influence: 8.3] [Reference Citation Analysis]
187 Rostambeigi N, Dekarske AS, Austin EE, Golzarian J, Cressman EN. Cost effectiveness of radioembolization compared with conventional transarterial chemoembolization for treatment of hepatocellular carcinoma. J Vasc Interv Radiol. 2014;25:1075-1084. [PMID: 24861664 DOI: 10.1016/j.jvir.2014.04.014] [Cited by in Crossref: 30] [Cited by in F6Publishing: 23] [Article Influence: 4.3] [Reference Citation Analysis]
188 Zhu PP, Yuan SG, Liao Y, Qin LL, Liao WJ. High level of intercellular adhesion molecule-1 affects prognosis of patients with hepatocellular carcinoma. World J Gastroenterol. 2015;21:7254-7263. [PMID: 26109813 DOI: 10.3748/wjg.v21.i23.7254] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
189 Bremner KE, Bayoumi AM, Sherman M, Krahn MD. Management of solitary 1 cm to 2 cm liver nodules in patients with compensated cirrhosis: a decision analysis. Can J Gastroenterol 2007;21:491-500. [PMID: 17703248 DOI: 10.1155/2007/182383] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
190 Suarez Y, França AC, Llovet JM, Fuster J, Bruix J. THE CURRENT STATUS OF LIVER TRANSPLANTATION FOR PRIMARY HEPATIC MALIGNANCY. Clinics in Liver Disease 2000;4:591-605. [DOI: 10.1016/s1089-3261(05)70128-8] [Cited by in Crossref: 21] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
191 Yeh SA, Chen YS, Perng DS. The role of radiotherapy in the treatment of hepatocellular carcinoma with portal vein tumor thrombus. J Radiat Res 2015;56:325-31. [PMID: 25411553 DOI: 10.1093/jrr/rru104] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
192 Saxena A, Meteling B, Kapoor J, Golani S, Danta M, Morris DL, Bester L. Yttrium-90 radioembolization is a safe and effective treatment for unresectable hepatocellular carcinoma: a single centre experience of 45 consecutive patients. Int J Surg. 2014;12:1403-1408. [PMID: 25091398 DOI: 10.1016/j.ijsu.2014.07.269] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
193 Ban D, Shimada K, Yamamoto Y, Nara S, Esaki M, Sakamoto Y, Kosuge T. Efficacy of a hepatectomy and a tumor thrombectomy for hepatocellular carcinoma with tumor thrombus extending to the main portal vein. J Gastrointest Surg. 2009;13:1921-1928. [PMID: 19727969 DOI: 10.1007/s11605-009-0998-0] [Cited by in Crossref: 40] [Cited by in F6Publishing: 35] [Article Influence: 3.3] [Reference Citation Analysis]
194 Katamura Y, Aikata H, Kimura Y, Kawaoka T, Takaki S, Waki K, Hiramatsu A, Kawakami Y, Takahashi S, Ishikawa M, Hieda M, Kakizawa H, Chayama K. Intra-arterial 5-fluorouracil/interferon combination therapy for hepatocellular carcinoma with portal vein tumor thrombosis and extrahepatic metastases: Chemotherapy for hepatoma. Journal of Gastroenterology and Hepatology 2010;25:1117-22. [DOI: 10.1111/j.1440-1746.2009.06110.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
195 Pietrosi G, Miraglia R, Luca A, Vizzini GB, Fili' D, Riccardo V, D'Antoni A, Petridis I, Maruzzelli L, Biondo D, Gridelli B. Arterial chemoembolization/embolization and early complications after hepatocellular carcinoma treatment: a safe standardized protocol in selected patients with Child class A and B cirrhosis. J Vasc Interv Radiol. 2009;20:896-902. [PMID: 19497762 DOI: 10.1016/j.jvir.2009.03.032] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 2.0] [Reference Citation Analysis]
196 Changou CA, Shiah HS, Chen LT, Liu S, Luh F, Liu SH, Cheng YC, Yen Y. A Phase II Clinical Trial on the Combination Therapy of PHY906 Plus Capecitabine in Hepatocellular Carcinoma. Oncologist 2021;26:e367-73. [PMID: 33140457 DOI: 10.1002/onco.13582] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
197 Yoshidome H, Takeuchi D, Kimura F, Shimizu H, Ohtsuka M, Kato A, Furukawa K, Yoshitomi H, Miyazaki M. Treatment strategy for hepatocellular carcinoma with major portal vein or inferior vena cava invasion: a single institution experience. J Am Coll Surg. 2011;212:796-803. [PMID: 21530845 DOI: 10.1016/j.jamcollsurg.2011.01.002] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 3.1] [Reference Citation Analysis]
198 Yang B, You X, Yuan ML, Qin TQ, Duan LJ, He J, Fei ZJ, Zhou X, Zan RY, Liao ZY. Transarterial Ethanol Ablation Combined with Transarterial Chemoembolization for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. Hepat Mon. 2016;16:e37584. [PMID: 27799963 DOI: 10.5812/hepatmon.37584] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
199 Becker G, Soezgen T, Olschewski M, Laubenberger J, Blum HE, Allgaier HP. Combined TACE and PEI for palliative treatment of unresectable hepatocellular carcinoma. World J Gastroenterol 2005;11:6104-9. [PMID: 16273634 DOI: 10.3748/wjg.v11.i39.6104] [Cited by in CrossRef: 54] [Cited by in F6Publishing: 44] [Article Influence: 3.6] [Reference Citation Analysis]
200 Befeler AS, Di Bisceglie AM. Hepatocellular carcinoma: diagnosis and treatment. Gastroenterology. 2002;122:1609-1619. [PMID: 12016426 DOI: 10.1053/gast.2002.33411] [Cited by in Crossref: 374] [Cited by in F6Publishing: 342] [Article Influence: 19.7] [Reference Citation Analysis]
201 Kubota N, Ojima H, Hatano M, Yamazaki K, Masugi Y, Tsujikawa H, Fujii-Nishimura Y, Ueno A, Kurebayashi Y, Shinoda M, Kitago M, Abe Y, Kitagawa Y, Sakamoto M. Clinicopathological features of hepatocellular carcinoma with fatty change: Tumors with macrovesicular steatosis have better prognosis and aberrant expression patterns of perilipin and adipophilin. Pathol Int 2020;70:199-209. [PMID: 31930673 DOI: 10.1111/pin.12889] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
202 Kemp W, Pianko S, Nguyen S, Bailey MJ, Roberts SK. Survival in hepatocellular carcinoma: impact of screening and etiology of liver disease. J Gastroenterol Hepatol. 2005;20:873-881. [PMID: 15946134 DOI: 10.1111/j.1440-1746.2005.03844.x] [Cited by in Crossref: 45] [Cited by in F6Publishing: 40] [Article Influence: 3.0] [Reference Citation Analysis]
203 Varela M, Sala M, Llovet JM, Bruix J. Natural history and prognostic prediction of patients with hepatocellular carcinoma: REVIEW: NATURAL HISTORY AND PROGNOSTIC PREDICTION. Alimentary Pharmacology & Therapeutics 2003;17:98-102. [DOI: 10.1046/j.1365-2036.17.s2.11.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
204 Nitta H, Beppu T, Imai K, Hayashi H, Chikamoto A, Baba H. Adjuvant hepatic arterial infusion chemotherapy after hepatic resection of hepatocellular carcinoma with macroscopic vascular invasion. World J Surg. 2013;37:1034-1042. [PMID: 23435678 DOI: 10.1007/s00268-013-1957-1] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
205 Forner A, Ayuso C, Isabel Real M, Sastre J, Robles R, Sangro B, Varela M, de la Mata M, Buti M, Martí-Bonmatí L, Bru C, Tabernero J, Llovet JM, Bruix J. [Diagnosis and treatment of hepatocellular carcinoma]. Med Clin (Barc) 2009;132:272-87. [PMID: 19248879 DOI: 10.1016/j.medcli.2008.11.024] [Cited by in Crossref: 56] [Cited by in F6Publishing: 33] [Article Influence: 4.7] [Reference Citation Analysis]
206 Levy I, Sherman M. Staging of hepatocellular carcinoma: assessment of the CLIP, Okuda, and Child-Pugh staging systems in a cohort of 257 patients in Toronto. Gut. 2002;50:881-885. [PMID: 12010894 DOI: 10.1136/gut.50.6.881] [Cited by in Crossref: 171] [Cited by in F6Publishing: 151] [Article Influence: 9.0] [Reference Citation Analysis]
207 Adam R, Del Gaudio M. Evolution of liver transplantation for hepatocellular carcinoma. J Hepatol. 2003;39:888-895. [PMID: 14642602 DOI: 10.1016/j.jhep.2003.10.003] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 1.5] [Reference Citation Analysis]
208 Chuma M, Taguchi H, Yamamoto Y, Shimizu S, Nakanishi M, Ogawa K, Sho T, Horimoto H, Kobayashi T, Nakai M. Efficacy of therapy for advanced hepatocellular carcinoma: intra-arterial 5-fluorouracil and subcutaneous interferon with image-guided radiation. J Gastroenterol Hepatol. 2011;26:1123-1132. [PMID: 21501224 DOI: 10.1111/j.1440-1746.2011.06745.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.3] [Reference Citation Analysis]
209 Bae BK, Kim JC. The response of thrombosis in the portal vein or hepatic vein in hepatocellular carcinoma to radiation therapy. Radiat Oncol J 2016;34:168-76. [PMID: 27545294 DOI: 10.3857/roj.2016.01669] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
210 Tejeda-Maldonado J, García-Juárez I, Aguirre-Valadez J, González-Aguirre A, Vilatobá-Chapa M, Armengol-Alonso A, Escobar-Penagos F, Torre A, Sánchez-Ávila JF, Carrillo-Pérez DL. Diagnosis and treatment of hepatocellular carcinoma: An update. World J Hepatol 2015;7:362-76. [PMID: 25848464 DOI: 10.4254/wjh.v7.i3.362] [Cited by in Crossref: 70] [Cited by in F6Publishing: 60] [Article Influence: 11.7] [Reference Citation Analysis]
211 Villa E, Colantoni A, Cammà C, Grottola A, Buttafoco P, Gelmini R, Ferretti I, Manenti F. Estrogen receptor classification for hepatocellular carcinoma: comparison with clinical staging systems. J Clin Oncol 2003;21:441-6. [PMID: 12560432 DOI: 10.1200/JCO.2003.11.051] [Cited by in Crossref: 42] [Cited by in F6Publishing: 20] [Article Influence: 2.3] [Reference Citation Analysis]
212 Zhao C, Nguyen MH. Hepatocellular Carcinoma Screening and Surveillance: Practice Guidelines and Real-Life Practice. J Clin Gastroenterol. 2016;50:120-133. [PMID: 26583266 DOI: 10.1097/mcg.0000000000000446] [Cited by in Crossref: 32] [Cited by in F6Publishing: 11] [Article Influence: 6.4] [Reference Citation Analysis]
213 Lin DX, Zhang QY, Li X, Ye QW, Lin F, Li LL. An aggressive approach leads to improved survival in hepatocellular carcinoma patients with portal vein tumor thrombus. J Cancer Res Clin Oncol. 2011;137:139-149. [PMID: 20340033 DOI: 10.1007/s00432-010-0868-x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 29] [Article Influence: 3.3] [Reference Citation Analysis]
214 Krumeich LN, Mancinelli J, Cucchiara A, Eddinger K, Aufhauser D Jr, Goldberg DW, Siegelman ES, Rosen M, Reddy KR, Hoteit M, Furth EE, Olthoff KM, Shaked A, Levine M, Abt P. Occult Hepatocellular Carcinoma Associated With Transjugular Intrahepatic Portosystemic Shunts in Liver Transplant Recipients. Liver Transpl 2021;27:1248-61. [PMID: 33853207 DOI: 10.1002/lt.26073] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
215 Colombo M. Hepatocellular carcinoma in patients with HCV. Best Practice & Research Clinical Gastroenterology 2000;14:327-39. [DOI: 10.1053/bega.1999.0079] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
216 Chern MC, Chuang VP, Cheng T, Lin ZH, Lin YM. Transcatheter arterial chemoembolization for advanced hepatocellular carcinoma with inferior vena cava and right atrial tumors. Cardiovasc Intervent Radiol. 2008;31:735-744. [PMID: 18427894 DOI: 10.1007/s00270-008-9342-4] [Cited by in Crossref: 34] [Cited by in F6Publishing: 27] [Article Influence: 2.6] [Reference Citation Analysis]
217 Llovet JM, Bruix J. Prospective validation of the Cancer of the Liver Italian Program (CLIP) score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. Hepatology. 2000;32:679-680. [PMID: 10991637 DOI: 10.1053/jhep.2000.16475] [Cited by in Crossref: 89] [Cited by in F6Publishing: 84] [Article Influence: 4.2] [Reference Citation Analysis]
218 Talwalkar JA, Gores GJ. Diagnosis and staging of hepatocellular carcinoma. Gastroenterology. 2004;127:S126-S132. [PMID: 15508076 DOI: 10.1053/j.gastro.2004.09.026] [Cited by in Crossref: 88] [Cited by in F6Publishing: 66] [Article Influence: 5.2] [Reference Citation Analysis]
219 Singal AG, Marrero JA, Yopp A. Screening process failures for hepatocellular carcinoma. J Natl Compr Canc Netw 2014;12:375-82. [PMID: 24616543 DOI: 10.6004/jnccn.2014.0039] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 3.3] [Reference Citation Analysis]
220 Bolondi L, Sofia S, Siringo S, Gaiani S, Casali A, Zironi G, Piscaglia F, Gramantieri L, Zanetti M, Sherman M. Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis. Gut 2001;48:251-9. [PMID: 11156649 DOI: 10.1136/gut.48.2.251] [Cited by in Crossref: 455] [Cited by in F6Publishing: 392] [Article Influence: 22.8] [Reference Citation Analysis]
221 Lee HW, Suh K. Advancements of liver transplantation for hepatocellular carcinoma in Korea. Japanese Journal of Clinical Oncology 2017;47:93-100. [DOI: 10.1093/jjco/hyw168] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 1.6] [Reference Citation Analysis]
222 Yang MJ, An SY, Moon EJ, Lee MS, Hwang JA, Cheong JY, Won JH, Kim JK, Wang HJ, Cho SW. [Comparison of radiofrequency ablation and transarterial chemoembolization for the treatment of a single hepatocellular carcinoma smaller than 4 cm]. Korean J Hepatol. 2009;15:474-485. [PMID: 20037266 DOI: 10.3350/kjhep.2009.15.4.474] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
223 Perry JF, Charlton B, Koorey DJ, Waugh RC, Gallagher PJ, Crawford MD, Verran DJ, McCaughan GW, Strasser SI. Outcome of patients with hepatocellular carcinoma referred to a tertiary centre with availability of multiple treatment options including cadaveric liver transplantation. Liver Int. 2007;27:1240-1248. [PMID: 17919236 DOI: 10.1111/j.1478-3231.2007.01569.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.2] [Reference Citation Analysis]
224 Ni W, Zhang Y, Zhan Z, Ye F, Liang Y, Huang J, Chen K, Chen L, Ding Y. A novel lncRNA uc.134 represses hepatocellular carcinoma progression by inhibiting CUL4A-mediated ubiquitination of LATS1. J Hematol Oncol 2017;10:91. [PMID: 28420424 DOI: 10.1186/s13045-017-0449-4] [Cited by in Crossref: 83] [Cited by in F6Publishing: 82] [Article Influence: 20.8] [Reference Citation Analysis]
225 Llovet JM, Montal R, Villanueva A. Randomized trials and endpoints in advanced HCC: Role of PFS as a surrogate of survival. Journal of Hepatology 2019;70:1262-77. [DOI: 10.1016/j.jhep.2019.01.028] [Cited by in Crossref: 59] [Cited by in F6Publishing: 54] [Article Influence: 29.5] [Reference Citation Analysis]
226 Imedio ER, Beveridge RD, Urtasun JA, Campos GB, Estellés DL, Esparcia MF, Daroqui JC, Huerta ÁS, Ortiz AG, Salcedo JM. Safety and efficacy of sorafenib in the treatment of advanced hepatocellular carcinoma: a single center experience. Med Oncol 2014;31:948. [PMID: 24740650 DOI: 10.1007/s12032-014-0948-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
227 Colombo M. Screening for Cancer in Viral Hepatitis. Clinics in Liver Disease 2001;5:109-22. [DOI: 10.1016/s1089-3261(05)70156-2] [Cited by in Crossref: 33] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
228 Xing M, Kokabi N, Camacho JC, Kim HS. Prospective longitudinal quality of life and survival outcomes in patients with advanced infiltrative hepatocellular carcinoma and portal vein thrombosis treated with Yttrium-90 radioembolization. BMC Cancer 2018;18:75. [PMID: 29329568 DOI: 10.1186/s12885-017-3921-1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
229 Sugahara S, Nakayama H, Fukuda K, Mizumoto M, Tokita M, Abei M, Shoda J, Matsuzaki Y, Thono E, Tsuboi K, Tokuuye K. Proton-beam therapy for hepatocellular carcinoma associated with portal vein tumor thrombosis. Strahlenther Onkol. 2009;185:782-788. [PMID: 20013087 DOI: 10.1007/s00066-009-2020-x] [Cited by in Crossref: 79] [Cited by in F6Publishing: 59] [Article Influence: 6.6] [Reference Citation Analysis]
230 He M, Li Q, Zou R, Shen J, Fang W, Tan G, Zhou Y, Wu X, Xu L, Wei W, Le Y, Zhou Z, Zhao M, Guo Y, Guo R, Chen M, Shi M. Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial. JAMA Oncol. 2019;5:953-960. [PMID: 31070690 DOI: 10.1001/jamaoncol.2019.0250] [Cited by in Crossref: 62] [Cited by in F6Publishing: 49] [Article Influence: 62.0] [Reference Citation Analysis]
231 Maida M, Orlando E, Cammà C, Cabibbo G. Staging systems of hepatocellular carcinoma: a review of literature. World J Gastroenterol. 2014;20:4141-4150. [PMID: 24764652 DOI: 10.3748/wjg.v20.i15.4141] [Cited by in CrossRef: 59] [Cited by in F6Publishing: 54] [Article Influence: 9.8] [Reference Citation Analysis]
232 Zhang XP, Wang K, Li N, Zhong CQ, Wei XB, Cheng YQ, Gao YZ, Wang H, Cheng SQ. Survival benefit of hepatic resection versus transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: a systematic review and meta-analysis. BMC Cancer 2017;17:902. [PMID: 29282010 DOI: 10.1186/s12885-017-3895-z] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
233 Choi JH, Chung WJ, Bae SH, Song DS, Song MJ, Kim YS, Yim HJ, Jung YK, Suh SJ, Park JY, Kim DY, Kim SU, Cho SB. Randomized, prospective, comparative study on the effects and safety of sorafenib vs. hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis. Cancer Chemother Pharmacol. 2018;82:469-478. [PMID: 29982870 DOI: 10.1007/s00280-018-3638-0] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 8.7] [Reference Citation Analysis]
234 Wei XB, Xu J, Li N, Yu Y, Shi J, Guo WX, Cheng HY, Wu MC, Lau WY, Cheng SQ. The role of three-dimensional imaging in optimizing diagnosis, classification and surgical treatment of hepatocellular carcinoma with portal vein tumor thrombus. HPB (Oxford) 2016;18:287-95. [PMID: 27017169 DOI: 10.1016/j.hpb.2015.10.007] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
235 Golabi P, Jeffers T, Younoszai Z, Otgonsuren M, Sayiner M, Mishra A, Venkatesan C, Younossi ZM. Independent Predictors of Mortality and Resource Utilization in Viral Hepatitis Related Hepatocellular Carcinoma. Ann Hepatol 2017;16:555-64. [PMID: 28611258 DOI: 10.5604/01.3001.0010.0290] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
236 Wesolowski R, Chung JY, Singh A, Kim R. Hepatocellular carcinoma metastatic to uvea. Retin Cases Brief Rep 2010;4:178-80. [PMID: 25390396 DOI: 10.1097/ICB.0b013e31819f1fd3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
237 Zhang R, Guo H, Xu J, Li B, Liu YJ, Cheng C, Zhou C, Zhao Y, Liu Y. Activated platelets inhibit hepatocellular carcinoma cell differentiation and promote tumor progression via platelet-tumor cell binding. Oncotarget 2016;7:60609-22. [PMID: 27542264 DOI: 10.18632/oncotarget.11300] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
238 Saverio Ferrari F, Stella A, Pasquinucci P, Vigni F, Civeli L, Pieraccini M, Magnolfi F. Treatment of small hepatocellular carcinoma: a comparison of techniques and long-term results: . European Journal of Gastroenterology & Hepatology 2006;18:659-72. [DOI: 10.1097/00042737-200606000-00014] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
239 Hafeez Bhatti AB, Dar FS, Waheed A, Shafique K, Sultan F, Shah NH. Hepatocellular Carcinoma in Pakistan: National Trends and Global Perspective. Gastroenterol Res Pract 2016;2016:5942306. [PMID: 26955390 DOI: 10.1155/2016/5942306] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 2.4] [Reference Citation Analysis]
240 Bruix J, Llovet JM. Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology. 2002;35:519-524. [PMID: 11870363 DOI: 10.1053/jhep.2002.32089] [Cited by in Crossref: 801] [Cited by in F6Publishing: 717] [Article Influence: 42.2] [Reference Citation Analysis]
241 Vibert E, Azoulay D, Cunha AS, Adam R, Samuel D, Castaing D. Portal stenting for hepatocellular carcinoma extending into the portal vein in cirrhotic patients. J Surg Oncol. 2013;107:696-701. [PMID: 23280593 DOI: 10.1002/jso.23306] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
242 Yoo PS, Enestvedt CK, Kulkarni S. Anatomic Considerations in the Surgical Resection of Hepatocellular Carcinoma. Journal of Clinical Gastroenterology 2013;47:S11-5. [DOI: 10.1097/mcg.0b013e318280ce5f] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
243 Lee JS, Thorgeirsson SS. Comparative and integrative functional genomics of HCC. Oncogene 2006;25:3801-9. [PMID: 16799621 DOI: 10.1038/sj.onc.1209561] [Cited by in Crossref: 78] [Cited by in F6Publishing: 77] [Article Influence: 5.2] [Reference Citation Analysis]
244 Shen L, Xi M, Zhao L, Zhang X, Wang X, Huang Z, Chen Q, Zhang T, Shen J, Liu M, Huang J. Combination Therapy after TACE for Hepatocellular Carcinoma with Macroscopic Vascular Invasion: Stereotactic Body Radiotherapy versus Sorafenib. Cancers (Basel) 2018;10:E516. [PMID: 30558224 DOI: 10.3390/cancers10120516] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
245 Changchien CS, Chen CL, Yen YH, Wang JH, Hu TH, Lee CM, Wang CC, Cheng YF, Huang YJ, Lin CY. Analysis of 6381 hepatocellular carcinoma patients in southern Taiwan: prognostic features, treatment outcome, and survival. J Gastroenterol. 2008;43:159-170. [PMID: 18306990 DOI: 10.1007/s00535-007-2134-9] [Cited by in Crossref: 45] [Cited by in F6Publishing: 44] [Article Influence: 3.5] [Reference Citation Analysis]
246 Hollebecque A, Cattan S, Romano O, Sergent G, Mourad A, Louvet A, Dharancy S, Boleslawski E, Truant S, Pruvot FR. Safety and efficacy of sorafenib in hepatocellular carcinoma: the impact of the Child-Pugh score. Aliment Pharmacol Ther. 2011;34:1193-1201. [PMID: 21958438 DOI: 10.1111/j.1365-2036.2011.04860.x] [Cited by in Crossref: 79] [Cited by in F6Publishing: 70] [Article Influence: 7.9] [Reference Citation Analysis]
247 Singal AG, Yopp A, S Skinner C, Packer M, Lee WM, Tiro JA. Utilization of hepatocellular carcinoma surveillance among American patients: A systematic review. J Gen Intern Med. 2012;27:861-867. [PMID: 22215266 DOI: 10.1007/s11606-011-1952-x] [Cited by in Crossref: 166] [Cited by in F6Publishing: 136] [Article Influence: 18.4] [Reference Citation Analysis]
248 Chiew Woon L, Joycelyn Jie Xin L, Su Pin C. Nivolumab for the treatment of hepatocellular carcinoma. Expert Opinion on Biological Therapy 2020;20:687-93. [DOI: 10.1080/14712598.2020.1749593] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
249 Llovet JM, Sala M, Castells L, Suarez Y, Vilana R, Bianchi L, Ayuso C, Vargas V, Rodés J, Bruix J. Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma. Hepatology. 2000;31:54-58. [PMID: 10613728 DOI: 10.1002/hep.510310111] [Cited by in Crossref: 179] [Cited by in F6Publishing: 155] [Article Influence: 8.5] [Reference Citation Analysis]
250 Zhu Q, Luo M, Zhou C, Chen Z, Huang W, Huang J, Zhao S, Yu X. [Effect of danusertib on cell cycle, apoptosis and autophagy of hepatocellular carcinoma HepG2 cells in vitro]. Nan Fang Yi Ke Da Xue Xue Bao 2018;38:1476-84. [PMID: 30613017 DOI: 10.12122/j.issn.1673-4254.2018.12.13] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
251 Wang J, Wang FW. Refusal of cancer-directed surgery strongly impairs survival of patients with localized hepatocellular carcinoma. Int J Surg Oncol 2010;2010:381795. [PMID: 22312489 DOI: 10.1155/2010/381795] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
252 Ahn J, Flamm SL. Hepatocellular carcinoma. Dis Mon 2004;50:556-73. [PMID: 15616490 DOI: 10.1016/j.disamonth.2004.10.001] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 1.4] [Reference Citation Analysis]
253 Sapisochin G, Goldaracena N, Laurence JM, Dib M, Barbas A, Ghanekar A, Cleary SP, Lilly L, Cattral MS, Marquez M, Selzner M, Renner E, Selzner N, McGilvray ID, Greig PD, Grant DR. The extended Toronto criteria for liver transplantation in patients with hepatocellular carcinoma: A prospective validation study. Hepatology. 2016;64:2077-2088. [PMID: 27178646 DOI: 10.1002/hep.28643] [Cited by in Crossref: 148] [Cited by in F6Publishing: 121] [Article Influence: 29.6] [Reference Citation Analysis]
254 Willatt JM, Hussain HK, Adusumilli S, Marrero JA. MR Imaging of hepatocellular carcinoma in the cirrhotic liver: challenges and controversies. Radiology. 2008;247:311-330. [PMID: 18430871 DOI: 10.1148/radiol.2472061331] [Cited by in Crossref: 274] [Cited by in F6Publishing: 220] [Article Influence: 21.1] [Reference Citation Analysis]
255 Li Y, Liu F, Yang L, Meng Y, Li A, Pan M. External-beam radiation therapy versus surgery in the treatment of hepatocellular carcinoma with inferior vena cava/right atrium tumor thrombi. Asia Pac J Clin Oncol 2019;15:316-22. [PMID: 31309718 DOI: 10.1111/ajco.13194] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
256 Wu M, Schuster M, Tadros M. Update on Management of Portal Vein Thrombosis and the Role of Novel Anticoagulants. J Clin Transl Hepatol 2019;7:154-64. [PMID: 31293916 DOI: 10.14218/JCTH.2018.00057] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
257 Hata M, Tokuuye K, Sugahara S, Tohno E, Nakayama H, Fukumitsu N, Mizumoto M, Abei M, Shoda J, Minami M, Akine Y. Proton Beam Therapy for Aged Patients With Hepatocellular Carcinoma. International Journal of Radiation Oncology*Biology*Physics 2007;69:805-12. [DOI: 10.1016/j.ijrobp.2007.04.016] [Cited by in Crossref: 44] [Cited by in F6Publishing: 29] [Article Influence: 3.1] [Reference Citation Analysis]
258 Eichler K, Zangos S, Gruber-Rouh T, Vogl TJ, Mack MG. Magnetic resonance-guided laser-induced thermotherapy in patients with oligonodular hepatocellular carcinoma: long-term results over a 15-year period. J Clin Gastroenterol. 2012;46:796-801. [PMID: 22955262 DOI: 10.1097/mcg.0b013e3182641806] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 1.6] [Reference Citation Analysis]
259 Singal AG, Tiro JA, Gupta S. Improving hepatocellular carcinoma screening: applying lessons from colorectal cancer screening. Clin Gastroenterol Hepatol. 2013;11:472-477. [PMID: 23200983 DOI: 10.1016/j.cgh.2012.11.010] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 3.8] [Reference Citation Analysis]
260 Cheung CY, Lam MF, Chow KM, Lee W, Cheng YL, Yuen SK, Wong PN, Mo KL, Leung KT, Wong SH, Ho YW, Chau KF. Hepatocellular carcinoma after kidney transplantation: analysis of Hong Kong Renal Registry. Renal Failure 2014;36:865-9. [DOI: 10.3109/0886022x.2014.899879] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
261 Qiu B, Li K, Dong X, Liu FQ. Transjugular Intrahepatic Portosystemic Shunt for Portal Hypertension in Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. Cardiovasc Intervent Radiol. 2017;40:1372-1382. [PMID: 28488102 DOI: 10.1007/s00270-017-1655-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
262 Pinter M, Wichlas M, Schmid K, Plank C, Müller C, Wrba F, Peck-radosavljevic M. Thalidomide in advanced hepatocellular carcinoma as antiangiogenic treatment approach: a phase I/II trial: . European Journal of Gastroenterology & Hepatology 2008;20:1012-9. [DOI: 10.1097/meg.0b013e3283036740] [Cited by in Crossref: 14] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
263 Chen LJ, Chang YJ, Chang YJ. Survival Predictability Between the American Joint Committee on Cancer 8th Edition Staging System and the Barcelona Clinic Liver Cancer Classification in Patients with Hepatocellular Carcinoma. Oncologist 2021;26:e445-53. [PMID: 32969134 DOI: 10.1002/onco.13535] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
264 Ikeda M, Okusaka T, Ueno H, Morizane C, Iwasa S, Hagihara A, Kojima Y. Hepatic arterial infusion chemotherapy with epirubicin in patients with advanced hepatocellular carcinoma and portal vein tumor thrombosis. Oncology 2007;72:188-93. [PMID: 18097170 DOI: 10.1159/000112805] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
265 Kojiro S, Yano H, Ogasawara S, Momosaki S, Takemoto Y, Nishida N, Kojiro M. Antiproliferative effects of 5-fluorouracil and interferon-alpha in combination on a hepatocellular carcinoma cell line in vitro and in vivo. Journal of Gastroenterology and Hepatology 2006;21:129-37. [DOI: 10.1111/j.1440-1746.2005.04154.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
266 Kim MN, Kim BK, Kim SU, Park JY, Ahn SH, Han KH, Kim DY. Longitudinal assessment of alpha-fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis. Scand J Gastroenterol 2019;54:1283-90. [PMID: 31593481 DOI: 10.1080/00365521.2019.1673478] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
267 Young AL, Malik HZ, Abu-Hilal M, Guthrie JA, Wyatt J, Prasad KR, Toogood GJ, Lodge JP. Large hepatocellular carcinoma: time to stop preoperative biopsy. J Am Coll Surg. 2007;205:453-462. [PMID: 17765162 DOI: 10.1016/j.jamcollsurg.2007.04.033] [Cited by in Crossref: 35] [Cited by in F6Publishing: 24] [Article Influence: 2.5] [Reference Citation Analysis]
268 Ohira S, Kanayama N, Wada K, Ikawa T, Hirata T, Kishi N, Karino T, Washio H, Ueda Y, Miyazaki M, Koizumi M, Teshima T. Improvement of image quality and assessment of respiratory motion for hepatocellular carcinoma with portal vein tumor thrombosis using contrast-enhanced four-dimensional dual-energy computed tomography. PLoS One 2021;16:e0244079. [PMID: 33481820 DOI: 10.1371/journal.pone.0244079] [Reference Citation Analysis]
269 Zayed SA, Zahran NM, Khorshied MM, Abdel-Aziz AO, Mahmoud O, Morsy SA, Shousha HI, Elbaz TM, Nabeel MM, Harb ARK. Genetic variations in death receptor domain 4 gene and the susceptibility to hepatitis C related hepatocellular carcinoma. J Med Virol. 2019;91:1537-1544. [PMID: 30945308 DOI: 10.1002/jmv.25476] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
270 Tu T, Budzinska MA, Maczurek AE, Cheng R, Di Bartolomeo A, Warner FJ, McCaughan GW, McLennan SV, Shackel NA. Novel aspects of the liver microenvironment in hepatocellular carcinoma pathogenesis and development. Int J Mol Sci. 2014;15:9422-9458. [PMID: 24871369 DOI: 10.3390/ijms15069422] [Cited by in Crossref: 47] [Cited by in F6Publishing: 36] [Article Influence: 6.7] [Reference Citation Analysis]
271 Ribeiro de Souza A, Reig M, Bruix J. Systemic treatment for advanced hepatocellular carcinoma: the search of new agents to join sorafenib in the effective therapeutic armamentarium. Expert Opinion on Pharmacotherapy 2016;17:1923-36. [DOI: 10.1080/14656566.2016.1225722] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
272 Zamora-Valdes D, Taner T, Nagorney DM. Surgical Treatment of Hepatocellular Carcinoma. Cancer Control 2017;24:1073274817729258. [PMID: 28975836 DOI: 10.1177/1073274817729258] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 5.3] [Reference Citation Analysis]
273 Singal AG, Mukherjee A, Elmunzer BJ, Higgins PD, Lok AS, Zhu J, Marrero JA, Waljee AK. Machine learning algorithms outperform conventional regression models in predicting development of hepatocellular carcinoma. Am J Gastroenterol 2013;108:1723-30. [PMID: 24169273 DOI: 10.1038/ajg.2013.332] [Cited by in Crossref: 106] [Cited by in F6Publishing: 81] [Article Influence: 13.3] [Reference Citation Analysis]
274 Schwartz JD, Sung M, Schwartz M, Lehrer D, Mandeli J, Liebes L, Goldenberg A, Volm M. Thalidomide in advanced hepatocellular carcinoma with optional low-dose interferon-alpha2a upon progression. Oncologist 2005;10:718-27. [PMID: 16249352 DOI: 10.1634/theoncologist.10-9-718] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 1.9] [Reference Citation Analysis]
275 Wu FX, Lu HR, Zhu SL, Li ZH, Zou L, Bai T, Chen J, Yang TB, Liang SX. Efficacy of three-dimensional conformal radiotherapy combined with transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus. Onco Targets Ther 2016;9:7141-7. [PMID: 27942219 DOI: 10.2147/OTT.S113161] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
276 Araki K, Harimoto N, Yamanaka T, Ishii N, Tsukagoshi M, Igarashi T, Watanabe A, Kubo N, Tsushima Y, Shirabe K. Efficiency of regional functional liver volume assessment using Gd-EOB-DTPA-enhanced magnetic resonance imaging for hepatocellular carcinoma with portal vein tumor thrombus. Surg Today 2020;50:1496-506. [PMID: 32613270 DOI: 10.1007/s00595-020-02062-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
277 Kirstein MM, Voigtländer T, Schweitzer N, Hinrichs JB, Marquardt J, Wörns MA, Kloeckner R, Fründt TW, Ittrich H, Wacker F, Rodt T, Manns MP, Wege H, Weinmann A, Vogel A. Transarterial chemoembolization versus sorafenib in patients with hepatocellular carcinoma and extrahepatic disease. United European Gastroenterol J 2018;6:238-46. [PMID: 29511553 DOI: 10.1177/2050640617716597] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 2.8] [Reference Citation Analysis]
278 Lencioni R, Crocetti L. A Critical Appraisal of the Literature on Local Ablative Therapies for Hepatocellular Carcinoma. Clinics in Liver Disease 2005;9:301-14. [DOI: 10.1016/j.cld.2004.12.002] [Cited by in Crossref: 42] [Cited by in F6Publishing: 30] [Article Influence: 2.6] [Reference Citation Analysis]
279 Costentin CE, Decaens T, Laurent A, Nault J, Paule B, Letoublon C, Luciani A, Calderaro J, Adam R, Bricault I, Amaddeo G, Cherqui D, Mallat A, Samuel D, Duvoux C, Ganne-carrié N, Roudot-thoraval F, Vibert E. Sorafenib vs surgical resection for hepatocellular carcinoma with macrovascular invasion: A propensity score analysis. Liver Int 2017;37:1869-76. [DOI: 10.1111/liv.13491] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
280 Hussain A, Patel PJ, Rhodes F, Srivastava A, Patch D, Rosenberg W. Decompensated cirrhosis is the commonest presentation for NAFLD patients undergoing liver transplant assessment. Clin Med (Lond) 2020;20:313-8. [PMID: 32414722 DOI: 10.7861/clinmed.2019-0250] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
281 Onishi H, Nouso K, Nakamura S, Katsui K, Wada N, Morimoto Y, Miyahara K, Takeuchi Y, Kuwaki K, Yasunaka T. Efficacy of hepatic arterial infusion chemotherapy in combination with irradiation for advanced hepatocellular carcinoma with portal vein invasion. Hepatol Int. 2015;9:105-112. [PMID: 25788384 DOI: 10.1007/s12072-014-9592-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
282 Reichl P, Mikulits W. Accuracy of novel diagnostic biomarkers for hepatocellular carcinoma: An update for clinicians (Review). Oncol Rep. 2016;36:613-625. [PMID: 27278244 DOI: 10.3892/or.2016.4842] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 6.4] [Reference Citation Analysis]
283 Yamamoto Y, Ikoma H, Morimura R, Konishi H, Murayama Y, Komatsu S, Shiozaki A, Kuriu Y, Kubota T, Nakanishi M. Clinical analysis of anatomical resection for the treatment of hepatocellular carcinoma based on the stratification of liver function. World J Surg. 2014;38:1154-1163. [PMID: 24305927 DOI: 10.1007/s00268-013-2369-y] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.9] [Reference Citation Analysis]
284 Ishikawa T, Imai M, Kamimura H, Tsuchiya A, Togashi T, Watanabe K, Seki K, Ohta H, Yoshida T, Kamimura T. Improved survival for hepatocellular carcinoma with portal vein tumor thrombosis treated by intra-arterial chemotherapy combining etoposide, carboplatin, epirubicin and pharmacokinetic modulating chemotherapy by 5-FU and enteric-coated tegafur/uracil: a pilot study. World J Gastroenterol 2007;13:5465-70. [PMID: 17907289 DOI: 10.3748/wjg.v13.i41.5465] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.4] [Reference Citation Analysis]
285 Hagiwara S, Kudo M, Kawasaki T, Nagashima M, Minami Y, Chung H, Fukunaga T, Kitano M, Nakatani T. Prognostic factors for portal venous invasion in patients with hepatocellular carcinoma. J Gastroenterol. 2006;41:1214-1219. [PMID: 17287901 DOI: 10.1007/s00535-006-1950-7] [Cited by in Crossref: 42] [Cited by in F6Publishing: 34] [Article Influence: 3.0] [Reference Citation Analysis]
286 Oladeru OT, Miccio JA, Yang J, Xue Y, Ryu S, Stessin AM. Conformal external beam radiation or selective internal radiation therapy-a comparison of treatment outcomes for hepatocellular carcinoma. J Gastrointest Oncol 2016;7:433-40. [PMID: 27284477 DOI: 10.21037/jgo.2015.10.04] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 2.6] [Reference Citation Analysis]
287 Lee J, Lim KT. Phytoglycoprotein (38  kDa) induces cell cycle (G₀/G₁) arrest and apoptosis in HepG2 cells. J Cell Biochem 2011;112:3129-39. [PMID: 21695715 DOI: 10.1002/jcb.23239] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
288 Andersson KL, Salomon JA, Goldie SJ, Chung RT. Cost effectiveness of alternative surveillance strategies for hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol. 2008;6:1418-1424. [PMID: 18848905 DOI: 10.1016/j.cgh.2008.08.005] [Cited by in Crossref: 139] [Cited by in F6Publishing: 109] [Article Influence: 10.7] [Reference Citation Analysis]
289 Zhang YF, Le Y, Wei W, Zou RH, Wang JH, OuYang HY, Xiao CZ, Zhong XP, Shi M, Guo RP. Optimal surgical strategy for hepatocellular carcinoma with portal vein tumor thrombus: a propensity score analysis. Oncotarget 2016;7:38845-56. [PMID: 27072577 DOI: 10.18632/oncotarget.8642] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
290 Peng BG, He Q, Li JP, Zhou F. Adjuvant transcatheter arterial chemoembolization improves efficacy of hepatectomy for patients with hepatocellular carcinoma and portal vein tumor thrombus. Am J Surg. 2009;198:313-318. [PMID: 19285298 DOI: 10.1016/j.amjsurg.2008.09.026] [Cited by in Crossref: 87] [Cited by in F6Publishing: 87] [Article Influence: 7.3] [Reference Citation Analysis]
291 Lee JS, Heo J, Libbrecht L, Chu IS, Kaposi-Novak P, Calvisi DF, Mikaelyan A, Roberts LR, Demetris AJ, Sun Z, Nevens F, Roskams T, Thorgeirsson SS. A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med. 2006;12:410-416. [PMID: 16532004 DOI: 10.1038/nm1377] [Cited by in Crossref: 677] [Cited by in F6Publishing: 604] [Article Influence: 45.1] [Reference Citation Analysis]
292 Han DH, Joo DJ, Kim MS, Choi GH, Choi JS, Park YN, Seong J, Han KH, Kim SI. Living Donor Liver Transplantation for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis after Concurrent Chemoradiation Therapy. Yonsei Med J. 2016;57:1276-1281. [PMID: 27401662 DOI: 10.3349/ymj.2016.57.5.1276] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
293 Sayiner M, Golabi P, Younossi ZM. Disease Burden of Hepatocellular Carcinoma: A Global Perspective. Dig Dis Sci 2019;64:910-7. [DOI: 10.1007/s10620-019-05537-2] [Cited by in Crossref: 86] [Cited by in F6Publishing: 70] [Article Influence: 43.0] [Reference Citation Analysis]
294 Izzo F, Piccirillo M, Albino V, Palaia R, Belli A, Granata V, Setola S, Fusco R, Petrillo A, Orlando R, Tosone G, Scordino F, Curley SA. Prospective screening increases the detection of potentially curable hepatocellular carcinoma: results in 8,900 high-risk patients. HPB (Oxford) 2013;15:985-90. [PMID: 23607636 DOI: 10.1111/hpb.12080] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
295 Shetty SK, Rosen MP, Raptopoulos V, Goldberg SN. Cost-effectiveness of percutaneous radiofrequency ablation for malignant hepatic neoplasms. J Vasc Interv Radiol 2001;12:823-33. [PMID: 11435538 DOI: 10.1016/s1051-0443(07)61507-3] [Cited by in Crossref: 29] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
296 Murakami E, Aikata H, Miyaki D, Nagaoki Y, Katamura Y, Kawaoka T, Takaki S, Hiramatsu A, Waki K, Takahashi S. Hepatic arterial infusion chemotherapy using 5-fluorouracil and systemic interferon-α for advanced hepatocellular carcinoma in combination with or without three-dimensional conformal radiotherapy to venous tumor thrombosis in hepatic vein or inferior vena cava. Hepatol Res. 2012;42:442-453. [PMID: 22176468 DOI: 10.1111/j.1872-034x.2011.00943.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
297 Lee HJ, Kang HJ, Kim KM, Yu ES, Kim KH, Kim SM, Kim TW, Shim JH, Lim YS, Lee HC, Chung YH, Lee YS. Fibroblast growth factor receptor isotype expression and its association with overall survival in patients with hepatocellular carcinoma. Clin Mol Hepatol. 2015;21:60-70. [PMID: 25834803 DOI: 10.3350/cmh.2015.21.1.60] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
298 Yeung RH, Chapman TR, Bowen SR, Apisarnthanarax S. Proton beam therapy for hepatocellular carcinoma. Expert Rev Anticancer Ther. 2017;17:911-924. [PMID: 28825506 DOI: 10.1080/14737140.2017.1368392] [Cited by in Crossref: 18] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
299 Zhuang M, Xin G, Wei Z, Li S, Xing Z, Ji C, Du J, Niu H, Huang W. Dihydrodiosgenin inhibits endothelial cell-derived factor VIII and platelet-mediated hepatocellular carcinoma metastasis. Cancer Manag Res 2019;11:4871-82. [PMID: 31239763 DOI: 10.2147/CMAR.S202225] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 3.5] [Reference Citation Analysis]
300 Yamamoto T, Nagano H, Imai Y, Fukuda K, Matsumoto H, Kondo M, Ota H, Nakamura M, Wada H, Noda T, Damdinsuren B, Dono K, Umeshita K, Nakamori S, Sakon M, Wakasa K, Monden M. Successful treatment of multiple hepatocellular carcinoma with tumor thrombi in the major portal branches by intraarterial 5-fluorouracil perfusion chemotherapy combined with subcutaneous interferon-alpha and hepatectomy. Int J Clin Oncol 2007;12:150-4. [PMID: 17443284 DOI: 10.1007/s10147-006-0630-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
301 Sorrentino P, Tarantino L, D’Angelo S, Terracciano L, Ferbo U, Bracigliano A, Panico L, De Chiara G, Lepore M, De Stefano N. Validation of an extension of the international non-invasive criteria for the diagnosis of hepatocellular carcinoma to the characterization of macroscopic portal vein thrombosis. J Gastroenterol Hepatol. 2011;26:669-677. [PMID: 21054520 DOI: 10.1111/j.1440-1746.2010.06564.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
302 Ribero D, Abdalla EK, Thomas MB, Vauthey JN. Liver resection in the treatment of hepatocellular carcinoma. Expert Rev Anticancer Ther 2006;6:567-79. [PMID: 16613544 DOI: 10.1586/14737140.6.4.567] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
303 Llovet JM, Vilana R, Bianchi L, Brú C. [Radiofrequency in the treatment of hepatocellular carcinoma]. Gastroenterol Hepatol 2001;24:303-11. [PMID: 11459568 DOI: 10.1016/s0210-5705(01)70180-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
304 Evason KJ, Grenert JP, Ferrell LD, Kakar S. Atypical hepatocellular adenoma-like neoplasms with β-catenin activation show cytogenetic alterations similar to well-differentiated hepatocellular carcinomas. Hum Pathol. 2013;44:750-758. [PMID: 23084586 DOI: 10.1016/j.humpath.2012.07.019] [Cited by in Crossref: 58] [Cited by in F6Publishing: 40] [Article Influence: 6.4] [Reference Citation Analysis]
305 Azab M, Zaki S, El-Shetey AG, Abdel-Moty MF, Alnoomani NM, Gomaa AA, Abdel-Fatah S, Mohiy S, Atia F. Radiofrequency ablation combined with percutaneous ethanol injection in patients with hepatocellular carcinoma. Arab J Gastroenterol. 2011;12:113-118. [PMID: 22055587 DOI: 10.1016/j.ajg.2011.07.005] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
306 Kairaluoma V, Karjalainen M, Pohjanen VM, Saarnio J, Niemelä J, Huhta H, Helminen O. Treatment trends and outcomes of hepatocellular carcinoma in a single center for 35 years. Minerva Surg 2021;76:252-63. [PMID: 33890436 DOI: 10.23736/S2724-5691.21.08426-1] [Reference Citation Analysis]
307 Pawlik TM, Poon RT, Abdalla EK, Ikai I, Nagorney DM, Belghiti J, Kianmanesh R, Ng IO, Curley SA, Yamaoka Y. Hepatectomy for hepatocellular carcinoma with major portal or hepatic vein invasion: results of a multicenter study. Surgery. 2005;137:403-410. [PMID: 15800485 DOI: 10.1016/j.surg.2004.12.012] [Cited by in Crossref: 161] [Cited by in F6Publishing: 137] [Article Influence: 10.1] [Reference Citation Analysis]
308 Sieghart W, Hucke F, Peck-Radosavljevic M. Transarterial chemoembolization: modalities, indication, and patient selection. J Hepatol. 2015;62:1187-1195. [PMID: 25681552 DOI: 10.1016/j.jhep.2015.02.010] [Cited by in Crossref: 118] [Cited by in F6Publishing: 95] [Article Influence: 19.7] [Reference Citation Analysis]
309 Forner A, Rodríguez-Lopez C, Reig M. Natural history and staging for hepatocellular carcinoma. Clin Liver Dis (Hoboken) 2012;1:183-5. [PMID: 31186883 DOI: 10.1002/cld.129] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
310 Helton WS, Di Bisceglie A, Chari R, Schwartz M, Bruix J. Treatment strategies for hepatocellular carcinoma in cirrhosis. J Gastrointest Surg 2003;7:401-11. [PMID: 12654567 DOI: 10.1016/s1091-255x(02)00161-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
311 Chen X, Liu L, Pan X. Portal vein tumor thrombus in advanced hepatocellular carcinoma: A case report. Oncol Lett 2015;9:2495-8. [PMID: 26137096 DOI: 10.3892/ol.2015.3115] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
312 Han KH, Seong J, Kim JK, Ahn SH, Lee do Y, Chon CY. Pilot clinical trial of localized concurrent chemoradiation therapy for locally advanced hepatocellular carcinoma with portal vein thrombosis. Cancer. 2008;113:995-1003. [PMID: 18615601 DOI: 10.1002/cncr.23684] [Cited by in Crossref: 109] [Cited by in F6Publishing: 92] [Article Influence: 8.4] [Reference Citation Analysis]
313 Uka K, Aikata H, Takaki S, Miki D, Kawaoka T, Jeong SC, Takahashi S, Toyota N, Ito K, Chayama K. Pretreatment predictor of response, time to progression, and survival to intraarterial 5-fluorouracil/interferon combination therapy in patients with advanced hepatocellular carcinoma. J Gastroenterol. 2007;42:845-853. [PMID: 17940838 DOI: 10.1007/s00535-007-2099-8] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 2.9] [Reference Citation Analysis]
314 Kouroumalis E, Samonakis D, Skordilis P. Octreotide treatment of hepatocellular carcinoma. Hepatology 2003;37:477. [PMID: 12540801 DOI: 10.1053/jhep.2003.50026] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
315 Rim CH, Yoon WS. Leaflet manual of external beam radiation therapy for hepatocellular carcinoma: a review of the indications, evidences, and clinical trials. Onco Targets Ther. 2018;11:2865-2874. [PMID: 29844684 DOI: 10.2147/ott.s164651] [Cited by in Crossref: 18] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
316 Volk ML, Lok AS, Ubel PA, Vijan S. Beyond utilitarianism: a method for analyzing competing ethical principles in a decision analysis of liver transplantation. Med Decis Making 2008;28:763-72. [PMID: 18725405 DOI: 10.1177/0272989X08316999] [Cited by in Crossref: 14] [Cited by in F6Publishing: 3] [Article Influence: 1.1] [Reference Citation Analysis]
317 Zhou D, Liu X, Wang X, Yan F, Wang P, Yan H, Jiang Y, Yang Z. A prognostic nomogram based on LASSO Cox regression in patients with alpha-fetoprotein-negative hepatocellular carcinoma following non-surgical therapy. BMC Cancer 2021;21:246. [PMID: 33685417 DOI: 10.1186/s12885-021-07916-3] [Reference Citation Analysis]
318 Piscaglia F, Gianstefani A, Ravaioli M, Golfieri R, Cappelli A, Giampalma E, Sagrini E, Imbriaco G, Pinna AD, Bolondi L. Criteria for diagnosing benign portal vein thrombosis in the assessment of patients with cirrhosis and hepatocellular carcinoma for liver transplantation: Portal Vein Thrombosis and Hepatocellular Carcinoma. Liver Transpl 2010;16:658-67. [DOI: 10.1002/lt.22044] [Cited by in Crossref: 55] [Cited by in F6Publishing: 45] [Article Influence: 5.0] [Reference Citation Analysis]
319 Zhu K, Chen J, Lai L, Meng X, Zhou B, Huang W, Cai M, Shan H. Hepatocellular carcinoma with portal vein tumor thrombus: treatment with transarterial chemoembolization combined with sorafenib--a retrospective controlled study. Radiology. 2014;272:284-293. [PMID: 24708192 DOI: 10.1148/radiol.14131946] [Cited by in Crossref: 75] [Cited by in F6Publishing: 70] [Article Influence: 10.7] [Reference Citation Analysis]
320 Wang Y, Yuan L, Ge RL, Sun Y, Wei G. Survival benefit of surgical treatment for hepatocellular carcinoma with inferior vena cava/right atrium tumor thrombus: results of a retrospective cohort study. Ann Surg Oncol. 2013;20:914-922. [PMID: 22956071 DOI: 10.1245/s10434-012-2646-2] [Cited by in Crossref: 73] [Cited by in F6Publishing: 61] [Article Influence: 8.1] [Reference Citation Analysis]
321 Ikai I, Yamamoto Y, Yamamoto N, Terajima H, Hatano E, Shimahara Y, Yamaoka Y. Results of hepatic resection for hepatocellular carcinoma invading major portal and/or hepatic veins. Surgical Oncology Clinics of North America 2003;12:65-75. [DOI: 10.1016/s1055-3207(02)00082-0] [Cited by in Crossref: 70] [Cited by in F6Publishing: 32] [Article Influence: 3.9] [Reference Citation Analysis]
322 Kirstein MM, Wirth TC. Multimodale Therapie des hepatozellulären Karzinoms. Internist 2020;61:164-9. [DOI: 10.1007/s00108-019-00722-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
323 Giorgio A, Calisti G, Montesarchio L, Scognamiglio U, Matteucci P, Coppola C, Scarano F, Amendola F, Giorgio V. Hepatocellular carcinoma invading portal venous system in cirrhosis: long term results of percutaneous radiofrequency ablation of both the nodule and portal vein tumor thrombus. A case control study. Anticancer Res. 2014;34:6785-6790. [PMID: 25368292 DOI: 10.2214/ajr.08.2087] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
324 Kim DH, Cho E, Cho SB, Choi SK, Kim S, Yu J, Koh YI, Sim DW, Jun CH. Complete response of hepatocellular carcinoma with right atrium and pulmonary metastases treated by combined treatments (a possible treatment effect of natural killer cell): A case report and literature review. Medicine (Baltimore) 2018;97:e12866. [PMID: 30334999 DOI: 10.1097/MD.0000000000012866] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
325 Shehta A, Farouk A, Elghawalby AN, Elshobary M, Aboelenin A, Fouad A, Ali MA. Outcomes of Hepatic Resection for Hepatocellular Carcinoma Associated with Portal Vein Invasion. J Surg Res 2021;266:269-83. [PMID: 34038849 DOI: 10.1016/j.jss.2021.04.011] [Reference Citation Analysis]
326 Pons F, Varela M, Llovet JM. Staging systems in hepatocellular carcinoma. HPB (Oxford). 2005;7:35-41. [PMID: 18333159 DOI: 10.1080/13651820410024058] [Cited by in Crossref: 153] [Cited by in F6Publishing: 130] [Article Influence: 13.9] [Reference Citation Analysis]
327 Llovet JM, Mas X, Aponte JJ, Fuster J, Navasa M, Christensen E, Rodés J, Bruix J. Cost effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantation. Gut. 2002;50:123-128. [PMID: 11772979 DOI: 10.1136/gut.50.1.123] [Cited by in Crossref: 202] [Cited by in F6Publishing: 169] [Article Influence: 10.6] [Reference Citation Analysis]
328 Cosgrove DP, Reyes DK, Pawlik TM, Feng AL, Kamel IR, Geschwind JH. Open-Label Single-Arm Phase II Trial of Sorafenib Therapy with Drug-eluting Bead Transarterial Chemoembolization in Patients with Unresectable Hepatocellular Carcinoma: Clinical Results. Radiology 2015;277:594-603. [DOI: 10.1148/radiol.2015142481] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 3.5] [Reference Citation Analysis]
329 Nguyen VT, Law MG, Dore GJ. Hepatitis B-related hepatocellular carcinoma: epidemiological characteristics and disease burden. J Viral Hepat. 2009;16:453-463. [PMID: 19302335 DOI: 10.1111/j.1365-2893.2009.01117.x] [Cited by in Crossref: 185] [Cited by in F6Publishing: 189] [Article Influence: 15.4] [Reference Citation Analysis]
330 Li L, Liu Y, Guo Y, Liu B, Zhao Y, Li P, Song F, Zheng H, Yu J, Song T, Niu R, Li Q, Wang XW, Zhang W, Chen K. Regulatory MiR-148a-ACVR1/BMP circuit defines a cancer stem cell-like aggressive subtype of hepatocellular carcinoma. Hepatology. 2015;61:574-584. [PMID: 25271001 DOI: 10.1002/hep.27543] [Cited by in Crossref: 59] [Cited by in F6Publishing: 49] [Article Influence: 9.8] [Reference Citation Analysis]
331 Zhu Y, Dong M, Yang J, Zhang J. Evaluation of Iodine-125 Interstitial Brachytherapy Using Micro-Positron Emission Tomography/Computed Tomography with 18F-Fluorodeoxyglucose in Hepatocellular Carcinoma HepG2 Xenografts. Med Sci Monit 2019;25:371-80. [PMID: 30636171 DOI: 10.12659/MSM.912590] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
332 Befeler AS. Chemoembolization and bland embolization: a critical appraisal. Clin Liver Dis 2005;9:287-300, vii. [PMID: 15831274 DOI: 10.1016/j.cld.2004.12.011] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
333 Fernandes ESM, Rodrigues PD, Álvares-da-Silva MR, Scaffaro LA, Farenzena M, Teixeira UF, Waechter FL. Treatment strategies for locally advanced hepatocellular carcinoma. Transl Gastroenterol Hepatol 2019;4:12. [PMID: 30976715 DOI: 10.21037/tgh.2019.01.02] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
334 Tarantino L, Busto G, Nasto A, Fristachi R, Cacace L, Talamo M, Accardo C, Bortone S, Gallo P, Tarantino P, Nasto RA, Di Minno MN, Ambrosino P. Percutaneous electrochemotherapy in the treatment of portal vein tumor thrombosis at hepatic hilum in patients with hepatocellular carcinoma in cirrhosis: A feasibility study. World J Gastroenterol. 2017;23:906-918. [PMID: 28223736 DOI: 10.3748/wjg.v23.i5.906] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 25] [Article Influence: 6.8] [Reference Citation Analysis]
335 Singal AG, Chan V, Getachew Y, Guerrero R, Reisch JS, Cuthbert JA. Predictors of liver transplant eligibility for patients with hepatocellular carcinoma in a safety net hospital. Dig Dis Sci. 2012;57:580-586. [PMID: 21953138 DOI: 10.1007/s10620-011-1904-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
336 He SL, Shen J, Sun XJ, Zhu XJ, Liu LM, Dong JC. Efficacy of capecitabine and oxaliplatin regimen for extrahepatic metastasis of hepatocellular carcinoma following local treatments. World J Gastroenterol. 2013;19:4552-4558. [PMID: 23901232 DOI: 10.3748/wjg.v19.i28.4552] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
337 Tong AK, Kao YH, Too CW, Chin KF, Ng DC, Chow PK. Yttrium-90 hepatic radioembolization: clinical review and current techniques in interventional radiology and personalized dosimetry. Br J Radiol 2016;89:20150943. [PMID: 26943239 DOI: 10.1259/bjr.20150943] [Cited by in Crossref: 47] [Cited by in F6Publishing: 16] [Article Influence: 9.4] [Reference Citation Analysis]
338 Kim JH, Lee JM, Yoon JH, Lee DH, Lee KB, Han JK, Choi BI. Portal Vein Thrombosis in Patients with Hepatocellular Carcinoma: Diagnostic Accuracy of Gadoxetic Acid-enhanced MR Imaging. Radiology. 2016;279:773-783. [PMID: 26780538 DOI: 10.1148/radiol.2015150124] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 3.2] [Reference Citation Analysis]
339 Sotiropoulos GC, Bockhorn M, Sgourakis G, Brokalaki EI, Molmenti EP, Neuhäuser M, Radtke A, Wohlschlaeger J, Baba HA, Broelsch CE, Lang H. R0 Liver Resections for Primary Malignant Liver Tumors in the Noncirrhotic Liver: A Diagnosis-Related Analysis. Dig Dis Sci 2009;54:887-94. [DOI: 10.1007/s10620-008-0408-6] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
340 Kulik LM, Carr BI, Mulcahy MF, Lewandowski RJ, Atassi B, Ryu RK, Sato KT, Benson A 3rd, Nemcek AA Jr, Gates VL, Abecassis M, Omary RA, Salem R. Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology. 2008;47:71-81. [PMID: 18027884 DOI: 10.1002/hep.21980] [Cited by in Crossref: 401] [Cited by in F6Publishing: 327] [Article Influence: 30.8] [Reference Citation Analysis]
341 Takano M, Kokudo T, Miyazaki Y, Kageyama Y, Takahashi A, Amikura K, Sakamoto H. Complete response with sorafenib and transcatheter arterial chemoembolization in unresectable hepatocellular carcinoma. World J Gastroenterol 2016;22:9445-50. [PMID: 27895433 DOI: 10.3748/wjg.v22.i42.9445] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
342 Yoo D, Kim KM, Jin Y, Shim JH, Ko G, Yoon H, Sung K, Lee J, Kang Y, Lim Y, Lee HC, Chung Y, Lee YS, Suh DJ. Clinical outcome of 251 patients with extrahepatic metastasis at initial diagnosis of hepatocellular carcinoma: Does transarterial chemoembolization improve survival in these patients?: Efficacy of TACE in HCC with metastasis. Journal of Gastroenterology and Hepatology 2011;26:145-54. [DOI: 10.1111/j.1440-1746.2010.06341.x] [Cited by in Crossref: 73] [Cited by in F6Publishing: 60] [Article Influence: 6.6] [Reference Citation Analysis]
343 Singal AG, Nehra M, Adams-Huet B, Yopp AC, Tiro JA, Marrero JA, Lok AS, Lee WM. Detection of hepatocellular carcinoma at advanced stages among patients in the HALT-C trial: where did surveillance fail? Am J Gastroenterol. 2013;108:425-432. [PMID: 23337478 DOI: 10.1038/ajg.2012.449] [Cited by in Crossref: 133] [Cited by in F6Publishing: 117] [Article Influence: 16.6] [Reference Citation Analysis]
344 Bedossa P, Hytiroglou P, Yeh MM. Vascular Disorders. Macsween's Pathology of the Liver. Elsevier; 2018. pp. 636-72. [DOI: 10.1016/b978-0-7020-6697-9.00011-x] [Cited by in Crossref: 5] [Article Influence: 1.7] [Reference Citation Analysis]
345 Chen XP, Huang ZY. Surgical treatment of hepatocellular carcinoma in China: surgical techniques, indications, and outcomes. Langenbecks Arch Surg. 2005;390:259-265. [PMID: 15875211 DOI: 10.1007/s00423-005-0552-9] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.3] [Reference Citation Analysis]
346 Llovet JM, Fuster J, Bruix J. The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transpl. 2004;10:S115-S120. [PMID: 14762851 DOI: 10.1002/lt.20034] [Cited by in Crossref: 459] [Cited by in F6Publishing: 401] [Article Influence: 27.0] [Reference Citation Analysis]
347 Minagawa M, Makuuchi M, Takayama T, Ohtomo K. Selection criteria for hepatectomy in patients with hepatocellular carcinoma and portal vein tumor thrombus. Ann Surg. 2001;233:379-384. [PMID: 11224626 DOI: 10.1097/00000658-200103000-00012] [Cited by in Crossref: 149] [Cited by in F6Publishing: 124] [Article Influence: 7.5] [Reference Citation Analysis]
348 Liang RB, Zhao Y, He MK, Wen DS, Bu XY, Huang YX, Lai ZC, Xu YJ, Kan A, Wei W, Zhang YJ, Chen MS, Guo RP, Li QJ, Shi M. Hepatic Arterial Infusion Chemotherapy of Oxaliplatin, Fluorouracil, and Leucovorin With or Without Sorafenib as Initial Treatment for Advanced Hepatocellular Carcinoma. Front Oncol 2021;11:619461. [PMID: 34055599 DOI: 10.3389/fonc.2021.619461] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
349 Schotten C, Bechmann LP, Manka P, Theysohn J, Dechêne A, El Fouly A, Barbato F, Neumann U, Radünz S, Sydor S, Heider D, Venerito M, Canbay A, Gerken G, Herrmann K, Wedemeyer H, Best J. NAFLD-Associated Comorbidities in Advanced Stage HCC Do Not Alter the Safety and Efficacy of Yttrium-90 Radioembolization. Liver Cancer 2019;8:491-504. [PMID: 31799206 DOI: 10.1159/000501484] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
350 Yu WB, Rao A, Vu V, Xu L, Rao JY, Wu JX. Management of centrally located hepatocellular carcinoma: Update 2016. World J Hepatol 2017;9:627-34. [PMID: 28539990 DOI: 10.4254/wjh.v9.i13.627] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 5.5] [Reference Citation Analysis]
351 Truty MJ, Vauthey JN. Surgical resection of high-risk hepatocellular carcinoma: patient selection, preoperative considerations, and operative technique. Ann Surg Oncol. 2010;17:1219-1225. [PMID: 20405326 DOI: 10.1245/s10434-010-0976-5] [Cited by in Crossref: 59] [Cited by in F6Publishing: 52] [Article Influence: 5.4] [Reference Citation Analysis]
352 Singal A, Volk ML, Waljee A, Salgia R, Higgins P, Rogers MA, Marrero JA. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther. 2009;30:37-47. [PMID: 19392863 DOI: 10.1111/j.1365-2036.2009.04014.x] [Cited by in Crossref: 454] [Cited by in F6Publishing: 357] [Article Influence: 37.8] [Reference Citation Analysis]
353 Heinrich S, Sprinzl M, Schmidtmann I, Heil E, Koch S, Czauderna C, Heinrich B, Philippe P Diggs L, Wörns MA, Kloeckner R, Galle PR, Marquardt JU, Weinmann A. Validation of prognostic accuracy of MESH, HKLC, and BCLC classifications in a large German cohort of hepatocellular carcinoma patients. United European Gastroenterol J 2020;8:444-52. [PMID: 32213028 DOI: 10.1177/2050640620904524] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
354 Nakajima T, Moriguchi M, Mitsumoto Y, Katagishi T, Kimura H, Shintani H, Deguchi T, Okanoue T, Kagawa K, Ashihara T. Simple tumor profile chart based on cell kinetic parameters and histologic grade is useful for estimating the natural growth rate of hepatocellular carcinoma. Hum Pathol. 2002;33:92-99. [PMID: 11823978 DOI: 10.1053/hupa.2002.30194] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 1.2] [Reference Citation Analysis]
355 Hoshida Y, Shiratori Y, Omata M. Cost-effectiveness of adjuvant interferon therapy after surgical resection of Hepatitis C-related hepatocellular carcinoma: Interferon after resection of HCC. Liver 2002;22:479-85. [DOI: 10.1034/j.1600-0676.2002.01736.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
356 Cross TJS, Villanueva A, Shetty S, Wilkes E, Collins P, Adair A, Jones RL, Foxton MR, Meyer T, Stern N, Warshow U, Khan N, Prince M, Khakoo S, Alexander GJ, Khan S, Reeves H, Marshall A, Williams R. A national survey of the provision of ultrasound surveillance for the detection of hepatocellular carcinoma. Frontline Gastroenterol 2016;7:82-9. [PMID: 28840911 DOI: 10.1136/flgastro-2015-100617] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
357 Zeng ZC, Fan J, Tang ZY, Zhou J, Qin LX, Wang JH, Sun HC, Wang BL, Zhang JY, Jiang GL. A comparison of treatment combinations with and without radiotherapy for hepatocellular carcinoma with portal vein and/or inferior vena cava tumor thrombus. Int J Radiat Oncol Biol Phys. 2005;61:432-443. [PMID: 15667964 DOI: 10.1016/j.ijrobp.2004.05.025] [Cited by in Crossref: 136] [Cited by in F6Publishing: 111] [Article Influence: 8.5] [Reference Citation Analysis]
358 Zeeneldin AA, Salem SE, Darwish AD, El-Gammal MM, Hussein MM, Saadeldin M. Untreated hepatocellular carcinoma in Egypt: outcome and prognostic factors. J Hepatocell Carcinoma 2015;2:3-9. [PMID: 27508189 DOI: 10.2147/JHC.S73828] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
359 Garancini M, Pinotti E, Nespoli S, Romano F, Gianotti L, Giardini V. Hepatic resection beyond barcelona clinic liver cancer indication: When and how. World J Hepatol 2016;8:513-9. [PMID: 27099652 DOI: 10.4254/wjh.v8.i11.513] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
360 Marrero JA, Fontana RJ, Barrat A, Askari F, Conjeevaram HS, Su GL, Lok AS. Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology. 2005;41:707-716. [PMID: 15795889 DOI: 10.1002/hep.20636] [Cited by in Crossref: 443] [Cited by in F6Publishing: 383] [Article Influence: 27.7] [Reference Citation Analysis]
361 Liu PH, Lee YH, Hsia CY, Hsu CY, Huang YH, Chiou YY, Lin HC, Huo TI. Surgical resection versus transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombosis: a propensity score analysis. Ann Surg Oncol. 2014;21:1825-1833. [PMID: 24499831 DOI: 10.1245/s10434-014-3510-3] [Cited by in Crossref: 58] [Cited by in F6Publishing: 61] [Article Influence: 8.3] [Reference Citation Analysis]
362 Liu X, Jang H, Khalili K, Kim TK, Atri M. Successful Integration of Contrast-enhanced US into Routine Abdominal Imaging. RadioGraphics 2018;38:1454-77. [DOI: 10.1148/rg.2018170152] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
363 Lee JH, Kim DH, Ki YK, Nam JH, Heo J, Woo HY, Kim DW, Kim WT. Three-dimensional conformal radiotherapy for portal vein tumor thrombosis alone in advanced hepatocellular carcinoma. Radiat Oncol J. 2014;32:170-178. [PMID: 25324989 DOI: 10.3857/roj.2014.32.3.170] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
364 Koo JE, Kim JH, Lim YS, Park SJ, Won HJ, Sung KB, Suh DJ. Combination of transarterial chemoembolization and three-dimensional conformal radiotherapy for hepatocellular carcinoma with inferior vena cava tumor thrombus. Int J Radiat Oncol Biol Phys. 2010;78:180-187. [PMID: 19926229 DOI: 10.1016/j.ijrobp.2009.07.1730] [Cited by in Crossref: 68] [Cited by in F6Publishing: 52] [Article Influence: 5.7] [Reference Citation Analysis]
365 Figueras J, Ibáñez L, Ramos E, Rafecas A, Fabregat J, Torras J, Jaurrieta E, Valls C, Serrano T, Camprubí I, Xiol X. La resección es un buen tratamiento del hepatocarcinoma sobre el hígado cirrótico en pacientes seleccionados. Cirugía Española 2002;71:28-33. [DOI: 10.1016/s0009-739x(02)71921-0] [Cited by in Crossref: 7] [Article Influence: 0.4] [Reference Citation Analysis]
366 Lin CY, Kee KM, Wang JH, Lee CM, Chen CL, Changchien CS, Hu TH, Cheng YF, Hsu HC, Wang CC. Is the Cancer of the Liver Italian Program system an adequate weighting for survival of hepatocellular carcinoma? Evaluation of intrascore prognostic value among 36 subgroups. Liver Int. 2009;29:74-81. [PMID: 18331238 DOI: 10.1111/j.1478-3231.2008.01702.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
367 Lee VH, Leung DK, Luk MY, Tong CC, Law MW, Ng SC, Wong KK, Poon RT, Kwong DL, Leung TW. Yttrium-90 radioembolization for advanced inoperable hepatocellular carcinoma. Onco Targets Ther 2015;8:3457-64. [PMID: 26640386 DOI: 10.2147/OTT.S92473] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
368 Chu HH, Chun SY, Kim JH, Kim PH, Il Gwon D, Ko HK, Kim N. A prediction model for overall survival after transarterial chemoembolization for hepatocellular carcinoma invading the hepatic vein or inferior vena cava. Eur Radiol 2021;31:4232-42. [PMID: 33241523 DOI: 10.1007/s00330-020-07536-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
369 Strassburg CP. HCC-Associated Liver Transplantation - Where Are the Limits and What Are the New Regulations? Visc Med 2016;32:263-71. [PMID: 27722163 DOI: 10.1159/000446385] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
370 Chan SL, Chong CC, Chan AW, Poon DM, Chok KS. Management of hepatocellular carcinoma with portal vein tumor thrombosis: Review and update at 2016. World J Gastroenterol 2016;22:7289-300. [PMID: 27621575 DOI: 10.3748/wjg.v22.i32.7289] [Cited by in CrossRef: 65] [Cited by in F6Publishing: 53] [Article Influence: 16.3] [Reference Citation Analysis]
371 Kim HC, Lee JH, Chung JW, Kang B, Yoon JH, Kim YJ, Lee HS, Jae HJ, Park JH. Transarterial chemoembolization with additional cisplatin infusion for hepatocellular carcinoma invading the hepatic vein. J Vasc Interv Radiol. 2013;24:274-283. [PMID: 23369561 DOI: 10.1016/j.jvir.2012.11.002] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 3.1] [Reference Citation Analysis]
372 Adhoute X, Penaranda G, Raoul JL, Le Treut P, Bollon E, Hardwigsen J, Castellani P, Perrier H, Bourlière M. Usefulness of staging systems and prognostic scores for hepatocellular carcinoma treatments. World J Hepatol 2016;8:703-15. [PMID: 27330679 DOI: 10.4254/wjh.v8.i17.703] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
373 Bruix J, Llovet JM. Prognostic assessment and evaluation of the benefits of treatment. J Clin Gastroenterol. 2002;35:S138-S142. [PMID: 12394217 DOI: 10.1097/00004836-200211002-00010] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 1.3] [Reference Citation Analysis]
374 Ahn YE, Suh SJ, Yim HJ, Seo YS, Yoon EL, Kim TH, Lee YS, Yim SY, Kim HR, Kang SH, Jung YK, Kim JH, Yeon JE, Um SH, Byun KS. Comparison of Sorafenib versus Hepatic Arterial Infusion Chemotherapy-Based Treatment for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis. Gut Liver. 2021;15:284-294. [PMID: 32307975 DOI: 10.5009/gnl19367] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
375 Sithinamsuwan P, Piratvisuth T, Tanomkiat W, Apakupakul N, Tongyoo S. Review of 336 patients with hepatocellular carcinoma at Songklanagarind Hospital. World J Gastroenterol 2000;6:339-43. [PMID: 11819593 DOI: 10.3748/wjg.v6.i3.339] [Cited by in CrossRef: 36] [Cited by in F6Publishing: 26] [Article Influence: 1.7] [Reference Citation Analysis]
376 van Malenstein H, van Pelt J, Verslype C. Molecular classification of hepatocellular carcinoma anno 2011. Eur J Cancer. 2011;47:1789-1797. [PMID: 21612914 DOI: 10.1016/j.ejca.2011.04.027] [Cited by in Crossref: 56] [Cited by in F6Publishing: 47] [Article Influence: 5.6] [Reference Citation Analysis]
377 Wang EA, Broadwell SR, Bellavia RJ, Stein JP. Selective internal radiation therapy with SIR-Spheres in hepatocellular carcinoma and cholangiocarcinoma. J Gastrointest Oncol. 2017;8:266-278. [PMID: 28480066 DOI: 10.21037/jgo.2016.11.08] [Cited by in Crossref: 17] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
378 Abdelaziz A, Elbaz T, Shousha HI, Mahmoud S, Ibrahim M, Abdelmaksoud A, Nabeel M. Efficacy and survival analysis of percutaneous radiofrequency versus microwave ablation for hepatocellular carcinoma: an Egyptian multidisciplinary clinic experience. Surg Endosc. 2014;28:3429-3434. [PMID: 24935203 DOI: 10.1007/s00464-014-3617-4] [Cited by in Crossref: 58] [Cited by in F6Publishing: 50] [Article Influence: 8.3] [Reference Citation Analysis]
379 Petrelli F, Coinu A, Borgonovo K, Cabiddu M, Ghilardi M, Lonati V, Barni S. Oxaliplatin-based chemotherapy: a new option in advanced hepatocellular carcinoma. a systematic review and pooled analysis. Clin Oncol (R Coll Radiol). 2014;26:488-496. [PMID: 24856442 DOI: 10.1016/j.clon.2014.04.031] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 3.9] [Reference Citation Analysis]
380 Abdalla EK, Denys A, Hasegawa K, Leung TW, Makuuchi M, Murthy R, Ribero D, Zorzi D, Vauthey JN, Torzilli G. Treatment of large and advanced hepatocellular carcinoma. Ann Surg Oncol. 2008;15:979-985. [PMID: 18236115 DOI: 10.1245/s10434-007-9727-7] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 1.6] [Reference Citation Analysis]
381 Keane FK, Wo JY, Zhu AX, Hong TS. Liver-Directed Radiotherapy for Hepatocellular Carcinoma. Liver Cancer 2016;5:198-209. [PMID: 27493895 DOI: 10.1159/000367764] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
382 Kuntz E, Kuntz H. Malignant liver tumours. Hepatology. Berlin: Springer Berlin Heidelberg; 2002. pp. 699-730. [DOI: 10.1007/978-3-662-04680-7_37] [Reference Citation Analysis]
383 Guss D, Sherigar J, Mohanty SR. Missed Diagnosis of Liver Cirrhosis Leads to Disparities in Care for Older Patients. Gastroenterology Res 2018;11:333-9. [PMID: 30344803 DOI: 10.14740/gr1074w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
384 Miranda Magalhaes Santos JM, Clemente Oliveira B, Araujo-Filho JAB, Assuncao-Jr AN, de M Machado FA, Carlos Tavares Rocha C, Horvat JV, Menezes MR, Horvat N. State-of-the-art in radiomics of hepatocellular carcinoma: a review of basic principles, applications, and limitations. Abdom Radiol (NY). 2020;45:342-353. [PMID: 31707435 DOI: 10.1007/s00261-019-02299-3] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 15.0] [Reference Citation Analysis]
385 Pracht M, Edeline J, Lenoir L, Latournerie M, Mesbah H, Audrain O, Rolland Y, Clément B, Raoul JL, Garin E. Lobar hepatocellular carcinoma with ipsilateral portal vein tumor thrombosis treated with yttrium-90 glass microsphere radioembolization: preliminary results. Int J Hepatol. 2013;2013:827649. [PMID: 23476792 DOI: 10.1155/2013/827649] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
386 Dollinger MM, Behrens CM, Lesske J, Behl S, Behrmann C, Fleig WE. Thymostimulin in advanced hepatocellular carcinoma: a phase II trial. BMC Cancer 2008;8:72. [PMID: 18366627 DOI: 10.1186/1471-2407-8-72] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
387 Liu Y, Zhang Q, Yang X, Li Y, Zhu B, Niu S, Huang Y, Hu Y, Wang X. Effects of various interventions on the occurrence of macrovascular invasion of hepatocellular carcinoma after the baseline serum γ-glutamyltransferase stratification. Onco Targets Ther 2019;12:1671-9. [PMID: 30881022 DOI: 10.2147/OTT.S184302] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
388 Luo J, Yan Z, Liu Q, Qu X, Wang J. Endovascular placement of iodine-125 seed strand and stent combined with chemoembolization for treatment of hepatocellular carcinoma with tumor thrombus in main portal vein. J Vasc Interv Radiol. 2011;22:479-489. [PMID: 21463757 DOI: 10.1016/j.jvir.2010.11.029] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 2.9] [Reference Citation Analysis]
389 Lee HS, Choi GH, Choi JS, Kim KS, Han K, Seong J, Ahn SH, Kim DY, Park JY, Kim SU, Kim BK. Surgical Resection After Down-Staging of Locally Advanced Hepatocellular Carcinoma by Localized Concurrent Chemoradiotherapy. Ann Surg Oncol 2014;21:3646-53. [DOI: 10.1245/s10434-014-3652-3] [Cited by in Crossref: 30] [Cited by in F6Publishing: 18] [Article Influence: 4.3] [Reference Citation Analysis]
390 Li SH, Wang QX, Sun P, Li Q, Yang ZY, Shi M, Wei W, Guo RP. Surgical Strategy for Hepatocellular Carcinoma Patients with Portal/Hepatic Vein Tumor Thrombosis. PLoS One. 2015;10:e0130021. [PMID: 26076461 DOI: 10.1371/journal.pone.0130021] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 4.2] [Reference Citation Analysis]
391 Katamura Y, Aikata H, Takaki S, Azakami T, Kawaoka T, Waki K, Hiramatsu A, Kawakami Y, Takahashi S, Kenjo M, Toyota N, Ito K, Chayama K. Intra-arterial 5-fluorouracil/interferon combination therapy for advanced hepatocellular carcinoma with or without three-dimensional conformal radiotherapy for portal vein tumor thrombosis. J Gastroenterol. 2009;44:492-502. [PMID: 19330281 DOI: 10.1007/s00535-009-0033-y] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 3.4] [Reference Citation Analysis]
392 Saccheri S, Lovaria A, Sangiovanni A, Nicolini A, De Fazio C, Ronchi G, Fasani P, Del Ninno E, Colombo M. Segmental Transcatheter Arterial Chemoembolization Treatment in Patients with Cirrhosis and Inoperable Hepatocellular Carcinomas. Journal of Vascular and Interventional Radiology 2002;13:995-9. [DOI: 10.1016/s1051-0443(07)61863-6] [Cited by in Crossref: 19] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
393 Uka K, Aikata H, Takaki S, Miki D, Jeong SC, Hiramatsu A, Kodama H, Shirakawa H, Kawakami Y, Takahashi S, Toyota N, Ito K, Chayama K. Similar effects of recombinant interferon-?-2b and natural interferon-? when combined with intra-arterial 5-fluorouracil for the treatment of advanced hepatocellular carcinoma. Liver Int 2007;0:070908015728003-???. [DOI: 10.1111/j.1478-3231.2007.01554.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 10] [Article Influence: 0.1] [Reference Citation Analysis]
394 Liang L, Chen TH, Li C, Xing H, Han J, Wang MD, Zhang H, Lau WY, Wu MC, Shen F, Yang T. A systematic review comparing outcomes of surgical resection and non-surgical treatments for patients with hepatocellular carcinoma and portal vein tumor thrombus. HPB (Oxford). 2018;20:1119-1129. [PMID: 30056066 DOI: 10.1016/j.hpb.2018.06.1804] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
395 Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012;379:1245-1255. [PMID: 22353262 DOI: 10.1016/s0140-6736(11)61347-0] [Cited by in Crossref: 2892] [Cited by in F6Publishing: 1541] [Article Influence: 321.3] [Reference Citation Analysis]
396 Llovet JM, Villanueva A, Lachenmayer A, Finn RS. Advances in targeted therapies for hepatocellular carcinoma in the genomic era. Nat Rev Clin Oncol. 2015;12:408-424. [PMID: 26054909 DOI: 10.1038/nrclinonc.2015.103] [Cited by in Crossref: 260] [Cited by in F6Publishing: 233] [Article Influence: 43.3] [Reference Citation Analysis]
397 Chen J, Huang K, Wu J, Zhu H, Shi Y, Wang Y, Zhao G. Survival after anatomic resection versus nonanatomic resection for hepatocellular carcinoma: a meta-analysis. Dig Dis Sci. 2011;56:1626-1633. [PMID: 21082347 DOI: 10.1007/s10620-010-1482-0] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 3.6] [Reference Citation Analysis]
398 Kim KM, Kim JH, Park IS, Ko GY, Yoon HK, Sung KB, Lim YS, Lee HC, Chung YH, Lee YS. Reappraisal of repeated transarterial chemoembolization in the treatment of hepatocellular carcinoma with portal vein invasion. J Gastroenterol Hepatol. 2009;24:806-814. [PMID: 19207681 DOI: 10.1111/j.1440-1746.2008.05728.x] [Cited by in Crossref: 98] [Cited by in F6Publishing: 89] [Article Influence: 8.2] [Reference Citation Analysis]
399 Shimoda M, Iso Y, Tomita S, Fujimori T, Murakami K, Sawada T, Kubota K. Middle bile duct cancer with portal vein tumor thrombus. World J Surg Oncol 2008;6:48. [PMID: 18471304 DOI: 10.1186/1477-7819-6-48] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
400 Kee KM, Wang JH, Lee CM, Chen CL, Changchien CS, Hu TH, Cheng YF, Hsu HC, Wang CC, Chen TY, Lin CY, Lu SN. Validation of clinical AJCC/UICC TNM staging system for hepatocellular carcinoma: analysis of 5,613 cases from a medical center in southern Taiwan. Int J Cancer. 2007;120:2650-2655. [PMID: 17304512 DOI: 10.1002/ijc.22616] [Cited by in Crossref: 74] [Cited by in F6Publishing: 63] [Article Influence: 5.3] [Reference Citation Analysis]
401 Zhang X, Wang F, Gu G, Wu Q. High HBV Load Weakens Predictive Effect of Serum miR-122 on Response to Sorafenib in Hepatocellular Carcinoma Patients. J Oncol 2021;2021:9938207. [PMID: 34194500 DOI: 10.1155/2021/9938207] [Reference Citation Analysis]
402 Norikura T, Kojima-Yuasa A, Shimizu M, Huang X, Xu S, Kametani S, Rho SN, Kennedy DO, Matsui-Yuasa I. Mechanism of growth inhibitory effect of Blumea balsamifera extract in hepatocellular carcinoma. Biosci Biotechnol Biochem 2008;72:1183-9. [PMID: 18460811 DOI: 10.1271/bbb.70586] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
403 Murray LJ, Sykes J, Brierley J, Kim JJ, Wong RKS, Ringash J, Craig T, Velec M, Lindsay P, Knox JJ, Dawson LA. Baseline Albumin-Bilirubin (ALBI) Score in Western Patients With Hepatocellular Carcinoma Treated With Stereotactic Body Radiation Therapy (SBRT). Int J Radiat Oncol Biol Phys. 2018;101:900-909. [PMID: 29976502 DOI: 10.1016/j.ijrobp.2018.04.011] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
404 DuBay D, Sandroussi C, Sandhu L, Cleary S, Guba M, Cattral MS, McGilvray I, Ghanekar A, Selzner M, Greig PD, Grant DR. Liver transplantation for advanced hepatocellular carcinoma using poor tumor differentiation on biopsy as an exclusion criterion. Ann Surg. 2011;253:166-172. [PMID: 21294289 DOI: 10.1097/sla.0b013e31820508f1] [Cited by in Crossref: 170] [Cited by in F6Publishing: 83] [Article Influence: 17.0] [Reference Citation Analysis]
405 Lee HA, Rim CH. Efficacy of Local Treatments for Hepatocellular Carcinoma Involving the Inferior Vena Cava and/or Right Atrium. J Hepatocell Carcinoma 2020;7:435-46. [PMID: 33376712 DOI: 10.2147/JHC.S285357] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
406 Lee JW, Hwang SH, Kim DY, Han KH, Yun M. Prognostic Value of FDG Uptake of Portal Vein Tumor Thrombosis in Patients With Locally Advanced Hepatocellular Carcinoma. Clin Nucl Med. 2017;42:e35-e40. [PMID: 27775940 DOI: 10.1097/rlu.0000000000001422] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
407 Yu Y, Feng M. Radiotherapy for Hepatocellular Carcinoma. Semin Radiat Oncol 2018;28:277-87. [PMID: 30309638 DOI: 10.1016/j.semradonc.2018.06.005] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 4.3] [Reference Citation Analysis]
408 Lee JH, Kim HY, Kim YJ, Yoon JH, Chung JW, Lee HS. Barcelona Clinic Liver Cancer staging system and survival of untreated hepatocellular carcinoma in a hepatitis B virus endemic area. J Gastroenterol Hepatol. 2015;30:696-705. [PMID: 25250761 DOI: 10.1111/jgh.12788] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
409 Colombo M. Natural history and pathogenesis of hepatitis C virus related hepatocellular carcinoma. Journal of Hepatology 1999;31:25-30. [DOI: 10.1016/s0168-8278(99)80370-5] [Cited by in Crossref: 49] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
410 Trung TB, Hung VP, Hoang HT, Tung LM, Lee J. Detection of liver cancer cells by using ELISA and coupling of anti-glypican 3 antibody and magnetite nanoparticles. Geosystem Engineering 2015;18:219-25. [DOI: 10.1080/12269328.2015.1070698] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
411 Silva M, Moya A, Berenguer M, Sanjuan F, López-Andujar R, Pareja E, Torres-Quevedo R, Aguilera V, Montalva E, De Juan M. Expanded criteria for liver transplantation in patients with cirrhosis and hepatocellular carcinoma. Liver Transpl. 2008;14:1449-1460. [PMID: 18825681 DOI: 10.1002/lt.21576] [Cited by in Crossref: 73] [Cited by in F6Publishing: 64] [Article Influence: 6.1] [Reference Citation Analysis]
412 Jang JW, Bae SH, Choi JY, Oh HJ, Kim MS, Lee SY, Kim CW, Chang UI, Nam SW, Cha SB. A combination therapy with transarterial chemo-lipiodolization and systemic chemo-infusion for large extensive hepatocellular carcinoma invading portal vein in comparison with conservative management. Cancer Chemother Pharmacol. 2007;59:9-15. [PMID: 16614848 DOI: 10.1007/s00280-006-0239-0] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 1.5] [Reference Citation Analysis]
413 Freeman RB. Transplantation for hepatocellular carcinoma: The Milan criteria and beyond. Liver Transpl. 2006;12:S8-13. [PMID: 17051567 DOI: 10.1002/lt.20936] [Cited by in Crossref: 37] [Cited by in F6Publishing: 31] [Article Influence: 2.6] [Reference Citation Analysis]
414 Schwartz M. Liver transplantation for hepatocellular carcinoma. Gastroenterology. 2004;127:S268-S276. [PMID: 15508093 DOI: 10.1053/j.gastro.2004.09.041] [Cited by in Crossref: 115] [Cited by in F6Publishing: 99] [Article Influence: 6.8] [Reference Citation Analysis]
415 Di Marco V, De Vita F, Koskinas J, Semela D, Toniutto P, Verslype C. Sorafenib: from literature to clinical practice. Ann Oncol. 2013;24 Suppl 2:ii30-ii37. [PMID: 23715941 DOI: 10.1093/annonc/mdt055] [Cited by in Crossref: 54] [Cited by in F6Publishing: 49] [Article Influence: 6.8] [Reference Citation Analysis]
416 Son JH, Choi SH, Kim SY, Jang HY, Byun JH, Won HJ, Lee SJ, Lim YS. Validation of US Liver Imaging Reporting and Data System Version 2017 in Patients at High Risk for Hepatocellular Carcinoma. Radiology 2019;292:390-7. [PMID: 31210614 DOI: 10.1148/radiol.2019190035] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 11.0] [Reference Citation Analysis]
417 Yoo GS, Yu JI, Park HC. Proton therapy for hepatocellular carcinoma: Current knowledges and future perspectives. World J Gastroenterol 2018;24:3090-100. [PMID: 30065555 DOI: 10.3748/wjg.v24.i28.3090] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 13] [Article Influence: 7.3] [Reference Citation Analysis]
418 Uka K, Aikata H, Takaki S, Kawaoka T, Saneto H, Miki D, Takahashi S, Toyota N, Ito K, Chayama K. Systemic gemcitabine combined with intra-arterial low-dose cisplatin and 5-fluorouracil for advanced hepatocellular carcinoma: seven cases. World J Gastroenterol 2008;14:2602-8. [PMID: 18442216 DOI: 10.3748/wjg.14.2602] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
419 Rossi S, Ghittoni G, Ravetta V, Torello Viera F, Rosa L, Serassi M, Scabini M, Vercelli A, Tinelli C, Dal Bello B. Contrast-enhanced ultrasonography and spiral computed tomography in the detection and characterization of portal vein thrombosis complicating hepatocellular carcinoma. Eur Radiol. 2008;18:1749-1756. [PMID: 18369630 DOI: 10.1007/s00330-008-0931-z] [Cited by in Crossref: 87] [Cited by in F6Publishing: 67] [Article Influence: 6.7] [Reference Citation Analysis]
420 Kim PH, Choi SH, Kim JH, Park SH. Comparison of Radioembolization and Sorafenib for the Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: A Systematic Review and Meta-Analysis of Safety and Efficacy. Korean J Radiol. 2019;20:385-398. [PMID: 30799569 DOI: 10.3348/kjr.2018.0496] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 6.5] [Reference Citation Analysis]
421 Serenari M, Cappelli A, Cucchetti A, Mosconi C, Strigari L, Monari F, Ravaioli M, Rizzini EL, Fanti S, Golfieri R, Cescon M. Deceased Donor Liver Transplantation After Radioembolization for Hepatocellular Carcinoma and Portal Vein Tumoral Thrombosis: A Pilot Study. Liver Transpl 2021. [PMID: 34355489 DOI: 10.1002/lt.26257] [Reference Citation Analysis]
422 Li M, Zhao Y, Liu X, Dang Z, Wang X, Jiang Y, Yang Z. Association and interaction between model for end-stage liver disease score and minimally invasive treatment with regard to mortality of patients with hepatitis B virus-associated hepatocellular carcinoma and portal vein tumor thrombi. Oncol Lett 2019;17:119-26. [PMID: 30655746 DOI: 10.3892/ol.2018.9590] [Reference Citation Analysis]
423 Arguedas MR. Screening for hepatocellular carcinoma: Why, when, how? Curr Gastroenterol Rep 2003;5:57-62. [DOI: 10.1007/s11894-003-0010-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
424 Kanwal F, Tapper EB, Ho C, Asrani SK, Ovchinsky N, Poterucha J, Flores A, Ankoma-Sey V, Luxon B, Volk M. Development of Quality Measures in Cirrhosis by the Practice Metrics Committee of the American Association for the Study of Liver Diseases. Hepatology. 2019;69:1787-1797. [PMID: 30586188 DOI: 10.1002/hep.30489] [Cited by in Crossref: 39] [Cited by in F6Publishing: 28] [Article Influence: 19.5] [Reference Citation Analysis]
425 Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. The Lancet 2003;362:1907-17. [DOI: 10.1016/s0140-6736(03)14964-1] [Cited by in Crossref: 3076] [Cited by in F6Publishing: 1215] [Article Influence: 170.9] [Reference Citation Analysis]
426 Shaw J, Patidar KR, Reuter B, Hajezifar N, Dharel N, Wade JB, Bajaj JS. Focused Education Increases Hepatocellular Cancer Screening in Patients with Cirrhosis Regardless of Functional Health Literacy. Dig Dis Sci 2021;66:2603-9. [PMID: 32889600 DOI: 10.1007/s10620-020-06583-x] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
427 Marrero JA, Kudo M, Bronowicki JP. The challenge of prognosis and staging for hepatocellular carcinoma. Oncologist. 2010;15 Suppl 4:23-33. [PMID: 21115578 DOI: 10.1634/theoncologist.2010-s4-23] [Cited by in Crossref: 79] [Cited by in F6Publishing: 42] [Article Influence: 7.9] [Reference Citation Analysis]
428 Yeh JL, Peng YC, Tung CF, Chen GH, Chow WK, Chang CS, Yeh HZ, Poon SK. Clinical predictors of large esophagogastric varices in patients with hepatocellular carcinoma. Dig Dis Sci. 2002;47:723-729. [PMID: 11991599 DOI: 10.1023/a:1014719428637] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
429 Xiao J, Xing F, Liu Y, Lv Y, Wang X, Ling MT, Gao H, Ouyang S, Yang M, Zhu J, Xia Y, So KF, Tipoe GL. Garlic-derived compound S-allylmercaptocysteine inhibits hepatocarcinogenesis through targeting LRP6/Wnt pathway. Acta Pharm Sin B 2018;8:575-86. [PMID: 30109182 DOI: 10.1016/j.apsb.2017.10.003] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
430 Cao Y, Ding W, Zhang J, Gao Q, Yang H, Cao W, Wang Z, Fang L, Du R. Significant Down-Regulation of Urea Cycle Generates Clinically Relevant Proteomic Signature in Hepatocellular Carcinoma Patients with Macrovascular Invasion. J Proteome Res 2019;18:2032-44. [DOI: 10.1021/acs.jproteome.8b00921] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
431 Asghar U, Meyer T. Are there opportunities for chemotherapy in the treatment of hepatocellular cancer? J Hepatol. 2012;56:686-695. [PMID: 21971559 DOI: 10.1016/j.jhep.2011.07.031] [Cited by in Crossref: 114] [Cited by in F6Publishing: 104] [Article Influence: 11.4] [Reference Citation Analysis]
432 Salgia R, Singal AG. Hepatocellular Carcinoma and Other Liver Lesions. Medical Clinics of North America 2014;98:103-18. [DOI: 10.1016/j.mcna.2013.09.003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
433 Peng S, Zhao Y, Xu F, Jia C, Xu Y, Dai C. An updated meta-analysis of randomized controlled trials assessing the effect of sorafenib in advanced hepatocellular carcinoma. PLoS One. 2014;9:e112530. [PMID: 25460347 DOI: 10.1371/journal.pone.0112530] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
434 Chen J, Huang J, Chen M, Yang K, Chen J, Wang J, Xu L, Zhou Z, Zhang Y. Transcatheter arterial chemoembolization (TACE) versus hepatectomy in hepatocellular carcinoma with macrovascular invasion: a meta-analysis of 1683 patients. J Cancer 2017;8:2984-91. [PMID: 28928890 DOI: 10.7150/jca.20978] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
435 Feng M, Ben-Josef E. Radiation therapy for hepatocellular carcinoma. Semin Radiat Oncol. 2011;21:271-277. [PMID: 21939856 DOI: 10.1016/j.semradonc.2011.05.002] [Cited by in Crossref: 67] [Cited by in F6Publishing: 51] [Article Influence: 7.4] [Reference Citation Analysis]
436 Yang M, Fang Z, Yan Z, Luo J, Liu L, Zhang W, Wu L, Ma J, Yang Q, Liu Q. Transarterial chemoembolisation (TACE) combined with endovascular implantation of an iodine-125 seed strand for the treatment of hepatocellular carcinoma with portal vein tumour thrombosis versus TACE alone: a two-arm, randomised clinical trial. J Cancer Res Clin Oncol. 2014;140:211-219. [PMID: 24374800 DOI: 10.1007/s00432-013-1568-0] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 4.1] [Reference Citation Analysis]
437 Zhu R, Weng D, Lu S, Lin D, Wang M, Chen D, Lv J, Li H, Lv F, Xi L, Zhou J, Ma D, Li N. Double-Dose Adenovirus-Mediated Adjuvant Gene Therapy Improves Liver Transplantation Outcomes in Patients with Advanced Hepatocellular Carcinoma. Human Gene Therapy 2018;29:251-8. [DOI: 10.1089/hum.2017.114] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
438 Ahrar K, Gupta S. Hepatic artery embolization for hepatocellular carcinoma: technique, patient selection, and outcomes. Surg Oncol Clin N Am. 2003;12:105-126. [PMID: 12735133 DOI: 10.1016/s1055-3207(02)00089-3] [Cited by in Crossref: 28] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
439 Lau WY, Teoh YL, Win KM, Lee RC, de Villa VH, Kim YH, Liang PC, Santos-Ocampo RS, Lo RH, Lim KB, Tai DW, Ng DC, Irani FG, Gogna A, Chow PK. Current role of selective internal radiation with yttrium-90 in liver tumors. Future Oncol 2016;12:1193-204. [PMID: 27007495 DOI: 10.2217/fon-2016-0035] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
440 Li N, Wei XB, Cheng SQ. Application of cystoscope in surgical treatment of hepatocellular carcinoma with portal vein tumor thrombus. World J Gastroenterol 2016;22:5297-300. [PMID: 27298574 DOI: 10.3748/wjg.v22.i22.5297] [Reference Citation Analysis]
441 Wada H, Nagano H, Noda T, Damdinsuren B, Marubashi S, Miyamoto A, Takeda Y, Umeshita K, Dono K, Sakon M, Wakasa K, Monden M. Complete remission of hepatocellular carcinoma with portal vein tumor thrombus and lymph node metastases by arterial infusion of 5-fluorouracil and interferon-α combination therapy following hepatic resection. J Gastroenterol 2007;42:501-6. [DOI: 10.1007/s00535-007-2028-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
442 Ye JZ, Zhang YQ, Ye HH, Bai T, Ma L, Xiang BD, Li LQ. Appropriate treatment strategies improve survival of hepatocellular carcinoma patients with portal vein tumor thrombus. World J Gastroenterol. 2014;20:17141-17147. [PMID: 25493028 DOI: 10.3748/wjg.v20.i45.17141] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 29] [Article Influence: 4.5] [Reference Citation Analysis]
443 Kamiyama T, Nakanishi K, Yokoo H, Kamachi H, Tahara M, Kakisaka T, Tsuruga Y, Todo S, Taketomi A. Analysis of the risk factors for early death due to disease recurrence or progression within 1 year after hepatectomy in patients with hepatocellular carcinoma. World J Surg Oncol. 2012;10:107. [PMID: 22697061 DOI: 10.1186/1477-7819-10-107] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 4.2] [Reference Citation Analysis]
444 Damdinsuren B, Nagano H, Wada H, Noda T, Natsag J, Marubashi S, Miyamoto A, Takeda Y, Umeshita K, Doki Y, Dono K, Monden M. Interferon alpha receptors are important for antiproliferative effect of interferon-alpha against human hepatocellular carcinoma cells. Hepatol Res 2007;37:77-83. [PMID: 17300701 DOI: 10.1111/j.1872-034X.2007.00007.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
445 Hamaoka M, Kobayashi T, Kuroda S, Iwako H, Okimoto S, Kimura T, Aikata H, Nagata Y, Chayama K, Ohdan H. Hepatectomy after down-staging of hepatocellular carcinoma with portal vein tumor thrombus using chemoradiotherapy: A retrospective cohort study. International Journal of Surgery 2017;44:223-8. [DOI: 10.1016/j.ijsu.2017.06.082] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
446 Shah TU, Semelka RC, Pamuklar E, Firat Z, Gerber RD, Shrestha R, Russo MW. The risk of hepatocellular carcinoma in cirrhotic patients with small liver nodules on MRI. Am J Gastroenterol 2006;101:533-40. [PMID: 16542290 DOI: 10.1111/j.1572-0241.2006.00450.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
447 Medhat E, Abdel Aziz A, Nabeel M, Elbaz T, Zakaria Z, Shousha H, Amer A, Fouad Fathalah W, Maher R, Musa S. Value of microwave ablation in treatment of large lesions of hepatocellular carcinoma. J Dig Dis. 2015;16:456-463. [PMID: 25958973 DOI: 10.1111/1751-2980.12259] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 5.0] [Reference Citation Analysis]
448 Feuerlein S, Boll DT, Gupta RT, Ringe KI, Marin D, Merkle EM. Gadoxetate Disodium–Enhanced Hepatic MRI: Dose-Dependent Contrast Dynamics of Hepatic Parenchyma and Portal Vein. American Journal of Roentgenology 2011;196:W18-24. [DOI: 10.2214/ajr.10.4387] [Cited by in Crossref: 30] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
449 Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M, Rodes J, EASL Panel of Experts on HCC. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol. 2001;35:421-430. [PMID: 11592607 DOI: 10.1016/s0168-8278(01)00130-1] [Cited by in Crossref: 3112] [Cited by in F6Publishing: 1010] [Article Influence: 163.8] [Reference Citation Analysis]
450 Liu L, Miao R, Yang H, Lu X, Zhao Y, Mao Y, Zhong S, Huang J, Sang X, Zhao H. Prognostic factors after liver resection for hepatocellular carcinoma: a single-center experience from China. Am J Surg. 2012;203:741-750. [PMID: 22177551 DOI: 10.1016/j.amjsurg.2011.05.010] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 2.8] [Reference Citation Analysis]
451 Chok KS, Cheung TT, Chan SC, Poon RT, Fan ST, Lo CM. Surgical outcomes in hepatocellular carcinoma patients with portal vein tumor thrombosis. World J Surg. 2014;38:490-496. [PMID: 24132826 DOI: 10.1007/s00268-013-2290-4] [Cited by in Crossref: 51] [Cited by in F6Publishing: 54] [Article Influence: 7.3] [Reference Citation Analysis]
452 Mahvash A, Murthy R, Odisio BC, Raghav KP, Girard L, Cheung S, Nguyen V, Ensor J, Gadani S, Elsayes KM, Abdel-Wahab R, Hassan M, Shalaby AS, Yao JC, Wallace MJ, Kaseb AO. Yttrium-90 resin microspheres as an adjunct to sorafenib in patients with unresectable hepatocellular carcinoma. J Hepatocell Carcinoma 2016;3:1-7. [PMID: 27574586 DOI: 10.2147/JHC.S62261] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
453 Zeng ZC, Fan J, Tang ZY, Zhou J, Wang JH, Wang BL, Guo W. Prognostic factors for patients with hepatocellular carcinoma with macroscopic portal vein or inferior vena cava tumor thrombi receiving external-beam radiation therapy. Cancer Sci. 2008;99:2510-2517. [PMID: 19032365 DOI: 10.1111/j.1349-7006.2008.00981.x] [Cited by in Crossref: 37] [Cited by in F6Publishing: 25] [Article Influence: 2.8] [Reference Citation Analysis]
454 Pacella CM, Bizzarri G, Cecconi P, Caspani B, Magnolfi F, Bianchini A, Anelli V, Pacella S, Rossi Z. Hepatocellular Carcinoma: Long-term Results of Combined Treatment with Laser Thermal Ablation and Transcatheter Arterial Chemoembolization. Radiology 2001;219:669-78. [DOI: 10.1148/radiology.219.3.r01ma02669] [Cited by in Crossref: 87] [Cited by in F6Publishing: 70] [Article Influence: 4.4] [Reference Citation Analysis]
455 Tandon P, Garcia-Tsao G. Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies. Liver Int. 2009;29:502-510. [PMID: 19141028 DOI: 10.1111/j.1478-3231.2008.01957.x] [Cited by in Crossref: 199] [Cited by in F6Publishing: 184] [Article Influence: 15.3] [Reference Citation Analysis]
456 Guglielmi A, Ruzzenente A, Conci S, Valdegamberi A, Vitali M, Bertuzzo F, De Angelis M, Mantovani G, Iacono C. Hepatocellular carcinoma: surgical perspectives beyond the barcelona clinic liver cancer recommendations. World J Gastroenterol. 2014;20:7525-7533. [PMID: 24976693 DOI: 10.3748/wjg.v20.i24.7525] [Cited by in CrossRef: 40] [Cited by in F6Publishing: 32] [Article Influence: 6.7] [Reference Citation Analysis]
457 Ryon EL, Kronenfeld JP, Lee RM, Yopp A, Wang A, Lee AY, Luu S, Hsu C, Silberfein E, Russell MC, Goel N, Merchant NB, Datta J. Surgical management of hepatocellular carcinoma patients with portal vein thrombosis: The United States Safety Net and Academic Center Collaborative Analysis. J Surg Oncol 2021;123:407-15. [PMID: 33125746 DOI: 10.1002/jso.26282] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
458 Singal AG, Yopp AC, Gupta S, Skinner CS, Halm EA, Okolo E, Nehra M, Lee WM, Marrero JA, Tiro JA. Failure rates in the hepatocellular carcinoma surveillance process. Cancer Prev Res (Phila) 2012;5:1124-30. [PMID: 22846843 DOI: 10.1158/1940-6207.CAPR-12-0046] [Cited by in Crossref: 120] [Cited by in F6Publishing: 67] [Article Influence: 13.3] [Reference Citation Analysis]
459 Yang JF, Lo CH, Lee MS, Lin CS, Dai YH, Shen PC, Chao HL, Huang WY. Stereotactic ablative radiotherapy versus conventionally fractionated radiotherapy in the treatment of hepatocellular carcinoma with portal vein invasion: a retrospective analysis. Radiat Oncol 2019;14:180. [PMID: 31640728 DOI: 10.1186/s13014-019-1382-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
460 Xi M, Zhang L, Zhao L, Li QQ, Guo SP, Feng ZZ, Deng XW, Huang XY, Liu MZ. Effectiveness of stereotactic body radiotherapy for hepatocellular carcinoma with portal vein and/or inferior vena cava tumor thrombosis. PLoS One 2013;8:e63864. [PMID: 23737955 DOI: 10.1371/journal.pone.0063864] [Cited by in Crossref: 78] [Cited by in F6Publishing: 71] [Article Influence: 9.8] [Reference Citation Analysis]
461 Tsai AL, Burke CT, Kennedy AS, Moore DT, Mauro MA, Dixon RD, Stavas JM, Bernard SA, Khandani AH, O’Neil BH. Use of yttrium-90 microspheres in patients with advanced hepatocellular carcinoma and portal vein thrombosis. J Vasc Interv Radiol. 2010;21:1377-1384. [PMID: 20691606 DOI: 10.1016/j.jvir.2010.04.027] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 3.1] [Reference Citation Analysis]
462 Novi M, Lauritano EC, Piscaglia AC, Barbaro B, Zocco MA, Pompili M, Gasbarrini A. Portal vein tumor thrombosis revascularization during sorafenib treatment for hepatocellular carcinoma. Am J Gastroenterol. 2009;104:1852-1854. [PMID: 19574982 DOI: 10.1038/ajg.2009.140] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
463 Sherman M. Hepatocellular carcinoma: screening and staging. Clin Liver Dis. 2011;15:323-324, vii-x. [PMID: 21689616 DOI: 10.1016/j.cld.2011.03.003] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 2.9] [Reference Citation Analysis]
464 Silva MF, Sherman M. Criteria for liver transplantation for HCC: what should the limits be? J Hepatol 2011;55:1137-47. [PMID: 21718672 DOI: 10.1016/j.jhep.2011.05.012] [Cited by in Crossref: 47] [Cited by in F6Publishing: 43] [Article Influence: 4.7] [Reference Citation Analysis]
465 Djokic M, Cemazar M, Bosnjak M, Dezman R, Badovinac D, Miklavcic D, Kos B, Stabuc M, Stabuc B, Jansa R, Popovic P, Smid LM, Sersa G, Trotovsek B. A Prospective Phase II Study Evaluating Intraoperative Electrochemotherapy of Hepatocellular Carcinoma. Cancers (Basel) 2020;12:E3778. [PMID: 33333941 DOI: 10.3390/cancers12123778] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
466 Huang M, Lin Q, Wang H, Chen J, Bai M, Wang L, Zhu K, Jiang Z, Guan S, Li Z, Qian J, Li M, Pang P, Shan H. Survival benefit of chemoembolization plus Iodine125 seed implantation in unresectable hepatitis B-related hepatocellular carcinoma with PVTT: a retrospective matched cohort study. Eur Radiol. 2016;26:3428-3436. [PMID: 26792430 DOI: 10.1007/s00330-015-4198-x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 4.4] [Reference Citation Analysis]
467 Shinoto M, Ebner DK, Yamada S. Particle Radiation Therapy for Gastrointestinal Cancers. Curr Oncol Rep 2016;18:17. [PMID: 26849660 DOI: 10.1007/s11912-016-0499-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
468 Lee J, Lim K. Apoptotic activity of ethanol extract from Styrax Japonica Siebold et al Zuccarini in HepG2 cells. Journal of Ethnopharmacology 2010;131:210-5. [DOI: 10.1016/j.jep.2010.06.026] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
469 Aldrighetti L, Pulitanò C, Catena M, Arru M, Guzzetti E, Halliday J, Ferla G. Liver resection with portal vein thrombectomy for hepatocellular carcinoma with vascular invasion. Ann Surg Oncol. 2009;16:1254. [PMID: 19277788 DOI: 10.1245/s10434-009-0383-y] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 2.0] [Reference Citation Analysis]
470 Dilou N, Patouillard B, Audigier JC. [Staging systems in hepatocellular carcinoma]. Gastroenterol Clin Biol 2004;28:359-66. [PMID: 15146151 DOI: 10.1016/s0399-8320(04)94936-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
471 Bruix J, Bru C. Rationale for Non-surgical Interventional Treatment of Hepatocellular Carcinoma. In: Bartolozzi C, Lencioni R, editors. Liver Malignancies. Berlin: Springer Berlin Heidelberg; 1999. pp. 245-53. [DOI: 10.1007/978-3-642-58641-5_16] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
472 Yu JI, Park JW, Park HC, Yoon SM, Lim DH, Lee JH, Lee HC, Kim SW, Kim JH. Clinical impact of combined transarterial chemoembolization and radiotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: An external validation study. Radiother Oncol. 2016;118:408-415. [PMID: 26830695 DOI: 10.1016/j.radonc.2015.11.019] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 4.2] [Reference Citation Analysis]
473 Chen X, Qiu F, Wu Z, Zhang Z, Huang Z, Chen Y, Zhang B, He S, Zhang W. Effects of Location and Extension of Portal Vein Tumor Thrombus on Long-Term Outcomes of Surgical Treatment for Hepatocellular Carcinoma. Ann Surg Oncol 2006;13:940-6. [DOI: 10.1245/aso.2006.08.007] [Cited by in Crossref: 86] [Cited by in F6Publishing: 55] [Article Influence: 5.7] [Reference Citation Analysis]
474 But DY, Lai CL, Yuen MF. Natural history of hepatitis-related hepatocellular carcinoma. World J Gastroenterol. 2008;14:1652-1656. [PMID: 18350595 DOI: 10.3748/wjg.14.1652.] [Reference Citation Analysis]
475 Hata M, Tokuuye K, Sugahara S, Fukumitsu N, Hashimoto T, Ohnishi K, Nemoto K, Ohara K, Matsuzaki Y, Akine Y. Proton beam therapy for hepatocellular carcinoma patients with severe cirrhosis. Strahlenther Onkol 2006;182:713-20. [PMID: 17149578 DOI: 10.1007/s00066-006-1564-2] [Cited by in Crossref: 42] [Cited by in F6Publishing: 29] [Article Influence: 3.0] [Reference Citation Analysis]
476 Masuoka HC, Rosen CB. Liver Transplantation for Hepatocellular Carcinoma: Expanding Frontiers and Building Bridges. Clinics in Liver Disease 2011;15:385-93. [DOI: 10.1016/j.cld.2011.03.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
477 Pawlik TM, Reyes DK, Cosgrove D, Kamel IR, Bhagat N, Geschwind JF. Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma. J Clin Oncol 2011;29:3960-7. [PMID: 21911714 DOI: 10.1200/JCO.2011.37.1021] [Cited by in Crossref: 196] [Cited by in F6Publishing: 112] [Article Influence: 19.6] [Reference Citation Analysis]
478 Chok KS, Ng KC, Lam CM, Ng KK, Poon RT, Fan ST. Selective portal vein clamping for radiofrequency ablation of hepatocellular carcinoma with portal vein invasion. J Gastrointest Surg 2005;9:489-93. [PMID: 15797228 DOI: 10.1016/j.gassur.2004.09.056] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
479 Liu C, Xing W, Si T, Yu H, Guo Z. Efficacy and safety of apatinib combined with transarterial chemoembolization for hepatocellular carcinoma with portal venous tumor thrombus: a retrospective study. Oncotarget 2017;8:100734-45. [PMID: 29246017 DOI: 10.18632/oncotarget.20140] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
480 Nusbaum JD, Smirniotopoulos J, Wright HC, Dash C, Parpia T, Shechtel J, Chang Y, Loffredo C, Shetty K. The Effect of Hepatocellular Carcinoma Surveillance in an Urban Population With Liver Cirrhosis. J Clin Gastroenterol. 2015;Epub ahead of print. [PMID: 25751372 DOI: 10.1097/mcg.0000000000000306] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
481 Kim JH, Yoon HK, Kim SY, Kim KM, Ko GY, Gwon DI, Sung KB. Transcatheter arterial chemoembolization vs. chemoinfusion for unresectable hepatocellular carcinoma in patients with major portal vein thrombosis. Aliment Pharmacol Ther. 2009;29:1291-1298. [PMID: 19392861 DOI: 10.1111/j.1365-2036.2009.04016.x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 41] [Article Influence: 3.3] [Reference Citation Analysis]
482 Baek YH, Kim KT, Lee SW, Jeong JS, Park BH, Nam KJ, Cho JH, Kim YH, Roh YH, Lee HS, Choi YM, Han SY. Efficacy of hepatic arterial infusion chemotherapy in advanced hepatocellular carcinoma. World J Gastroenterol 2012;18:3426-34. [PMID: 22807613 DOI: 10.3748/wjg.v18.i26.3426] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
483 Bai Y, Wu J, Zeng Y, Chen J, Wang S, Chen S, Qiu F, Zhou S, You S, Tian Y, Wang Y, Yan M. Nomogram for Predicting Long-Term Survival after Synchronous Resection for Hepatocellular Carcinoma and Inferior Vena Cava Tumor Thrombosis: A Multicenter Retrospective Study. J Oncol. 2020;2020:3264079. [PMID: 32322268 DOI: 10.1155/2020/3264079] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
484 Yoon SM, Ryoo BY, Lee SJ, Kim JH, Shin JH, An JH, Lee HC, Lim YS. Efficacy and Safety of Transarterial Chemoembolization Plus External Beam Radiotherapy vs Sorafenib in Hepatocellular Carcinoma With Macroscopic Vascular Invasion: A Randomized Clinical Trial. JAMA Oncol. 2018;4:661-669. [PMID: 29543938 DOI: 10.1001/jamaoncol.2017.5847] [Cited by in Crossref: 130] [Cited by in F6Publishing: 86] [Article Influence: 65.0] [Reference Citation Analysis]
485 Lee JM, Jang BK, Lee YJ, Choi WY, Choi SM, Chung WJ, Hwang JS, Kang KJ, Kim YH, Chauhan AK. Survival outcomes of hepatic resection compared with transarterial chemoembolization or sorafenib for hepatocellular carcinoma with portal vein tumor thrombosis. Clin Mol Hepatol. 2016;22:160-167. [PMID: 27044767 DOI: 10.3350/cmh.2016.22.1.160] [Cited by in Crossref: 46] [Cited by in F6Publishing: 44] [Article Influence: 9.2] [Reference Citation Analysis]
486 Iñarrairaegui M, Thurston KG, Bilbao JI, D'avola D, Rodriguez M, Arbizu J, Martinez-cuesta A, Sangro B. Radioembolization with Use of Yttrium-90 Resin Microspheres in Patients with Hepatocellular Carcinoma and Portal Vein Thrombosis. Journal of Vascular and Interventional Radiology 2010;21:1205-12. [DOI: 10.1016/j.jvir.2010.04.012] [Cited by in Crossref: 95] [Cited by in F6Publishing: 86] [Article Influence: 8.6] [Reference Citation Analysis]
487 Shi J, He Y, Sun J, Guo W, Li N, Xue J, Cheng S. The impact of sphingosine kinase 1 on the prognosis of hepatocellular carcinoma patients with portal vein tumor thrombus. Annals of Hepatology 2015;14:198-206. [DOI: 10.1016/s1665-2681(19)30782-3] [Cited by in Crossref: 9] [Article Influence: 1.5] [Reference Citation Analysis]
488 Morris-stiff G, Gomez D, de Liguori Carino N, Prasad K. Surgical management of hepatocellular carcinoma: Is the jury still out? Surgical Oncology 2009;18:298-321. [DOI: 10.1016/j.suronc.2008.08.003] [Cited by in Crossref: 39] [Cited by in F6Publishing: 32] [Article Influence: 3.3] [Reference Citation Analysis]
489 Marrero JA. Staging systems for hepatocellular carcinoma: should we all use the BCLC system? J Hepatol. 2006;44:630-632. [PMID: 16503077 DOI: 10.1016/j.jhep.2006.02.003] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
490 Lang H, Sotiropoulos GC, Brokalaki EI, Schmitz KJ, Bertona C, Meyer G, Frilling A, Paul A, Malagó M, Broelsch CE. Survival and recurrence rates after resection for hepatocellular carcinoma in noncirrhotic livers. J Am Coll Surg. 2007;205:27-36. [PMID: 17617329 DOI: 10.1016/j.jamcollsurg.2007.03.002] [Cited by in Crossref: 86] [Cited by in F6Publishing: 69] [Article Influence: 6.1] [Reference Citation Analysis]
491 Lencioni R. Management of hepatocellular carcinoma with transarterial chemoembolization in the era of systemic targeted therapy. Crit Rev Oncol Hematol. 2012;83:216-224. [PMID: 22142656 DOI: 10.1016/j.critrevonc.2011.10.008] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 2.6] [Reference Citation Analysis]
492 Majno PE, Sarasin FP, Mentha G, Hadengue A. Primary liver resection and salvage transplantation or primary liver transplantation in patients with single, small hepatocellular carcinoma and preserved liver function: An outcome-oriented decision analysis. Hepatology. 2000;31:899-906. [PMID: 10733546 DOI: 10.1053/he.2000.5763] [Cited by in Crossref: 234] [Cited by in F6Publishing: 215] [Article Influence: 11.1] [Reference Citation Analysis]
493 Meyer C, Pieper CC, Ahmadzadehfar H, Lampe NA, Matuschek EME, Maschke TA, Enkirch SJ, Essler M, Spengler U, Schild HH. Yttrium-90 radioembolization of unresectable hepatocellular carcinoma - a single center experience. Onco Targets Ther 2017;10:4773-85. [PMID: 29033589 DOI: 10.2147/OTT.S137519] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
494 Germani G, Pleguezuelo M, Gurusamy K, Meyer T, Isgrò G, Burroughs AK. Clinical outcomes of radiofrequency ablation, percutaneous alcohol and acetic acid injection for hepatocelullar carcinoma: A meta-analysis. Journal of Hepatology 2010;52:380-8. [DOI: 10.1016/j.jhep.2009.12.004] [Cited by in Crossref: 186] [Cited by in F6Publishing: 155] [Article Influence: 16.9] [Reference Citation Analysis]
495 Li SH, Wang QX, Yang ZY, Jiang W, Li C, Sun P, Wei W, Shi M, Guo RP. Prognostic value of the neutrophil-to-lymphocyte ratio for hepatocellular carcinoma patients with portal/hepatic vein tumor thrombosis. World J Gastroenterol. 2017;23:3122-3132. [PMID: 28533669 DOI: 10.3748/wjg.v23.i17.3122] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
496 Okazaki E, Yamamoto A, Nishida N, Hamuro M, Ogino R, Hosono M, Shimatani Y, Tsutsumi S, Hamamoto S, Sohgawa E, Jogo A, Miki Y. Three-dimensional conformal radiotherapy for locally advanced hepatocellular carcinoma with portal vein tumour thrombosis: evaluating effectiveness of the model for end-stage liver disease (MELD) score compared with the Child-Pugh classification. Br J Radiol 2016;89:20150945. [PMID: 27164029 DOI: 10.1259/bjr.20150945] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
497 Barreto SG, Brooke-Smith M, Dolan P, Wilson TG, Padbury RT, Chen JW. Cirrhosis and microvascular invasion predict outcomes in hepatocellular carcinoma. ANZ J Surg. 2013;83:331-335. [PMID: 22943449 DOI: 10.1111/j.1445-2197.2012.06196.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
498 Kirchhoff TD, Rudolph KL, Layer G, Chavan A, Greten TF, Rosenthal H, Kubicka S, Galanski M, Manns MP, Schild H. Chemoocclusion vs chemoperfusion for treatment of advanced hepatocellular carcinoma: a randomised trial. Eur J Surg Oncol. 2006;32:201-207. [PMID: 16373084 DOI: 10.1016/j.ejso.2005.11.003] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 1.7] [Reference Citation Analysis]
499 Lau WY, Sangro B, Chen PJ, Cheng SQ, Chow P, Lee RC, Leung T, Han KH, Poon RT. Treatment for hepatocellular carcinoma with portal vein tumor thrombosis: the emerging role for radioembolization using yttrium-90. Oncology. 2013;84:311-318. [PMID: 23615394 DOI: 10.1159/000348325] [Cited by in Crossref: 91] [Cited by in F6Publishing: 87] [Article Influence: 11.4] [Reference Citation Analysis]
500 Fong ZV, Tanabe KK. The clinical management of hepatocellular carcinoma in the United States, Europe, and Asia: A comprehensive and evidence-based comparison and review: Review of International HCC Guidelines. Cancer 2014;120:2824-38. [DOI: 10.1002/cncr.28730] [Cited by in Crossref: 153] [Cited by in F6Publishing: 140] [Article Influence: 21.9] [Reference Citation Analysis]
501 Li X, Guo W, Guo L, Lau WY, Ge N, Wang K, Cheng S. Should transarterial chemoembolization be given before or after intensity-modulated radiotherapy to treat patients with hepatocellular carcinoma with portal vein tumor thrombus? a propensity score matching study. Oncotarget 2018;9:24537-47. [PMID: 29849959 DOI: 10.18632/oncotarget.25224] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
502 Hata M, Tokuuye K, Sugahara S, Fukumitsu N, Hashimoto T, Ohnishi K, Nemoto K, Ohara K, Matsuzaki Y, Akine Y. Proton beam therapy for hepatocellular carcinoma with limited treatment options. Cancer 2006;107:591-8. [PMID: 16804931 DOI: 10.1002/cncr.22039] [Cited by in Crossref: 54] [Cited by in F6Publishing: 39] [Article Influence: 3.6] [Reference Citation Analysis]
503 Llovet JM, Bruix J. Early diagnosis and treatment of hepatocellular carcinoma. Baillieres Best Pract Res Clin Gastroenterol 2000;14:991-1008. [PMID: 11139351 DOI: 10.1053/bega.2000.0143] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 1.7] [Reference Citation Analysis]
504 Ikai I, Hatano E, Hasegawa S, Fujii H, Taura K, Uyama N, Shimahara Y. Prognostic index for patients with hepatocellular carcinoma combined with tumor thrombosis in the major portal vein. J Am Coll Surg. 2006;202:431-438. [PMID: 16500247 DOI: 10.1016/j.jamcollsurg.2005.11.012] [Cited by in Crossref: 64] [Cited by in F6Publishing: 57] [Article Influence: 4.3] [Reference Citation Analysis]
505 Hoshida Y, Moriyama M, Otsuka M, Kato N, Goto T, Taniguchi H, Shiratori Y, Seki N, Omata M. Identification of genes associated with sensitivity to 5-fluorouracil and cisplatin in hepatoma cells. J Gastroenterol 2002;37:92-5. [DOI: 10.1007/bf03326423] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
506 Zhang L, Hu B, Li W, Huang P, Zhang S, Zhong B, Ni C. 125I Irradiation Stent for Hepatocellular Carcinoma with Main Portal Vein Tumor Thrombosis: A Systematic Review. Cardiovasc Intervent Radiol 2020;43:196-203. [DOI: 10.1007/s00270-019-02346-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
507 Chu HH, Kim JH, Shim JH, Yoon SM, Kim PH, Alrashidi I. Chemoembolization Plus Radiotherapy Versus Chemoembolization Plus Sorafenib for the Treatment of Hepatocellular Carcinoma Invading the Portal Vein: A Propensity Score Matching Analysis. Cancers (Basel) 2020;12:E1116. [PMID: 32365655 DOI: 10.3390/cancers12051116] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 9.0] [Reference Citation Analysis]
508 Al-Kalbani A, Kamel Y. Y-90 microshperes in the treatment of unresectable hepatocellular carcinoma. Saudi J Gastroenterol. 2008;14:90-92. [PMID: 19568509 DOI: 10.4103/1319-3767.39627] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
509 Lee J, Thorgeirsson SS. Genome-scale profiling of gene expression in hepatocellular carcinoma: Classification, survival prediction, and identification of therapeutic targets. Gastroenterology 2004;127:S51-5. [DOI: 10.1053/j.gastro.2004.09.015] [Cited by in Crossref: 122] [Cited by in F6Publishing: 106] [Article Influence: 7.2] [Reference Citation Analysis]
510 Turner PM, Turner TJ. Validation of the crisis triage rating scale for psychiatric emergencies. Can J Psychiatry. 1991;36:651-654. [PMID: 1773400 DOI: 10.1136/gut.51.4.459] [Cited by in Crossref: 76] [Cited by in F6Publishing: 69] [Article Influence: 2.6] [Reference Citation Analysis]
511 Moya A, Berenguer M, Aguilera V, Juan FS, Nicolás D, Pastor M, López-Andujar R, Rayón M, Orbis F, Mora J. Hepatocellular carcinoma: Can it be considered a controversial indication for liver transplantation in centers with high rates of hepatitis C? Liver Transpl. 2002;8:1020-1027. [PMID: 12424715 DOI: 10.1053/jlts.2002.35664] [Cited by in Crossref: 46] [Cited by in F6Publishing: 36] [Article Influence: 2.6] [Reference Citation Analysis]
512 Li S, Lyu N, Han X, Li J, Lai J, He M, Deng H, Shi M, Wang H, Zhao M. Hepatic Artery Infusion Chemotherapy Using Fluorouracil, Leucovorin, and Oxaliplatin versus Transarterial Chemoembolization as Initial Treatment for Locally Advanced Hepatocellular Carcinoma: A Propensity Score-Matching Analysis. J Vasc Interv Radiol 2021;32:1267-1276.e1. [PMID: 34166806 DOI: 10.1016/j.jvir.2021.06.008] [Reference Citation Analysis]
513 Sun B, Luo M, Lu Z, Meng Y, Wu S, Wu M. Clinical studies of laser ablation in treatment of primary liver carcinoma-associated portal vein tumor thrombus. Clin Appl Thromb Hemost 2010;16:694-7. [PMID: 19833619 DOI: 10.1177/1076029609336857] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
514 Silva MF, Wigg AJ. Current controversies surrounding liver transplantation for hepatocellular carcinoma. J Gastroenterol Hepatol. 2010;25:1217-1226. [PMID: 20594247 DOI: 10.1111/j.1440-1746.2010.06335.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
515 Schwartz JM, Ham JM. Treatment of Hepatocellular Carcinoma. Curr Treat Options Gastroenterol 2003;6:465-72. [PMID: 14585235 DOI: 10.1007/s11938-003-0048-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
516 Niguma T, Mimura T, Tutui N. Adjuvant arterial infusion chemotherapy after resection of hepatocellular carcinoma with portal thrombosis: a pilot study. J Hepatobiliary Pancreat Surg. 2005;12:249-253. [PMID: 15995815 DOI: 10.1007/s00534-004-0969-5] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.1] [Reference Citation Analysis]
517 Eltabbakh M, Zaghla H, Abdel-Razek W, Elshinnawy H, Ezzat S, Gomaa A, Waked I. Utility and cost-effectiveness of screening for hepatocellular carcinoma in a resource-limited setting. Med Oncol 2015;32:432. [PMID: 25502085 DOI: 10.1007/s12032-014-0432-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
518 European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018;69:182-236. [PMID: 29628281 DOI: 10.1016/j.jhep.2018.03.019] [Cited by in Crossref: 2122] [Cited by in F6Publishing: 1594] [Article Influence: 707.3] [Reference Citation Analysis]
519 Hou JZ, Zeng ZC, Zhang JY, Fan J, Zhou J, Zeng MS. Influence of tumor thrombus location on the outcome of external-beam radiation therapy in advanced hepatocellular carcinoma with macrovascular invasion. Int J Radiat Oncol Biol Phys. 2012;84:362-368. [PMID: 22381903 DOI: 10.1016/j.ijrobp.2011.12.024] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 3.4] [Reference Citation Analysis]
520 Wei W, Chua MS, Grepper S, So SK. Blockade of Wnt-1 signaling leads to anti-tumor effects in hepatocellular carcinoma cells. Mol Cancer 2009;8:76. [PMID: 19778454 DOI: 10.1186/1476-4598-8-76] [Cited by in Crossref: 63] [Cited by in F6Publishing: 55] [Article Influence: 5.3] [Reference Citation Analysis]
521 Kirikoshi H, Yoneda M, Mawatari H, Fujita K, Imajo K, Kato S, Suzuki K, Kobayashi N, Kubota K, Maeda S. Is hepatic arterial infusion chemotherapy effective treatment for advanced hepatocellular carcinoma resistant to transarterial chemoembolization? World J Gastroenterol. 2012;18:1933-1939. [PMID: 22563174 DOI: 10.3748/wjg.v18.i16.1933] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
522 Villanueva A, Minguez B, Forner A, Reig M, Llovet JM. Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy. Annu Rev Med 2010;61:317-28. [PMID: 20059340 DOI: 10.1146/annurev.med.080608.100623] [Cited by in Crossref: 160] [Cited by in F6Publishing: 143] [Article Influence: 14.5] [Reference Citation Analysis]
523 Peng SY, Wang XA, Huang CY, Li JT, Hong DF, Wang YF, Xu B. Better surgical treatment method for hepatocellular carcinoma with portal vein tumor thrombus. World J Gastroenterol 2018;24:4527-35. [PMID: 30386102 DOI: 10.3748/wjg.v24.i40.4527] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
524 Lang H, Broelsch CE. [Liver resection and transplantation for hepatic tumors]. Internist (Berl) 2007;48:30-9. [PMID: 17195060 DOI: 10.1007/s00108-006-1780-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
525 Fuster J, Charco R, Llovet JM, Bruix J, García-Valdecasas JC. Liver transplantation in hepatocellular carcinoma. Transpl Int. 2005;18:278-282. [PMID: 15730486 DOI: 10.1111/j.1432-2277.2004.00046.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 1.4] [Reference Citation Analysis]
526 European Association For The Study Of The Liver. European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56:908-943. [PMID: 22424438 DOI: 10.1016/j.jhep.2011.12.001] [Cited by in Crossref: 3642] [Cited by in F6Publishing: 3142] [Article Influence: 404.7] [Reference Citation Analysis]
527 Ruzzenente A, Capra F, Pachera S, Iacono C, Piccirillo G, Lunardi M, Pistoso S, Valdegamberi A, D’onofrio M, Guglielmi A. Is Liver Resection Justified in Advanced Hepatocellular Carcinoma? Results of an Observational Study in 464 Patients. J Gastrointest Surg 2009;13:1313-20. [DOI: 10.1007/s11605-009-0903-x] [Cited by in Crossref: 53] [Cited by in F6Publishing: 48] [Article Influence: 4.4] [Reference Citation Analysis]
528 Itamoto T, Nakahara H, Tashiro H, Haruta N, Asahara T, Naito A, Ito K. Hepatic arterial infusion of 5-fluorouracil and cisplatin for unresectable or recurrent hepatocellular carcinoma with tumor thrombus of the portal vein. J Surg Oncol. 2002;80:143-148. [PMID: 12115797 DOI: 10.1002/jso.10116] [Cited by in Crossref: 50] [Cited by in F6Publishing: 47] [Article Influence: 2.6] [Reference Citation Analysis]
529 Tang H, Dong X, Hassan M, Abbruzzese JL, Li D. Body mass index and obesity- and diabetes-associated genotypes and risk for pancreatic cancer. Cancer Epidemiol Biomarkers Prev. 2011;20:779-792. [PMID: 21357378 DOI: 10.1158/1055-9965] [Cited by in F6Publishing: 28] [Reference Citation Analysis]
530 Aboul Enein AA, Khaled IAA, Khorshied MM, Abdel-Aziz AO, Zahran N, El Saeed AM, Shousha HI, Abdel Rahman HA. Genetic variations in DNA-repair genes (XRCC1, 3, and 7) and the susceptibility to hepatocellular carcinoma in a cohort of Egyptians. J Med Virol 2020. [PMID: 32281666 DOI: 10.1002/jmv.25873] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
531 Hamada A, Yamakado K, Nakatsuka A, Takaki H, Akeboshi M, Takeda K. Hepatic Arterial Infusion Chemotherapy with Use of an Implanted Port System in Patients with Advanced Hepatocellular Carcinoma: Prognostic Factors. Journal of Vascular and Interventional Radiology 2004;15:835-41. [DOI: 10.1097/01.rvi.0000128815.35555.0e] [Cited by in Crossref: 18] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
532 Lee HA, Park S, Seo YS, Yoon WS, Rim CH, On Behalf Of The Korean Liver Cancer Study Group. Benefits of Local Treatment Including External Radiotherapy for Hepatocellular Carcinoma with Portal Invasion. Biology (Basel) 2021;10:326. [PMID: 33919745 DOI: 10.3390/biology10040326] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
533 Liu S, Guo W, Shi J, Li N, Yu X, Xue J, Fu X, Chu K, Lu C, Zhao J. MicroRNA-135a contributes to the development of portal vein tumor thrombus by promoting metastasis in hepatocellular carcinoma. J Hepatol. 2012;56:389-396. [PMID: 21888875 DOI: 10.1016/j.jhep.2011.08.008] [Cited by in Crossref: 109] [Cited by in F6Publishing: 102] [Article Influence: 10.9] [Reference Citation Analysis]
534 Chaparro M, González Moreno L, Trapero-Marugán M, Medina J, Moreno-Otero R. Review article: pharmacological therapy for hepatocellular carcinoma with sorafenib and other oral agents. Aliment Pharmacol Ther 2008;28:1269-77. [PMID: 18808443 DOI: 10.1111/j.1365-2036.2008.03857.x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 37] [Article Influence: 3.3] [Reference Citation Analysis]
535 Djokic M, Cemazar M, Popovic P, Kos B, Dezman R, Bosnjak M, Zakelj MN, Miklavcic D, Potrc S, Stabuc B, Tomazic A, Sersa G, Trotovsek B. Electrochemotherapy as treatment option for hepatocellular carcinoma, a prospective pilot study. Eur J Surg Oncol. 2018;44:651-657. [PMID: 29402556 DOI: 10.1016/j.ejso.2018.01.090] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 10.0] [Reference Citation Analysis]
536 Kim RD, Hemming AW. Hepatocellular Carcinoma: Resection or Transplantation. J Gastrointest Surg 2009;13:1023-5. [DOI: 10.1007/s11605-008-0784-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
537 Yokoyama K, Anan A, Iwata K, Nishizawa S, Morihara D, Ueda S, Sakurai K, Iwashita H, Hirano G, Sakamoto M. Limitation of repeated radiofrequency ablation in hepatocellular carcinoma: proposal of a three (times) × 3 (years) index. J Gastroenterol Hepatol. 2012;27:1044-1050. [PMID: 22433056 DOI: 10.1111/j.1440-1746.2012.07134.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
538 Boatta E, Corona M, Cannavale A, Fanelli F, Cirelli C, de Medici L. Endovascular treatment of hepatocellular carcinoma with drug eluting microparticles (DC-Beads): CT evaluation of response to the treatment. Indian J Radiol Imaging 2013;23:126-33. [PMID: 24082476 DOI: 10.4103/0971-3026.116564] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
539 Sarpel U, Schwartz M. Liver transplantation for hepatocellular carcinoma. Hepatol Res. 2007;37 Suppl 2:S264-S266. [PMID: 17877492 DOI: 10.1111/j.1872-034x.2007.00194.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
540 Song DS, Song MJ, Bae SH, Chung WJ, Jang JY, Kim YS, Lee SH, Park JY, Yim HJ, Cho SB, Park SY, Yang JM. A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis. J Gastroenterol. 2015;50:445-454. [PMID: 25027973 DOI: 10.1007/s00535-014-0978-3] [Cited by in Crossref: 63] [Cited by in F6Publishing: 60] [Article Influence: 9.0] [Reference Citation Analysis]
541 Jiang JF, Lao YC, Yuan BH, Yin J, Liu X, Chen L, Zhong JH. Treatment of hepatocellular carcinoma with portal vein tumor thrombus: advances and challenges. Oncotarget 2017;8:33911-21. [PMID: 28430610 DOI: 10.18632/oncotarget.15411] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 10.3] [Reference Citation Analysis]
542 Lee JS. The mutational landscape of hepatocellular carcinoma. Clin Mol Hepatol 2015;21:220-9. [PMID: 26523267 DOI: 10.3350/cmh.2015.21.3.220] [Cited by in Crossref: 63] [Cited by in F6Publishing: 49] [Article Influence: 10.5] [Reference Citation Analysis]
543 Perry JF, Strasser SI, George J, Farrell GC, Mccaughan GW. Pharmacotherapy of hepatocellular carcinoma. Expert Opinion on Pharmacotherapy 2005;4:2175-85. [DOI: 10.1517/14656566.4.12.2175] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
544 Bruix J, Raoul JL, Sherman M, Mazzaferro V, Bolondi L, Craxi A, Galle PR, Santoro A, Beaugrand M, Sangiovanni A, Porta C, Gerken G, Marrero JA, Nadel A, Shan M, Moscovici M, Voliotis D, Llovet JM. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J Hepatol. 2012;57:821-829. [PMID: 22727733 DOI: 10.1016/j.jhep.2012.06.014] [Cited by in Crossref: 473] [Cited by in F6Publishing: 438] [Article Influence: 52.6] [Reference Citation Analysis]
545 Rathore R, Safran H, Soares G, Dubel G, McNulty B, Ahn S, Iannitti D, Kennedy T. Phase I study of hepatic arterial infusion of oxaliplatin in advanced hepatocellular cancer: a brown university oncology group study. Am J Clin Oncol. 2010;33:43-46. [PMID: 19687731 DOI: 10.1097/coc.0b013e31819d8668] [Cited by in Crossref: 18] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
546 Gelatti U, Donato F, Tagger A, Fantoni C, Portolani N, Ribero ML, Martelli C, Trevisi P, Covolo L, Simonati C. Etiology of hepatocellular carcinoma influences clinical and pathologic features but not patient survival. Am J Gastroenterol. 2003;98:907-914. [PMID: 12738476 DOI: 10.1111/j.1572-0241.2003.t01-1-07289.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 1.1] [Reference Citation Analysis]
547 Testa R, Testa E, Giannini E, Botta F, Malfatti F, Chiarbonello B, Fumagalli A, Polegato S, Podesta E, Romagnoli P. Trans-catheter arterial chemoembolisation for hepatocellular carcinoma in patients with viral cirrhosis: role of combined staging systems, Cancer Liver Italian Program (CLIP) and Model for End-stage Liver Disease (MELD), in predicting outcome after treatment. Aliment Pharmacol Ther. 2003;17:1563-1569. [PMID: 12823161 DOI: 10.1046/j.1365-2036.2003.01647.x] [Cited by in Crossref: 42] [Cited by in F6Publishing: 39] [Article Influence: 2.3] [Reference Citation Analysis]
548 Singal AG, Pillai A, Tiro J. Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis. PLoS Med 2014;11:e1001624. [PMID: 24691105 DOI: 10.1371/journal.pmed.1001624] [Cited by in Crossref: 364] [Cited by in F6Publishing: 295] [Article Influence: 52.0] [Reference Citation Analysis]
549 Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25-34. [PMID: 19095497 DOI: 10.1016/s1470-2045(08)70285-7] [Cited by in Crossref: 3367] [Cited by in F6Publishing: 1731] [Article Influence: 259.0] [Reference Citation Analysis]
550 Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology. 2003;37:429-442. [PMID: 12540794 DOI: 10.1053/jhep.2003.50047] [Cited by in Crossref: 2017] [Cited by in F6Publishing: 1715] [Article Influence: 112.1] [Reference Citation Analysis]
551 Zheng Q, Yang H, Wei J, Tong J, Shu Y. The role and mechanisms of nanoparticles to enhance radiosensitivity in hepatocellular cell. Biomedicine & Pharmacotherapy 2013;67:569-75. [DOI: 10.1016/j.biopha.2013.04.003] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 3.4] [Reference Citation Analysis]
552 Zhao WC, Zhang HB, Yang N, Fu Y, Qian W, Chen BD, Fan LF, Yang GS. Preoperative predictors of short-term survival after hepatectomy for multinodular hepatocellular carcinoma. World J Gastroenterol. 2012;18:3272-3281. [PMID: 22783052 DOI: 10.3748/wjg.v18.i25.3272] [Cited by in F6Publishing: 10] [Reference Citation Analysis]
553 Hu J, Bao Q, Cao G, Zhu X, Yang R, Ji X, Xu L, Zheng K, Li W, Xing B, Wang X. Hepatic Arterial Infusion Chemotherapy Using Oxaliplatin Plus 5-Fluorouracil Versus Transarterial Chemoembolization/Embolization for the Treatment of Advanced Hepatocellular Carcinoma with Major Portal Vein Tumor Thrombosis. Cardiovasc Intervent Radiol 2020;43:996-1005. [PMID: 31974744 DOI: 10.1007/s00270-019-02406-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
554 Zhang B, Dong W, Luo H, Zhu X, Chen L, Li C, Zhu P, Zhang W, Xiang S, Zhang W, Huang Z, Chen X. Surgical treatment of hepato-pancreato-biliary disease in China: the Tongji experience. Sci China Life Sci 2016;59:995-1005. [DOI: 10.1007/s11427-016-5104-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
555 Zhang T, Huang J, Bai Y, Wu H, Zeng Y. Recurrence and survivals following hepatic resection for hepatocellular carcinoma with major portal/hepatic vein tumor thrombus: Resection of HCC with tumor thrombus. Hepatol Res 2014;44:761-8. [DOI: 10.1111/hepr.12185] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
556 Amini N, Ejaz A, Spolverato G, Maithel SK, Kim Y, Pawlik TM. Management of Lymph Nodes During Resection of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma: A Systematic Review. J Gastrointest Surg 2014;18:2136-48. [DOI: 10.1007/s11605-014-2667-1] [Cited by in Crossref: 56] [Cited by in F6Publishing: 47] [Article Influence: 8.0] [Reference Citation Analysis]
557 Arguedas MR, Chen VK, Eloubeidi MA, Fallon MB. Screening for hepatocellular carcinoma in patients with hepatitis C cirrhosis: a cost-utility analysis. Am J Gastroenterol. 2003;98:679-690. [PMID: 12650806 DOI: 10.1111/j.1572-0241.2003.07327.x] [Cited by in Crossref: 188] [Cited by in F6Publishing: 147] [Article Influence: 10.4] [Reference Citation Analysis]
558 Singal AG, Tiro J, Li X, Adams-Huet B, Chubak J. Hepatocellular Carcinoma Surveillance Among Patients With Cirrhosis in a Population-based Integrated Health Care Delivery System. J Clin Gastroenterol 2017;51:650-5. [PMID: 27870642 DOI: 10.1097/MCG.0000000000000708] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 7.3] [Reference Citation Analysis]
559 Takizawa D, Kakizaki S, Sohara N, Sato K, Takagi H, Arai H, Katakai K, Kojima A, Matsuzaki Y, Mori M. Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: Clinical Characteristics, Prognosis, and Patient Survival Analysis. Dig Dis Sci 2007;52:3290-5. [DOI: 10.1007/s10620-007-9808-2] [Cited by in Crossref: 94] [Cited by in F6Publishing: 72] [Article Influence: 6.7] [Reference Citation Analysis]
560 Simoneau E, Hassanain M, Madkhali A, Salman A, Nudo CG, Chaudhury P, Metrakos P. (18)F-Fluorodeoxyglucose positron-emission tomography could have a prognostic role in patients with advanced hepatocellular carcinoma. Curr Oncol. 2014;21:e551-e556. [PMID: 25089106 DOI: 10.3747/co.21.1959] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
561 Nakano M, Niizeki T, Nagamatsu H, Tanaka M, Kuromatsu R, Satani M, Okamura S, Iwamoto H, Shimose S, Shirono T, Noda Y, Koga H, Torimura T; Kurume Liver Cancer Study Group of Japan. Clinical effects and safety of intra-arterial infusion therapy of cisplatin suspension in lipiodol combined with 5-fluorouracil versus sorafenib, for advanced hepatocellular carcinoma with macroscopic vascular invasion without extra-hepatic spread: A prospective cohort study. Mol Clin Oncol 2017;7:1013-20. [PMID: 29285366 DOI: 10.3892/mco.2017.1442] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
562 Lang H, Sotiropoulos GC, Dömland M, Frühauf NR, Paul A, Hüsing J, Malagó M, Broelsch CE. Liver resection for hepatocellular carcinoma in non-cirrhotic liver without underlying viral hepatitis. Br J Surg 2005;92:198-202. [PMID: 15609381 DOI: 10.1002/bjs.4763] [Cited by in Crossref: 70] [Cited by in F6Publishing: 52] [Article Influence: 4.4] [Reference Citation Analysis]
563 Fontana RJ, Hamidullah H, Nghiem H, Greenson JK, Hussain H, Marrero J, Rudich S, McClure LA, Arenas J. Percutaneous radiofrequency thermal ablation of hepatocellular carcinoma: a safe and effective bridge to liver transplantation. Liver Transpl. 2002;8:1165-1174. [PMID: 12474157 DOI: 10.1053/jlts.2002.36394] [Cited by in Crossref: 117] [Cited by in F6Publishing: 114] [Article Influence: 6.5] [Reference Citation Analysis]
564 Llovet JM, Beaugrand M. Hepatocellular carcinoma: present status and future prospects. Journal of Hepatology 2003;38:136-49. [DOI: 10.1016/s0168-8278(02)00432-4] [Cited by in Crossref: 156] [Cited by in F6Publishing: 53] [Article Influence: 8.7] [Reference Citation Analysis]
565 Reichl P, Fang M, Starlinger P, Staufer K, Nenutil R, Muller P, Greplova K, Valik D, Dooley S, Brostjan C. Multicenter analysis of soluble Axl reveals diagnostic value for very early stage hepatocellular carcinoma. Int J Cancer. 2015;137:385-394. [PMID: 25529751 DOI: 10.1002/ijc.29394] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 4.5] [Reference Citation Analysis]
566 Byun HK, Kim HJ, Im YR, Kim DY, Han K, Seong J. Dose escalation in radiotherapy for incomplete transarterial chemoembolization of hepatocellular carcinoma. Strahlenther Onkol 2020;196:132-41. [DOI: 10.1007/s00066-019-01488-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
567 Meza-junco J, Montaño-loza A, Candelaria-myrna. Modalidades de tratamiento para pacientes con carcinoma hepatocelular: una serie retrospectiva de una sola institución en México. Gastroenterología y Hepatología 2004;27:11-7. [DOI: 10.1016/s0210-5705(03)70438-5] [Cited by in Crossref: 9] [Article Influence: 0.5] [Reference Citation Analysis]
568 Memon K, Kulik L, Lewandowski RJ, Wang E, Riaz A, Ryu RK, Sato KT, Marshall K, Gupta R, Nikolaidis P, Miller FH, Yaghmai V, Senthilnathan S, Baker T, Gates VL, Abecassis M, Benson AB 3rd, Mulcahy MF, Omary RA, Salem R. Radiographic response to locoregional therapy in hepatocellular carcinoma predicts patient survival times. Gastroenterology 2011;141:526-35, 535.e1-2. [PMID: 21664356 DOI: 10.1053/j.gastro.2011.04.054] [Cited by in Crossref: 117] [Cited by in F6Publishing: 98] [Article Influence: 11.7] [Reference Citation Analysis]
569 Farinati F, Marino D, Giorgio M, Trevisani F. A reappraisal of the Barcelona Clinic Liver Cancer model: natural history of untreated 'intermediate stage' hepatocellular carcinoma. J Intern Med 2004;256:529-30. [DOI: 10.1111/j.1365-2796.2004.01409.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
570 Yamazaki S, Takayama T. Surgical treatment of hepatocellular carcinoma: evidence-based outcomes. World J Gastroenterol. 2008;14:685-692. [PMID: 18205256 DOI: 10.3748/wjg.14.685] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
571 Park JY, Ahn SH, Yoon YJ, Kim JK, Lee HW, Lee DY, Chon CY, Moon YM, Han K. Repetitive short-course hepatic arterial infusion chemotherapy with high-dose 5-fluorouracil and cisplatin in patients with advanced hepatocellular carcinoma. Cancer 2007;110:129-37. [DOI: 10.1002/cncr.22759] [Cited by in Crossref: 78] [Cited by in F6Publishing: 68] [Article Influence: 5.6] [Reference Citation Analysis]
572 Colombo GL, Cammà C, Attili AF, Ganga R, Gaeta GB, Brancaccio G, Franzini JM, Volpe M, Turchetti G. Patterns of treatment and costs of intermediate and advanced hepatocellular carcinoma management in four Italian centers. Ther Clin Risk Manag 2015;11:1603-12. [PMID: 26527877 DOI: 10.2147/TCRM.S88208] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
573 Ikai I, Arii S, Kojiro M, Ichida T, Makuuchi M, Matsuyama Y, Nakanuma Y, Okita K, Omata M, Takayasu K. Reevaluation of prognostic factors for survival after liver resection in patients with hepatocellular carcinoma in a Japanese nationwide survey. Cancer. 2004;101:796-802. [PMID: 15305412 DOI: 10.1002/cncr.20426] [Cited by in Crossref: 320] [Cited by in F6Publishing: 263] [Article Influence: 18.8] [Reference Citation Analysis]
574 Llovet JM, Sala M, Bruix J. Nonsurgical treatment of hepatocellular carcinoma. Liver Transpl 2000;6:s11-5. [DOI: 10.1053/jlts.2000.18684] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 0.7] [Reference Citation Analysis]
575 Quirk M, Kim YH, Saab S, Lee EW. Management of hepatocellular carcinoma with portal vein thrombosis. World J Gastroenterol. 2015;21:3462-3471. [PMID: 25834310 DOI: 10.3748/wjg.v21.i12.3462] [Cited by in CrossRef: 50] [Cited by in F6Publishing: 38] [Article Influence: 10.0] [Reference Citation Analysis]
576 Zeng ZC, Tang ZY, Fan J, Zhou J, Qin LX, Ye SL, Sun HC, Wang BL, Yu Y, Wang JH. A comparison of chemoembolization combination with and without radiotherapy for unresectable hepatocellular carcinoma. Cancer J. 2004;10:307-316. [PMID: 15530260 DOI: 10.1097/00130404-200409000-00008] [Cited by in Crossref: 64] [Cited by in F6Publishing: 50] [Article Influence: 4.0] [Reference Citation Analysis]
577 Singal AG, Mittal S, Yerokun OA, Ahn C, Marrero JA, Yopp AC, Parikh ND, Scaglione SJ. Hepatocellular Carcinoma Screening Associated with Early Tumor Detection and Improved Survival Among Patients with Cirrhosis in the US. Am J Med. 2017;130:1099-1106.e1. [PMID: 28213044 DOI: 10.1016/j.amjmed.2017.01.021] [Cited by in Crossref: 52] [Cited by in F6Publishing: 38] [Article Influence: 13.0] [Reference Citation Analysis]
578 Miyachi Y, Kaido T, Yao S, Shirai H, Kobayashi A, Hamaguchi Y, Kamo N, Yagi S, Uemoto S. Bone Mineral Density as a Risk Factor for Patients Undergoing Surgery for Hepatocellular Carcinoma. World J Surg 2019;43:920-8. [PMID: 30465085 DOI: 10.1007/s00268-018-4861-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
579 Geh D, Manas DM, Reeves HL. Hepatocellular carcinoma in non-alcoholic fatty liver disease-a review of an emerging challenge facing clinicians. Hepatobiliary Surg Nutr 2021;10:59-75. [PMID: 33575290 DOI: 10.21037/hbsn.2019.08.08] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
580 Ratti F, Cipriani F, Paganelli M, Ferla G, Aldrighetti LA. Surgical approach to multifocal hepatocellular carcinoma with portal vein thrombosis and arterioportal shunt leading to portal hypertension and bleeding: a case report. World J Surg Oncol. 2012;10:34. [PMID: 22330617 DOI: 10.1186/1477-7819-10-34] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
581 Schwartz JD, Llovet JM. Molecular Targeting in Hepatocellular Carcinoma. In: Kaufman HL, Wadler S, Antman K, editors. Molecular Targeting in Oncology. Totowa: Humana Press; 2008. pp. 165-210. [DOI: 10.1007/978-1-59745-337-0_8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
582 Kamiyama T, Nakanishi K, Yokoo H, Tahara M, Nakagawa T, Kamachi H, Taguchi H, Shirato H, Matsushita M, Todo S. Efficacy of preoperative radiotherapy to portal vein tumor thrombus in the main trunk or first branch in patients with hepatocellular carcinoma. Int J Clin Oncol. 2007;12:363-368. [PMID: 17929118 DOI: 10.1007/s10147-007-0701-y] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 2.2] [Reference Citation Analysis]
583 Thompson SM, Wells ML, Andrews JC, Ehman EC, Menias CO, Hallemeier CL, Roberts LR, Venkatesh SK. Venous invasion by hepatic tumors: imaging appearance and implications for management. Abdom Radiol (NY) 2018;43:1947-67. [PMID: 28929197 DOI: 10.1007/s00261-017-1298-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
584 Ma KW, Chan ACY, Chok KSH, She WH, Cheung TT, Dai WC, Fung JYY, Lo CM. Liver transplantation: would it be the best and last chance of cure for hepatocellular carcinoma with major venous invasion? Hepatobiliary Surg Nutr 2021;10:308-14. [PMID: 34159158 DOI: 10.21037/hbsn.2020.03.09] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
585 Dettmer A, Kirchhoff TD, Gebel M, Zender L, Malek NP, Panning B, Chavan A, Rosenthal H, Kubicka S, Krusche S. Combination of repeated single-session percutaneous ethanol injection and transarterial chemoembolisation compared to repeated single-session percutaneous ethanol injection in patients with non-resectable hepatocellular carcinoma. World J Gastroenterol. 2006;12:3707-3715. [PMID: 16773687 DOI: 10.3748/wjg.v12.i23.3707] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 22] [Article Influence: 1.7] [Reference Citation Analysis]
586 Marrero JA. Screening tests for hepatocellular carcinoma. Clin Liver Dis. 2005;9:235-251, vi. [PMID: 15831271 DOI: 10.1016/j.cld.2004.12.006] [Cited by in Crossref: 48] [Cited by in F6Publishing: 45] [Article Influence: 3.0] [Reference Citation Analysis]
587 Montalto G, Cervello M, Giannitrapani L, Dantona F, Terranova A, Castagnetta LA. Epidemiology, risk factors, and natural history of hepatocellular carcinoma. Ann N Y Acad Sci. 2002;963:13-20. [PMID: 12095924 DOI: 10.1111/j.1749-6632.2002.tb04090.x] [Cited by in Crossref: 183] [Cited by in F6Publishing: 177] [Article Influence: 9.6] [Reference Citation Analysis]
588 Giorgio A, de Stefano G, Di Sarno A, Farella N, Giorgio V, Scognamiglio U, Mariniello A, Liorre G, Perrotta A, Mariniello N. Radiofrequency ablation of hepatocellular carcinoma extended into the portal vein: Preliminary results. J Ultrasound 2009;12:32-7. [PMID: 23396977 DOI: 10.1016/j.jus.2008.12.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
589 Chen J, Huang K, Wu J, Zhu H, Shi Y, Wang Y, Zhao G. Survival after anatomic resection versus nonanatomic resection for hepatocellular carcinoma: a meta-analysis. Dig Dis Sci. 2011;56:1626-1633. [PMID: 21082347 DOI: 10.1007/s10620-010-1482-0.] [Reference Citation Analysis]
590 Veltri A, Moretto P, Doriguzzi A, Pagano E, Carrara G, Gandini G. Radiofrequency thermal ablation (RFA) after transarterial chemoembolization (TACE) as a combined therapy for unresectable non-early hepatocellular carcinoma (HCC). Eur Radiol. 2006;16:661-669. [PMID: 16228211 DOI: 10.1007/s00330-005-0029-9] [Cited by in Crossref: 155] [Cited by in F6Publishing: 140] [Article Influence: 9.7] [Reference Citation Analysis]
591 Toman D, Vavra P, Jelinek P, Ostruszka P, Ihnat P, Foltys A, Pelikan A, Roman J. Effect of bariatric surgery on fatty liver disease in obese patients: A prospective one year follow-up study. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2021. [PMID: 33885048 DOI: 10.5507/bp.2021.021] [Reference Citation Analysis]
592 Ma KW, Cheung TT. Surgical resection of localized hepatocellular carcinoma: patient selection and special consideration. J Hepatocell Carcinoma. 2016;4:1-9. [PMID: 28097107 DOI: 10.2147/jhc.s96085] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 2.8] [Reference Citation Analysis]
593 Liu L, Shah SS, Naini BV, French S, Wu T, Torbenson MS, Chandan VS. Immunostains Used to Subtype Hepatic Adenomas Do Not Distinguish Hepatic Adenomas From Hepatocellular Carcinomas. American Journal of Surgical Pathology 2016;40:1062-9. [DOI: 10.1097/pas.0000000000000624] [Cited by in Crossref: 14] [Cited by in F6Publishing: 1] [Article Influence: 2.8] [Reference Citation Analysis]
594 Ziogas IA, Tsoulfas G. Advances and challenges in laparoscopic surgery in the management of hepatocellular carcinoma. World J Gastrointest Surg 2017;9:233-45. [PMID: 29359029 DOI: 10.4240/wjgs.v9.i12.233] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
595 Abdelaziz AO, Nabeel MM, Elbaz TM, Shousha HI, Hassan EM, Mahmoud SH, Rashed NA, Ibrahim MM, Abdelmaksoud AH. Microwave ablation versus transarterial chemoembolization in large hepatocellular carcinoma: prospective analysis. Scand J Gastroenterol. 2015;50:479-484. [PMID: 25592058 DOI: 10.3109/00365521.2014.1003397] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
596 Inoue Y, Hasegawa K, Ishizawa T, Aoki T, Sano K, Beck Y, Imamura H, Sugawara Y, Kokudo N, Makuuchi M. Is there any difference in survival according to the portal tumor thrombectomy method in patients with hepatocellular carcinoma? Surgery. 2009;145:9-19. [PMID: 19081470 DOI: 10.1016/j.surg.2008.09.005] [Cited by in Crossref: 63] [Cited by in F6Publishing: 51] [Article Influence: 5.3] [Reference Citation Analysis]
597 Grazi GL, Ercolani G, Pierangeli F, Del Gaudio M, Cescon M, Cavallari A, Mazziotti A. Improved results of liver resection for hepatocellular carcinoma on cirrhosis give the procedure added value. Ann Surg 2001;234:71-8. [PMID: 11420485 DOI: 10.1097/00000658-200107000-00011] [Cited by in Crossref: 248] [Cited by in F6Publishing: 225] [Article Influence: 12.4] [Reference Citation Analysis]
598 Aghemo A, Colombo M. Hepatocellular carcinoma in chronic hepatitis C: from bench to bedside. Semin Immunopathol 2013;35:111-20. [DOI: 10.1007/s00281-012-0330-z] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.2] [Reference Citation Analysis]
599 Kamiyama T, Kakisaka T, Orimo T, Wakayama K. Hepatectomy for hepatocellular carcinoma with portal vein tumor thrombus. World J Hepatol. 2017;9:1296-1304. [PMID: 29359012 DOI: 10.4254/wjh.v9.i36.1296] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
600 Fukumoto T, Kido M, Takebe A, Tanaka M, Kinoshita H, Kuramitsu K, Komatsu S, Tsugawa D, Goto T, Asari S, Toyama H, Ajiki T, Ku Y. New macroscopic classification and back-flow thrombectomy for advanced hepatocellular carcinoma with portal vein tumor thrombus invading the contralateral second portal branch. Surg Today. 2017;47:1094-1103. [PMID: 28324163 DOI: 10.1007/s00595-017-1507-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
601 Abdelaziz AO, Shousha HI, Said EM, Soliman ZA, Shehata AA, Nabil MM, Abdelmaksoud AH, Elbaz TM, Abdelsalam FM. Evaluation of liver steatosis, measured by controlled attenuation parameter, in patients with hepatitis C-induced advanced liver fibrosis and hepatocellular carcinoma. Eur J Gastroenterol Hepatol 2018;30:1384-8. [PMID: 30179227 DOI: 10.1097/MEG.0000000000001196] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
602 Volk ML, Vijan S, Marrero JA. A novel model measuring the harm of transplanting hepatocellular carcinoma exceeding Milan criteria. Am J Transplant. 2008;8:839-846. [PMID: 18318783 DOI: 10.1111/j.1600-6143.2007.02138.x] [Cited by in Crossref: 135] [Cited by in F6Publishing: 116] [Article Influence: 10.4] [Reference Citation Analysis]
603 Schwartz JD, Beutler AS. Therapy for unresectable hepatocellular carcinoma: review of the randomized clinical trials—II: systemic and local non-embolization-based therapies in unresectable and advanced hepatocellular carcinoma. Anti-Cancer Drugs 2004;15:439-52. [DOI: 10.1097/01.cad.0000131140.12228.bb] [Cited by in Crossref: 49] [Cited by in F6Publishing: 41] [Article Influence: 2.9] [Reference Citation Analysis]
604 Zhang J, Chen G, Zhang P, Zhang J, Li X, Gan D, Cao X, Han M, Du H, Ye Y. The threshold of alpha-fetoprotein (AFP) for the diagnosis of hepatocellular carcinoma: A systematic review and meta-analysis. PLoS One. 2020;15:e0228857. [PMID: 32053643 DOI: 10.1371/journal.pone.0228857] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 21.0] [Reference Citation Analysis]
605 Zhang YF, Guo RP, Zou RH, Shen JX, Wei W, Li SH, OuYang HY, Zhu HB, Xu L, Lao XM. Efficacy and safety of preoperative chemoembolization for resectable hepatocellular carcinoma with portal vein invasion: a prospective comparative study. Eur Radiol. 2016;26:2078-2088. [PMID: 26396105 DOI: 10.1007/s00330-015-4021-8] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
606 Tanaka Y, Nakazawa T, Komori S, Hidaka H, Okuwaki Y, Takada J, Watanabe M, Shibuya A, Minamino T, Yamamoto H, Kokubu S, Hayakawa K, Koizumi W. Radiotherapy for patients with unresectable advanced hepatocellular carcinoma with invasion to intrahepatic large vessels: Efficacy and outcomes: Radiotherapy for tumor thrombosis. J Gastroenterol Hepatol 2014;29:352-7. [DOI: 10.1111/jgh.12333] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
607 Yu SJ, Kim YJ. Effective treatment strategies other than sorafenib for the patients with advanced hepatocellular carcinoma invading portal vein. World J Hepatol. 2015;7:1553-1561. [PMID: 26085914 DOI: 10.4254/wjh.v7.i11.1553] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 4.0] [Reference Citation Analysis]
608 Zurera L, Canis M, Marchal T, García-revillo J, Martos J, Benito A, Fraga E. Estudio histopatológico del efecto de la quimioembolización pretrasplante en el hepatocarcinoma. Radiología 2008;50:47-53. [DOI: 10.1016/s0033-8338(08)71928-3] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]
609 Marrero JA, Fontana RJ, Su GL, Conjeevaram HS, Emick DM, Lok AS. NAFLD may be a common underlying liver disease in patients with hepatocellular Carcinoma in the United States: NAFLD May Be a Common Underlying Liver Disease in Patients With Hepatocellular Carcinoma in the United States. Hepatology 2002;36:1349-54. [DOI: 10.1002/hep.1840360609] [Cited by in Crossref: 255] [Cited by in F6Publishing: 115] [Article Influence: 18.2] [Reference Citation Analysis]
610 Pesi B, Giudici F, Moraldi L, Montesi G, Romagnoli S, Pinelli F, Stefano P, Batignani G. Hepatocellular carcinoma on cirrhosis complicated with tumoral thrombi extended to the right atrium: results in three cases treated with major hepatectomy and thrombectomy under hypothermic cardiocirculatory arrest and literature review. World J Surg Oncol. 2016;14:83. [PMID: 26971195 DOI: 10.1186/s12957-016-0831-7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 2.4] [Reference Citation Analysis]
611 Ruzzenente A, Manzoni GD, Molfetta M, Pachera S, Genco B, Donataccio M, Guglielmi A. Rapid progression of hepatocellular carcinoma after Radiofrequency Ablation. World J Gastroenterol. 2004;10:1137-1140. [PMID: 15069713 DOI: 10.3748/wjg.v10.i8.1137] [Cited by in CrossRef: 97] [Cited by in F6Publishing: 83] [Article Influence: 5.7] [Reference Citation Analysis]
612 Kim KH, Lee SY, Hwang H, Lee JY, Ji ES, An HJ, Kim JY, Yoo JS. Direct Monitoring of Fucosylated Glycopeptides of Alpha-Fetoprotein in Human Serum for Early Hepatocellular Carcinoma by Liquid Chromatography-Tandem Mass Spectrometry with Immunoprecipitation. Proteomics Clin Appl 2018;12:e1800062. [PMID: 29888876 DOI: 10.1002/prca.201800062] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
613 Huo L, Wei W, Yan Z, Lei Z, Xie Y, Gong R, Huang S, Jia N, Xia Y. Short-term and long-term outcomes of liver resection for HCC patients with portal vein tumor thrombus. Cell Biosci 2019;9:23. [PMID: 30886700 DOI: 10.1186/s13578-019-0285-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
614 Liu L, Jia J, Zeng G, Zhao Y, Qi X, He C, Guo W, Fan D, Han G, Li Z. Studies on immunoregulatory and anti-tumor activities of a polysaccharide from Salvia miltiorrhiza Bunge. Carbohydr Polym 2013;92:479-83. [PMID: 23218323 DOI: 10.1016/j.carbpol.2012.09.061] [Cited by in Crossref: 43] [Cited by in F6Publishing: 30] [Article Influence: 4.8] [Reference Citation Analysis]
615 Chiang KC, Yeh CN, Chen HY, Lee JM, Juang HH, Chen MF, Takano M, Kittaka A, Chen TC. 19-Nor-2α-(3-hydroxypropyl)-1α,25-dihydroxyvitamin D3 (MART-10) is a potent cell growth regulator with enhanced chemotherapeutic potency in liver cancer cells. Steroids. 2011;76:1513-1519. [PMID: 21888924 DOI: 10.1016/j.steroids.2011.08.006] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 2.6] [Reference Citation Analysis]
616 Vogeler M, Mohr I, Pfeiffenberger J, Sprengel SD, Klauss M, Teufel A, Chang DH, Springfeld C, Longerich T, Merle U, Mehrabi A, Weiss KH, Mieth M. Applicability of scoring systems predicting outcome of transarterial chemoembolization for hepatocellular carcinoma. J Cancer Res Clin Oncol 2020;146:1033-50. [PMID: 32107625 DOI: 10.1007/s00432-020-03135-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
617 Yamazaki S, Takayama T. Surgical treatment of hepatocellular carcinoma: evidence-based outcomes. World J Gastroenterol. 2008;14:685-692. [PMID: 18205256 DOI: 10.3748/wjg.14.685.] [Reference Citation Analysis]
618 Tanaka K, Yabushita Y, Nakagawa K, Kumamoto T, Matsuo K, Taguri M, Endo I. Debulking surgery followed by intraarterial 5-fluorouracil chemotherapy plus subcutaneous interferon alfa for massive hepatocellular carcinoma with multiple intrahepatic metastases: A pilot study. European Journal of Surgical Oncology (EJSO) 2013;39:1364-70. [DOI: 10.1016/j.ejso.2013.10.007] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
619 Sharma AM, Zhu D, Henry Z. Portal vein thrombosis: When to treat and how? Vasc Med. 2016;21:61-69. [PMID: 26584887 DOI: 10.1177/1358863x15611224] [Cited by in Crossref: 25] [Cited by in F6Publishing: 7] [Article Influence: 4.2] [Reference Citation Analysis]
620 Xu J, Wang Y, Zhang Y, Dang S, He S. Astemizole promotes the anti-tumor effect of vitamin D through inhibiting miR-125a-5p-meidated regulation of VDR in HCC. Biomed Pharmacother 2018;107:1682-91. [PMID: 30257386 DOI: 10.1016/j.biopha.2018.08.153] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
621 Sumie S, Kuromatsu R, Okuda K, Ando E, Takata A, Fukushima N, Watanabe Y, Kojiro M, Sata M. Microvascular invasion in patients with hepatocellular carcinoma and its predictable clinicopathological factors. Ann Surg Oncol. 2008;15:1375-1382. [PMID: 18324443 DOI: 10.1245/s10434-008-9846-9] [Cited by in Crossref: 249] [Cited by in F6Publishing: 233] [Article Influence: 19.2] [Reference Citation Analysis]
622 Lai YC, Shih CY, Jeng CM, Yang SS, Hu JT, Sung YC, Liu HT, Hou SM, Wu CH, Chen TK. Hepatic arterial infusion chemotherapy for hepatocellular carcinoma with portal vein tumor thrombosis. World J Gastroenterol. 2003;9:2666-2670. [PMID: 14669309 DOI: 10.3748/wjg.v9.i12.2666] [Cited by in CrossRef: 39] [Cited by in F6Publishing: 35] [Article Influence: 2.3] [Reference Citation Analysis]
623 Canellas R, Mehrkhani F, Patino M, Kambadakone A, Sahani D. Characterization of Portal Vein Thrombosis (Neoplastic Versus Bland) on CT Images Using Software-Based Texture Analysis and Thrombus Density (Hounsfield Units). AJR Am J Roentgenol. 2016;207:W81-W87. [PMID: 27490095 DOI: 10.2214/ajr.15.15928] [Cited by in Crossref: 28] [Cited by in F6Publishing: 8] [Article Influence: 5.6] [Reference Citation Analysis]
624 Talwalkar JA, Kamath PS. Influence of Recent Advances in Medical Management on Clinical Outcomes of Cirrhosis. Mayo Clinic Proceedings 2005;80:1501-8. [DOI: 10.4065/80.11.1501] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 2.3] [Reference Citation Analysis]
625 Bouza C, López-Cuadrado T, Alcázar R, Saz-Parkinson Z, Amate JM. Meta-analysis of percutaneous radiofrequency ablation versus ethanol injection in hepatocellular carcinoma. BMC Gastroenterol. 2009;9:31. [PMID: 19432967 DOI: 10.1186/1471-230x-9-31] [Cited by in Crossref: 101] [Cited by in F6Publishing: 45] [Article Influence: 8.4] [Reference Citation Analysis]
626 Rim CH, Jeong BK, Kim TH, Hee Kim J, Kang HC, Seong J. Effectiveness and feasibility of external beam radiotherapy for hepatocellular carcinoma with inferior vena cava and/or right atrium involvement: a multicenter trial in Korea (KROG 17-10). Int J Radiat Biol 2020;96:759-66. [PMID: 31977276 DOI: 10.1080/09553002.2020.1721607] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 7.0] [Reference Citation Analysis]
627 Aguayo A, Patt YZ. Nonsurgical Treatment of Hepatocellular Carcinoma. Clinics in Liver Disease 2001;5:175-89. [DOI: 10.1016/s1089-3261(05)70160-4] [Cited by in Crossref: 5] [Article Influence: 0.3] [Reference Citation Analysis]
628 Forner A, Gilabert M, Bruix J, Raoul JL. Treatment of intermediate-stage hepatocellular carcinoma. Nat Rev Clin Oncol. 2014;11:525-535. [PMID: 25091611 DOI: 10.1038/nrclinonc.2014] [Reference Citation Analysis]
629 Forner A, Gilabert M, Bruix J, Raoul JL. Treatment of intermediate-stage hepatocellular carcinoma. Nat Rev Clin Oncol. 2014;11:525-535. [PMID: 25091611 DOI: 10.1038/nrclinonc.2014.122] [Cited by in Crossref: 247] [Cited by in F6Publishing: 222] [Article Influence: 35.3] [Reference Citation Analysis]
630 Dionisi F, Widesott L, Lorentini S, Amichetti M. Is there a role for proton therapy in the treatment of hepatocellular carcinoma? A systematic review. Radiotherapy and Oncology 2014;111:1-10. [DOI: 10.1016/j.radonc.2014.02.001] [Cited by in Crossref: 34] [Cited by in F6Publishing: 25] [Article Influence: 4.9] [Reference Citation Analysis]
631 Lu XJ, Dong J, Ji LJ, Xiao LX, Ling CQ, Zhou J. Tolerability and efficacy of gamma knife radiosurgery on hepatocellular carcinoma with portal vein tumor thrombosis. Oncotarget. 2016;7:3614-3622. [PMID: 26473291 DOI: 10.18632/oncotarget.6118] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
632 Kim MS, Jin YJ, Lee JW, Lee JI, Kim YS, Lee SY, Chae MH. Complete remission of advanced hepatocellular carcinoma by sorafenib: A case report. World J Gastrointest Oncol. 2013;5:38-42. [PMID: 23556056 DOI: 10.4251/wjgo.v5.i2.38] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
633 Marı́n-hargreaves G, Azoulay D, Bismuth H. Hepatocellular carcinoma: surgical indications and results. Critical Reviews in Oncology/Hematology 2003;47:13-27. [DOI: 10.1016/s1040-8428(02)00213-5] [Cited by in Crossref: 55] [Cited by in F6Publishing: 30] [Article Influence: 3.1] [Reference Citation Analysis]
634 Kusano H, Ogasawara S, Akiba J, Nakayama M, Ueda K, Yano H. Antiproliferative effects of sorafenib and pegylated IFN‑α2b on human liver cancer cells in vitro and in vivo. Int J Oncol 2013;42:1897-903. [PMID: 23588838 DOI: 10.3892/ijo.2013.1904] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
635 Nagamatsu H, Sumie S, Niizeki T, Tajiri N, Iwamoto H, Aino H, Nakano M, Shimose S, Satani M, Okamura S. Hepatic arterial infusion chemoembolization therapy for advanced hepatocellular carcinoma: multicenter phase II study. Cancer Chemother Pharmacol. 2016;77:243-250. [PMID: 26754678 DOI: 10.1007/s00280-015-2892-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
636 DA Fonseca LG, Barroso-Sousa R, Bento AD, Blanco BP, Valente GL, Pfiffer TE, Hoff PM, Sabbaga J. Safety and efficacy of sorafenib in patients with Child-Pugh B advanced hepatocellular carcinoma. Mol Clin Oncol 2015;3:793-6. [PMID: 26171182 DOI: 10.3892/mco.2015.536] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
637 Cillo U, Bassanello M, Vitale A, Grigoletto FA, Burra P, Fagiuoli S, D'amico F, Ciarleglio FA, Boccagni P, Brolese A, Zanus G, D'amico DF. The critical issue of hepatocellular carcinoma prognostic classification: which is the best tool available? Journal of Hepatology 2004;40:124-31. [DOI: 10.1016/j.jhep.2003.09.027] [Cited by in Crossref: 133] [Cited by in F6Publishing: 119] [Article Influence: 7.8] [Reference Citation Analysis]
638 Forner A, Díaz-gonzález Á, Liccioni A, Vilana R. Prognosis prediction and staging. Best Practice & Research Clinical Gastroenterology 2014;28:855-65. [DOI: 10.1016/j.bpg.2014.08.002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
639 Kasai K, Ushio A, Kasai Y, Sawara K, Miyamoto Y, Oikawa K, Kuroda H, Takikawa Y, Suzuki K. Therapeutic efficacy of combination therapy with intra-arterial 5-fluorouracil and systemic pegylated interferon α-2b for advanced hepatocellular carcinoma with portal venous invasion. Cancer. 2012;118:3302-3310. [PMID: 22072099 DOI: 10.1002/cncr.26648] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
640 Kanwal F, Farid M, Martin P, Chen G, Gralnek IM, Dulai GS, Spiegel BMR. Treatment Alternatives for Hepatitis B Cirrhosis: A Cost-Effectiveness Analysis. Am J Gastroenterol 2006;101:2076-89. [DOI: 10.1111/j.1572-0241.2006.00769.x] [Cited by in Crossref: 53] [Cited by in F6Publishing: 50] [Article Influence: 3.5] [Reference Citation Analysis]
641 Trevisani F, Cantarini MC, Wands JR, Bernardi M. Recent advances in the natural history of hepatocellular carcinoma. Carcinogenesis. 2008;1299-1305. [PMID: 18515282 DOI: 10.1093/carcin/bgn113] [Cited by in Crossref: 105] [Cited by in F6Publishing: 89] [Article Influence: 8.1] [Reference Citation Analysis]
642 Harnois DM, Steers J, Andrews JC, Rubin JC, Pitot HC, Burgart L, Wiesner RH, Gores GJ. Preoperative hepatic artery chemoembolization followed by orthotopic liver transplantation for hepatocellular carcinoma. Liver Transpl Surg. 1999;5:192-199. [PMID: 10226109 DOI: 10.1002/lt.500050307] [Cited by in Crossref: 95] [Cited by in F6Publishing: 83] [Article Influence: 4.3] [Reference Citation Analysis]
643 Yu JI, Yoon SM, Park HC, Kim JH, Kim TH, Park JW, Seong J, Lee IJ, Jang HS, Kay CS. Multicenter validation study of a prognostic index for portal vein tumor thrombosis in hepatocellular carcinoma. Cancer Res Treat. 2014;46:348-357. [PMID: 25036573 DOI: 10.4143/crt.2013.142] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
644 Huang YJ, Hsu HC, Wang CY, Wang CJ, Chen HC, Huang EY, Fang FM, Lu SN. The treatment responses in cases of radiation therapy to portal vein thrombosis in advanced hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2009;73:1155-1163. [PMID: 18760547 DOI: 10.1016/j.ijrobp.2008.06.1486] [Cited by in Crossref: 56] [Cited by in F6Publishing: 52] [Article Influence: 4.3] [Reference Citation Analysis]
645 Xie CR, Sun HG, Sun Y, Zhao WX, Zhang S, Wang XM, Yin ZY. Significance of genetic variants in DLC1 and their association with hepatocellular carcinoma. Mol Med Rep. 2015;12:4203-4209. [PMID: 26095787 DOI: 10.3892/mmr.2015.3970] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
646 Dengler M, Staufer K, Huber H, Stauber R, Bantel H, Weiss KH, Starlinger P, Pock H, Klöters-Plachky P, Gotthardt DN, Rauch P, Lackner C, Stift J, Brostjan C, Gruenberger T, Kumada T, Toyoda H, Tada T, Weiss TS, Trauner M, Mikulits W. Soluble Axl is an accurate biomarker of cirrhosis and hepatocellular carcinoma development: results from a large scale multicenter analysis. Oncotarget 2017;8:46234-48. [PMID: 28526812 DOI: 10.18632/oncotarget.17598] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 8.7] [Reference Citation Analysis]
647 Wong VC, Wong MI, Lam CT, Lung ML, Lam KO, Lee VH. Hallmark microRNA signature in liquid biopsy identifies hepatocellular carcinoma and differentiates it from liver metastasis. J Cancer 2021;12:4585-94. [PMID: 34149922 DOI: 10.7150/jca.59933] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
648 Yang Y, Zhou Y, Lu M, An Y, Li R, Chen Y, Lu DR, Jin L, Zhou WP, Qian J, Wang HY. Association between fibroblast growth factor receptor 4 polymorphisms and risk of hepatocellular carcinoma. Mol Carcinog. 2012;51:515-521. [PMID: 21656577 DOI: 10.1002/mc.20805] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 2.0] [Reference Citation Analysis]
649 Worland T, Harrison B, Delmenico L, Dowling D. Hepatocellular Carcinoma Screening Utilising Serum Alpha-Fetoprotein Measurement and Abdominal Ultrasound Is More Effective than Ultrasound Alone in Patients with Non-viral Cirrhosis. J Gastrointest Cancer 2018;49:476-80. [PMID: 28920172 DOI: 10.1007/s12029-017-0006-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
650 Lee J. Novel combinational treatment of cisplatin with cyclophilin a inhibitors in human heptocellular carcinomas. Arch Pharm Res 2010;33:1401-9. [DOI: 10.1007/s12272-010-0914-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
651 Hatano E, Uemoto S, Yamaue H, Yamamoto M; the Japanese Society of Hepato-Biliary-Pancreatic Surgery. Significance of hepatic resection and adjuvant hepatic arterial infusion chemotherapy for hepatocellular carcinoma with portal vein tumor thrombus in the first branch of portal vein and the main portal trunk: a project study for hepatic surgery of the Jap. J Hepatobiliary Pancreat Sci 2018;25:395-402. [DOI: 10.1002/jhbp.574] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
652 Yada M, Masumoto A, Motomura K, Tajiri H, Morita Y, Suzuki H, Senju T, Koyanagi T. Indicators of sorafenib efficacy in patients with advanced hepatocellular carcinoma. World J Gastroenterol 2014;20:12581-7. [PMID: 25253961 DOI: 10.3748/wjg.v20.i35.12581] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 18] [Article Influence: 3.7] [Reference Citation Analysis]
653 Wang K, Guo WX, Chen MS, Mao YL, Sun BC, Shi J, Zhang YJ, Meng Y, Yang YF, Cong WM, Wu MC, Lau WY, Cheng SQ. Multimodality Treatment for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Large-Scale, Multicenter, Propensity Mathching Score Analysis. Medicine (Baltimore). 2016;95:e3015. [PMID: 26986115 DOI: 10.1097/md.0000000000003015] [Cited by in Crossref: 41] [Cited by in F6Publishing: 22] [Article Influence: 8.2] [Reference Citation Analysis]
654 Alqahtani SA, Sanai FM, Alolayan A, Abaalkhail F, Alsuhaibani H, Hassanain M, Alhazzani W, Alsuhaibani A, Algarni A, Forner A, Finn RS, Al-Hamoudi WK. Saudi Association for the Study of Liver diseases and Transplantation practice guidelines on the diagnosis and management of hepatocellular carcinoma. Saudi J Gastroenterol 2020;26:S1-S40. [PMID: 33078723 DOI: 10.4103/sjg.SJG_477_20] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
655 Takamoto T, Sugawara Y, Hashimoto T, Makuuchi M. Evaluating the current surgical strategies for hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol 2016;10:341-57. [PMID: 26558422 DOI: 10.1586/17474124.2016.1116381] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
656 Llovet JM, Real MI, Montaña X, Planas R, Coll S, Aponte J, Ayuso C, Sala M, Muchart J, Solà R, Rodés J, Bruix J. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. The Lancet 2002;359:1734-9. [DOI: 10.1016/s0140-6736(02)08649-x] [Cited by in Crossref: 2274] [Cited by in F6Publishing: 774] [Article Influence: 119.7] [Reference Citation Analysis]
657 Mizandari M, Azrumelashvili T, Paksashvili N, Kikodze N, Pantsulaia Ia, Janikashvili N, Chikovani T. Tumor Regression in HCC Patient with Portal Vein Tumor Thrombosis after Intraportal Radiofrequency Thermal Ablation. Case Reports Hepatol 2016;2016:6843121. [PMID: 27579192 DOI: 10.1155/2016/6843121] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
658 Pelizzaro F, Vitale A, Sartori A, Vieno A, Penzo B, Russo FP, Frigo AC, Giannini EG, Piccinnu M, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Sacco R, Celsa C, Marra F, Mega A, Guarino M, Gasbarrini A, Svegliati-Baroni G, Foschi FG, Olivani A, Masotto A, Coccoli P, Raimondo G, Azzaroli F, Vidili G, Brunetto MR, Trevisani F, Farinati F, On Behalf Of Ita Li Ca Study Group. Surveillance as Determinant of Long-Term Survival in Non-Transplanted Hepatocellular Carcinoma Patients. Cancers (Basel) 2021;13:897. [PMID: 33672751 DOI: 10.3390/cancers13040897] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
659 Rim CH, Kim CY, Yang DS, Yoon WS. External beam radiation therapy to hepatocellular carcinoma involving inferior vena cava and/or right atrium: A meta-analysis and systemic review. Radiother Oncol. 2018;129:123-129. [PMID: 29606524 DOI: 10.1016/j.radonc.201